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Resumen 
 El cáncer de pulmón es una de las principales causas de muerte relacionada con 
cáncer en el mundo, siendo el tercer tipo de cáncer más común. El cáncer de pulmón no 
microcítico (CPNM) representa casi el 85% de todos los cánceres de pulmón y la supervivencia 
a los 5 años va desde el 50% en estadios IA hasta el 15% en estadios IIIA. Hasta el momento, no 
se han descubierto biomarcadores capaces de predecir la progresión de la enfermedad en 
pacientes tanto en estadios resecables como en estadios avanzados, por lo que existe una 
clara necesidad de realizar estudios centrados en la búsqueda de biomarcadores pronósticos y 
diagnósticos en los diferentes tipos de muestra disponibles, como por ejemplo sangre, tejido 
fresco y tejido parafinado.  
El campo de la inmunología tumoral ha cambiado en la última década y actualmente se 
sabe que el sistema inmune juega un papel clave en cáncer. Las células inmunes que infiltran el 
tumor son un componente más del microambiente tumoral. Pese a que son potencialmente 
capaces de eliminar los antígenos tumorales, estas células no pueden evitar la formación y 
progresión tumoral. Esto es debido a que el tumor adquiere diversos mecanismos de 
regulación del microambiente tumoral con el objetivo de escapar del ataque del sistema 
inmune, como por ejemplo liberación de factores que impiden el correcto funcionamiento de 
los mecanismos de reacción inmune, modulación de vías co-estimuladoras y reclutamiento y 
activación de células inmunoreguladoras como las células T reguladoras, las células mieloides 
supresoras y los macrófagos asociados a tumores. El estudio de marcadores relacionados con 
la respuesta inmune y concretamente con los procesos de inmunoregulación puede 
proporcionarnos información pronóstica y predictiva relevante sobre los pacientes con cáncer.  
Por todo ello, el principal objetivo de esta tesis doctoral es analizar la presencia de 
marcadores relacionados con la inmunoregulación y evaluar su posible correlación con las 
variables clínico-patológicas y pronósticas en pacientes con CPNM mediante el uso de técnicas 
fiables y aplicables en la práctica clínica como la PCR cuantitativa y la inmunohistoquímica. Así 
mismo, esto nos permitirá conocer en mayor profundidad las características inmunológicas del 
microambiente tumoral en pacientes con CPNM. 
  
  
Summary 
Lung cancer is the leading cause of cancer-related death worldwide, and is the third 
most common cancer type; it can be classified into two subgroups based on histology: non-
small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The 5-year survival still 
remains poor and despite the existence of several distinct tumour phenotypes, therapeutic 
decisions are mainly based on clinical features such as stage or performance status. This 
highlights the need for new diagnostic and prognostic biomarkers in different types of samples 
(such as blood, fresh-frozen tissue or formalin-fixed, paraffin-embedded [FFPE] samples). 
The field of tumour immunology has changed in the last decade, and it is now 
accepted that the immune system plays a pivotal role in cancer. Although the immune cells 
that infiltrate the tumour microenvironment are potentially capable of eliminating tumour 
cells, they cannot prevent tumour development and progression. Tumours acquire 
mechanisms to regulate their immune microenvironment such as the release of a series of 
factors to subvert normal reaction mechanisms, the modulation of co-stimulatory pathways, 
also known as immune checkpoints, and the induction and attraction of suppressor cells 
(myeloid-derived suppressor cells, tumour-associated macrophages, and regulatory T cells). 
The potential effect of the patient’s immune system on clinical outcome is important for the 
identification of prognostic markers as well as markers that predict treatment responses. The 
study of immune-related markers, especially those implicated in immunoregulatory processes, 
could provide valuable prognostic information that could help in many applications in future 
clinical practice. 
Thus, the objective of this thesis is to characterise cancer immunoregulation 
biomarkers and to evaluate the possible correlation between these biomarkers and 
clinicopathological and prognostic variables in patients with NSCLC by the use of well-tested 
and accurate techniques such as quantitative PCR and immunohistochemistry. Furthermore, 
this study will provide information about the immunological features of the tumour 
microenvironment in NSCLCs. 
  
  
Resum 
El càncer de pulmó és una de les principals causes de mort relacionades amb càncer al 
món, sent a més a més el tercer tipus de càncer més comú. El càncer de pulmó no microcític  
(CPNM) representa el 85% de tots els casos de càncer de pulmó aproximadament i la 
supervivència als 5 anys continua sent molt baixa. Fins el moment, no s’han descobert 
biomarcadors capaços de predir la progressió de la malaltia tant en pacients en estadis inicials 
com en estadis avançats. Per aquest motiu, existeix una clara necessitat de realitzar estudis 
centrats en la recerca de biomarcadors pronòstics i predictius en els diferents tipus de mostres 
disponibles, com per exemple sang, teixit  fresc i teixit parafinat. 
El camp de la immunologia tumoural ha canviat en l'última dècada i actualment se sap 
que el sistema immune exerceix un paper clau en el càncer. Les cèl·lules immunològiques que 
infiltren el tumour són un component més del microambient tumoural. Malgrat que aquestes 
cèl·lules són potencialment capaces d'eliminar el antígens tumourals, s’ha evidenciat que no 
poden previndre la formació i progressió tumoural. Una de les raons per les quals s’observa 
aquest fenomen és que el tumour adquireix diversos mecanismes de regulació del 
microambient tumoural. Aquests mecanismes es basen en l'alliberació de factors que 
impedeixen el correcte funcionament del sistema immune, la modulació de vies 
coestimuladores i el reclutament i activació de cèl·lules immunoreguladores com poden ser les 
cèl·lules T reguladores, les cèl·lules mieloides supressores i els macròfags associats a tumour. 
L'estudi de marcadors relacionats amb la resposta immune i més concretament amb els 
processos d' immunoregulació pot proporcionar informació pronòstica i predictiva rellevant 
sobre els pacients amb càncer. 
Per tot això, el principal objectiu d’aquesta tesi doctoral és analitzar la presència de 
marcadors relacionats amb la immunoregulació i avaluar la seva possible correlació amb les 
variables clinicopatològiques i pronòstiques de pacients amb CPNM mitjançant l’ús de 
tècniques fiables i aplicables a la pràctica clínica com són la PCR quantitativa i la 
immunohistoquímica. Així mateix, aquestes anàlisis ens permetran conèixer amb major 
profunditat les característiques immunològiques del microambient tumoural de pacients amb 
CPNM. 
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1. CANCER 
1.1. THE CANCER CONCEPT 
Cancer is a term that describes a large number of pathologies which have the 
uncontrolled growth and the spread of abnormal cells in common. The carcinogenesis process 
implies dynamic changes in the genome which lead to the transformation of cells which are 
consequently released from the homeostatic mechanisms that control normal proliferation, as 
well as from their normal interactions with the microenvironment (Hanahan and Weinberg, 
2000). In addition to cancer cells, tumours exhibit another dimension of complexity: they 
contain a repertoire of recruited cells that contribute to the acquisition of hallmark traits by 
creating the ‘‘tumour microenvironment” in which neoplastic epithelial cells constitute a 
compartment that is distinct from the cells forming the tumour-associated stroma. Both 
tumour parenchyma and stroma contain distinct cell types that enable tumour growth and 
progression, such as immune cells, cancer stem cells, pericytes, endothelial cells, and cancer-
associated fibroblasts (Hanahan and Weinberg, 2011). 
1.2. THE MOLECULAR BIOLOGY OF CANCER  
In 2000, Hanahan and Weinberg proposed that there are six essential characteristics, 
known as the hallmarks of cancer, for the development of cancer disease (Hanahan and 
Weinberg, 2000). Some years later, in 2011, they incorporated four new hallmarks (Figure 1), 
and pointed out the importance of the microenvironment in the cancer process (Hanahan and 
Weinberg, 2011). Hence, the proposed hallmarks are as follows: 
1. Self-sufficiency in growth signals. In normal conditions, cells require mitogenic 
growth signals to move from a quiescent state into a proliferative state. By the 
union of signalling molecules (such as soluble growth factors or extracellular 
matrix components) to transmembrane receptors, growth signals are transmitted 
into cells. In the absence of these signals, normal cells are not capable of growing. 
However, tumoural cells grow even when these interactions do not take place 
because they can generate their own intrinsic growth signals. 
2. Evading growth suppressors. In normal conditions, cells receive antiproliferative 
signals in order to maintain their quiescence, many of which depend on the actions 
of tumour suppressor genes. For instance, RB (retinoblastoma-associated) protein 
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integrates signals from diverse extracellular and intracellular sources, making it a 
cell-cycle progression gatekeeper. Hence, when the RB pathway is disrupted, cells 
become insensitive to inhibitory growth signals and inappropriate replication 
continues. 
3. Apoptosis evasion. Programmed cell death by apoptosis is a natural barrier to 
cancer development. However, different strategies can be used by tumoural cells 
to escape from these mechanisms. One of the most common strategies is the loss 
of the proapoptotic regulator TP53, which induces apoptosis when DNA damage is 
detected. 
4. Enabling replicative immortality. The number of cell divisions that can occur 
during a lifetime in mammals is limited by an intrinsic cell program, which is known 
as the Hayflick limit. Once cells have achieved this limit, they stop growing and 
start senescing (Hayflick, 1997), which results from the loss of the protective 
function of telomeres. It has been shown that in neoplastic cells, telomeres 
maintain their length due to higher activity of the telomerase enzyme (Shay and 
Bacchetti, 1997). 
5. Inducing angiogenesis. Like normal tissues, tumours require nutrients and oxygen, 
and need to evacuate metabolic wastes. Hence, the generation of new vasculature 
from the pre-existing one is essential for tumour growth (Folkman, 2003). This 
process is known as angiogenesis and it is regulated by the equilibrium between 
inducer and inhibitor factors. Tumours have the capacity to activate the 
angiogenesis process by stimulating inducer factors. 
6. Invasion and metastasis. Neoplastic cells can escape from primary tumour masses 
and invade adjacent tissues or distant sites. The success of this process depends on 
the other five characteristics and on complex changes in the physiological 
relationship between cells and their microenvironment. 
7. Genome instability and mutations. Defects affecting components of the DNA-
maintenance machinery lead to the accumulation of a large number of alterations 
in neoplastic cells, which are related to the aforementioned characteristics. The 
different steps involved in tumour progression are a succession of clonal 
expansions produced by the accumulation of mutations that generate selectively 
advantageous neoplastic cells. 
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Figure 1. The ten hallmarks of cancer. This illustration represents the capabilities of cancer cells as 
proposed by Hanahan and Weinberg. One example is the ability of cancer cells to evade immunological 
destruction, in particular by T and B lymphocytes, macrophages, and natural killer cells. Also of great 
importance is the inflammation produced by innate immune cells. Reproduced from Hanahan and 
Weinberg, 2011. 
8. Inflammation. Tumours are densely infiltrated by immune cells which were 
initially thought to be acting against the tumour. However, it has now become 
clear that inflammation can contribute to tumourigenesis and tumour progression 
by supplying different molecules to the tumour microenvironment such as growth 
factors, angiogenic factors, and extracellular matrix-modifying enzymes. 
Inflammation seems to play a pivotal role in the earliest stages of cancer because 
inflammatory cells release potentially mutagenic chemicals that induce genetic 
mutations in the neoplastic cells. 
9. Reprogramming energy metabolism. During the neoplastic process, changes in 
energy metabolism are produced in order to avoid apoptosis and to maintain and 
stimulate the growth and division of neoplastic cells. 
10. Avoiding immune destruction. It has been proven that neoplastic cells have 
developed different strategies in order to avoid being detected by the immune 
system. For instance, inflammatory cells, such as regulatory T cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs), which are actively immunosuppressive, 
are recruited to the tumour environment, where they suppress the action of 
cytotoxic lymphocytes against tumour cells. 
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2. LUNG CANCER 
2.1. EPIDEMIOLOGY 
Currently, cancer is one of the principal causes of death in developed countries, 
making it an important health care problem. In 2008, 3.2 million new cancer cases were 
diagnosed and there were more than 1.7 million deaths related to this disease in Europe 
(Ferlay et al., 2010). Among the different types of cancer, lung cancer is the most frequently 
diagnosed and is the leading cause of cancer-related death worldwide, with more than 1.5 
million new cases diagnosed per year (Jemal et al., 2011). In Europe, lung cancer is the third 
most common cancer and causes the highest mortality. Moreover, gender analysis showed 
that lung cancer is the most frequent cancer among men and the third among women (Ferlay 
et al., 2010). Trends in lung cancer mortality in Spain are similar to those observed in the EU; 
20,000 new lung cancer cases are diagnosed each year, which represents 18.4% of all tumours 
diagnosed in men (18,000 cases) and 3.2% in women (2,000 cases; information obtained from 
the Spanish Lung Cancer Group website). Starting in the nineties, age-specific death rates in 
males decreased for each age group under 85 years old. However, a statistically significant 
annual increase of 6.3% in truncated mortality rates has been observed in women since 1992 
(Cayuela et al., 2008). 
2.2. RISK FACTORS 
Tobacco smoking (cigarettes, pipes, and cigars) is the principal cause of lung cancer 
due to the toxic compounds present in its smoke and is responsible for 85-90% of these 
tumours (Freedman et al., 2008). The carcinogens present in cigarette smoke lead to the 
accumulation of a large number of mutations: it has been observed that in lung cancer an 
average of 200 mutations are accumulated per tumour, which is far more than the 25-50 
mutations that have been observed in other frequent tumours such as breast and prostate 
cancer. Interestingly, the average number of somatic mutations that appeared in smokers is 
ten times higher than the number of mutations found in non-smoker lung cancer patients as 
shown in Figure 2 (Vogelstein et al., 2013). 
Furthermore, the risk of developing lung cancer increases depending on the intensity 
and duration of smoke exposure (Jemal et al., 2008), and this risk starts to decrease two or 
three years after smokers stop smoking (Ebbert et al., 2003; Peto et al., 2000). An increased 
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risk (approximately 30%) of developing lung cancer in passive smokers has also been observed 
(Bilello et al., 2002; Hirayama, 2000). Since not all smokers develop lung cancer, the existence 
of genetic variations related to susceptibility and predisposition has been postulated (Gorlova 
et al., 2006; Matakidou et al., 2005).  
Other factors that have been associated with lung cancer development are 
environmental or occupational carcinogens such as radon gas, arsenic, asbestos, and polycyclic 
hydrocarbons (Fraumeni, Jr., 1982;Tyczynski et al., 2003). Additionally diet type, alcohol 
consumption, and other diseases such as diffuse cystic fibrosis are also considered to be risk 
factors (Bilello et al., 2002; Hubbard et al., 2000). 
 
Figure 2. The average number of somatic mutations found in representative human cancers as 
detected by genome-wide sequencing studies. In lung cancer, the average number of somatic 
mutations that appeared in smokers is ten times higher than the number of mutations found in non-
smokers. Reproduced from Vogelstein et al., 2013. 
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2.3. PATHOLOGY 
The most commonly used pathological classification was published in 2002 and is 
based on histological and pathological techniques. Lung cancer is classified into four 
histological subtypes: small cell lung carcinoma (SCLC: 15% of cases), squamous cell carcinoma 
(SCC: 30%), adenocarcinoma (ADC: 35-40%), and large cell carcinoma (LCC: 10%), the last three 
subtypes are grouped into a greater entity: non-small cell lung carcinoma (NSCLC), which 
represents 80-85% of all lung cancer cases (Travis, 2002). NSCLC generally originates in the 
bronchial epithelium and is usually a slow-growing tumour with low sensitivity to 
chemotherapy and radiotherapy. Its three subtypes are discussed in more detail here:  
1. SCC originates in the squamous epithelium of the lungs or bronchi and displays 
certain morphological features such as intercellular bridging, squamous pearl 
formation, and individual cell keratinisation. They usually occur in the central 
portion of the lung or in one of the main airway branches and can form cavities in 
the lung if they grow to a large size. SCCs are closely associated with tobacco 
smoking. 
2. ADC originates in broncho-alveolar cells and is histologically heterogeneous. They 
are usually found in the peripheral areas of the lung and therefore are more likely 
to be surgically resected. In 2011 Travis et al. published a review that classified 
ADC histology into different subtypes: lepidic, acinar, papillary, and solid patterns; 
the micropapillary category was later added as a new histological subtype. Variants 
include invasive mucinous ADC, colloid, foetal, and enteric ADC (Travis et al., 
2011). 
3. LCC is the least frequent subtype. The prognosis is similar to that for ADCs but the 
tumours are usually more necrotic. This subtype has a neuroendocrine origin and 
they are usually found in the periphery of the lung. Their clinical evolution is 
aggressive due to their rapid growth and their capacity to generate metastasis 
(Travis, 2002). 
2.4. DIAGNOSIS AND PROGNOSIS 
Lung cancer is mainly diagnosed because patients develop symptomatic 
manifestations such as pain, haemoptysis, dyspnoea, and weight loss, or it is identified in a 
routine chest X-ray. A substantial number of patients with lung cancer show tumour spread at 
the time of diagnosis, and 40% of patients with NSCLC have distant metastases at presentation 
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(Morgensztern et al., 2010). Although most patients are initially diagnosed by chest 
radiograph, a range of technologies are now available for further staging, such as low-dose 
chest computed tomography (CT) or fluorodeoxyglucose (18F-FDG)-positron emission 
tomography (PET), which might play a major role in the prediction and assessment of future 
treatment responses (Cuaron et al., 2012). Moreover, bronchoscopic techniques and 
endoscopic ultrasound (EUS) or endobronchial ultrasound (EBUS) are now available for 
biopsying the tumour. Since routine screening for lung cancer is still a very expensive option, 
there is increasing interest in the development of risk models or biomarkers for predicting lung 
cancer (for a review see Jantus-Lewintre et al., 2012). 
Prognostic assessment is an important factor to take into consideration when selecting 
an appropriate treatment regimen. The variables that have been associated with prognosis so 
far can be grouped into different categories: a) tumour-related, such as primary site, cell type 
and disease extension; b) patient-related, such as performance status, comorbidity, and sex; 
and c) environmental factors, such as nutrition (Goldstraw et al., 2011). The anatomical extent 
of disease, as described by the TNM (Tumour/Nodules/Metastasis) classification shown in 
Table 1, is one of the most important prognostic factors in lung cancer (Shepherd et al., 2007). 
The seventh edition of the TNM classification, published in 2009, included some changes 
affecting the organisation of the different stages (Detterbeck et al., 2009). Although the TNM 
classification provides pivotal prognostic information (Figure 3), histological confirmation 
(including molecular characterisation of the tumour) is also needed in order to make adequate 
decisions regarding patient treatment (Goldstraw et al., 2007). 
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Table 1. The T, N, and M descriptors in the seventh edition of the TNM classification for lung cancer. T 
refers to the primary tumour, N refers to the regional lymph nodes, and M refers to distant metastases. 
Reproduced from Goldstraw et al. 2011 
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Figure 3. Prognostic information regarding TNM classification. The overall survival is expressed as 
median survival time and 5-year survival of NSCLC patients, classified by a) clinical stage and b) 
pathological state, according to the sixth edition of the TNM classification. Reproduced from Goldstraw 
et al., 2007. 
2.5. TREATMENT 
Lung cancer treatment essentially depends on anatomopathological classification, 
tumour stage, and performance status (PS). Surgery is still the standard treatment for early-
stage patients with a good PS, that accounts for 20-30% of diagnosed NSCLC patients (Myrdal 
et al., 2001). However, stereotactic body radiotherapy (SBRT) has emerged as an alternative 
treatment for stage I-II patients with a borderline medical indication for surgery (Robinson et 
al., 2013). It has also been demonstrated that adjuvant chemotherapy after surgery with 
platinum salts in combination with vinorelbine, etoposide, or docetaxel increases patient 
survival rates (Felip et al., 2010; Molina et al., 2008).  
In 2002, Carney pointed out that a treatment-efficacy plateau had been reached for 
NSCLC which could not be further improved with conventional chemotherapeutic drugs 
(Carney, 2002). However, since then, the overall survival (OS) has improved to a median of 12 
months and it is even longer in clinical trials due to the introduction of new drugs and patient 
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selection. This selection is based on recognising different histological lung cancer subtypes and 
driver mutations that determine the biology of the tumour and predict drug efficacy (Scagliotti 
et al., 2008). A meta-analysis of 16 randomised trials confirmed that the most efficient 
treatment for the advanced stages of lung cancer was chemotherapy, which significantly 
increased patient OS (Burdett et al., 2008). Currently, standard chemotherapy is the 
combination of a third-generation cytotoxic agent such as gemcitabine, vinorelbine, or 
paclitaxel, with a platinum compound. Furthermore, recent data has shown that histology is an 
important factor to consider when selecting a specific treatment because of safety and/or 
efficacy reasons: for instance, the pemetrexed label restricts its use to non-SCCs (Langer et al., 
2010). Radiotherapy also has an important role in the curative and palliative treatment of 
NSCLC patients. Although it can be indicated in patients with a good PS and non-resected 
disease, palliative intention is still its main use (Goldstraw et al., 2011). 
In recent years specific anti-target therapies have emerged, which have increased 
NSCLC patient survival and decreased the toxicity that can be produced by conventional 
chemotherapy. Good examples are tyrosine-kinase inhibitors (TKIs) such as gefitinib and 
erlotinib, which are specific treatments for patients bearing mutations or deletions in the 
epidermal growth factor receptor (EGFR) gene. These mutations have been observed more 
frequently in women, in patients who have never smoked, and in those with ADC (Rosell et al., 
2009). Another example of personalised treatment that has improved objective responses and 
survival in combination with chemotherapy in patients with a non-SSC histology is 
bevacizumab, a recombinant, humanised, monoclonal vascular endothelial growth factor 
(VEGF) antibody (Soria et al., 2013). 
Recently, treatment with crizotinib, a small-molecule TKI that is highly specific for the 
inhibition of mesenchymal epithelial transition factor proto-oncogene, receptor tyrosine 
kinase (cMET), anaplastic lymphoma kinase (ALK), and reactive oxygen species proto-oncogene 
1, receptor tyrosine kinase (ROS1) has been approved in several countries. The best studied of 
these targets is the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma 
kinase (EML4-ALK). This 5’fusion is a potent oncogenic rearrangement that activates the 
downstream function of ALK. Two methods are currently available for clinical selection of 
patients with this oncogene. The standard diagnostic tool is a break-apart fluorescence in-situ 
hybridisation assay (FISH) and the alternative method is immunohistochemistry (IHC) with anti-
ALK monoclonal antibodies (Peters et al., 2013). 
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Over the last few decades, cancer immunotherapy has become a very attractive option 
for treating several cancer types. It refers to a number of approaches intended to activate the 
immune system in order to induce objective responses and disease stabilisation. Among the 
different possible options, blocking immune checkpoint molecules with monoclonal antibodies 
has emerged as a promising strategy. The CTLA4 (cytotoxic T-lymphocyte-associated antigen 4, 
also known as CD152) blocking antibody ipilimumab (BMS, Princeton, NJ) has already been 
approved by the federal drugs agency (FDA) for the treatment of patients with metastatic 
melanoma. In lung cancer, it is thought that infiltrating T cells might be partially responsive to 
CTLA4 blockade, and thus ipilimumab is currently being evaluated in a randomised phase III 
trial for the treatment of advanced NSCLC in combination with chemotherapy. Another 
monoclonal antibody, nivolumab, that blocks the interaction between the immune checkpoint 
molecule programmed cell death 1 (PD1) and its ligand (PDL1), is also being evaluated in 
NSCLC patients. On the basis of the promising preliminary activity seen in a large phase-Ib trial, 
more nivolumab clinical trials were recently initiated in patients with NSCLC (Drake et al., 
2014). 
Regarding the treatment of SCLC patients, early concurrent thoracic radiotherapy and 
prophylactic cranial irradiation should be considered for patients with or without metastases 
whose disease does not progress after induction chemotherapy and radiotherapy. A 
combination of chemotherapy, generally based on platinum, plus etoposide or irinotecan, is 
still the first-line standard treatment for metastatic disease. It is, however, noteworthy that 
despite high initial response rates, most patients eventually relapse, which then leaves few 
remaining treatment options, with the exception of topotecan (van Meerbeeck et al., 2011). 
2.6. LUNG CANCER MOLECULAR CLASSIFICATION 
Over recent decades, substantial advances have been made in the understanding of 
the molecular and cellular mechanisms driving lung cancer initiation, maintenance, and 
progression. These advances have led to the discovery of several novel drug targets and the 
development of new treatment strategies. NSCLC is one of the most genomically diverse 
tumours, and therefore there are a variety of molecularly defined subsets of patients 
characterised by specific sets of driver mutations (Figure 4). Among these driver mutations, 
some are potentially targetable molecules such as EGFR and ALK in ADC patients or PI3K in 
both histologies (Figure 5).  
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EGFR alterations are implicated in many types of cancer, including lung cancer. 
Overexpression or aberrant activation of this gene is present in approximately 60% of cases 
(Hirsch et al., 2003). EGFR encodes a transmembrane tyrosine kinase with an extracellular 
binding domain and an intracellular component including a tyrosine kinase domain. Binding to 
its ligand leads to receptor homo- or heterodimerization with other members of the EGFR 
family and activation of the tyrosine kinase domain (Scagliotti et al., 2004). In NSCLC, EGFR 
mutations have been observed in the first four exons of the intracellular tyrosine kinase 
domain, mainly (approximately 45%) in frame deletions in exon 19. The next commonest EGFR 
mutations are missense mutations, particularly L858R, a single nucleotide point mutation in 
exon 21 that leads to a single amino acid change from leucine to arginine at codon 858 
accounting for about 40% of cases. Less common mutations, including in-frame duplications or 
insertions in exon 20 (representing 5-10% of cases), have also been identified (Kosaka et al., 
2004; Okabe et al., 2007). In 2004, it was demonstrated that somatic mutations in the EGFR 
gene (exon 19 and 21) were correlated with sensitivity to TKI agents, whilst insertions in exon 
20 (or the T790M mutation) produced resistance to this specific treatment (Lynch et al., 2004; 
Paez et al., 2004). 
KRAS (Kirsten rat sarcoma viral oncogene homolog) is part of the RAS family of proto-
oncogenes, which in humans comprises KRAS, NRAS, and HRAS and encodes a G-protein with a 
critical role in controlling signal transduction pathways. These pathways regulate cell 
proliferation, differentiation, and survival. KRAS plays a critical role in downstream signal 
transduction induced by several growth factor receptors including EGFR. KRAS-activating 
mutations in codons 12 and 13 are the most frequent oncogenic alteration identified in lung 
ADCs, occurring in about 25-40% of cases (Downward, 2003; Karnoub and Weinberg, 2008). 
However, to date, none of these mutations have been correlated with prognosis or 
chemotherapy response in NSCLC patients (Camps et al., 2011). Interestingly, the EGFR and 
KRAS mutations are mutually exclusive in NSCLC patients. 
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Figure 4. Evolution of NSCLC subtyping from histological to molecular classification. EGFR, epidermal 
growth factor receptor; HER2, human epidermal growth factor receptor 2; MAP2K1, mitogen-activated 
protein kinase 1. Reproduced from Li et al., 2013. 
ALK rearrangements, which result in fusions of the intracellular kinase domain with the 
amino terminal end of EML4, are also very important in NSCLC. The rearrangement occurs in 
chromosome 2p (intron 13 of EML4 is fused to intron 19 of ALK) and causes a constitutive 
oligomerization that produces a mitogenic signal and therefore a malignant transformation 
(Soda et al., 2007). More recently, different partner genes have been identified in a small 
subset of ALK rearrangements (less than 1% of cases) including KIF5B (kinesin family member 
5b), TFG (TRK-fused gene) and KLC-1 (kinesin light chain 1). ALK rearrangements have been 
observed in 4% of ADC NSCLC patients, and are mutually exclusive to EGFR and KRAS 
mutations (Peters et al., 2013). ALK inhibition with the TKI crizotinib produces profound 
responses. However, drug resistance eventually develops, and there is evidence for the 
formation of secondary ALK point mutations and EGFR signalling activation implicated in some 
cases (Choi et al., 2010). 
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Figure 5. Potential targetable oncogenes by histological subtype. EGFR, epidermal growth factor 
receptor; ALK, anaplastic lymphoma kinase; DDR2, discoidin domain receptor tyrosine kinase 2; FGFR1, 
fibroblast growth factor receptor 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET, MET 
proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PTEN, 
phosphatase and tensin homology deleted on chromosome 10; RET, ret proto-oncogene; SCLC, small-
cell lung cancer. Reproduced from Morgensztern et al., 2015. 
PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) signalling plays important roles 
in metabolism, growth, survival, and motility. Both copy-number gains and mutations in 
PIK3CA have been identified in lung cancer. PIK3CA copy-number gains occur in approximately 
20% of lung cancers, with a higher frequency in SCCs. Preclinical data has suggested that 
cancers harbouring activating mutations in PIK3-catalytic subunit alpha (PIK3CA) may be 
among the most sensitive to single-agent PI3K pathway inhibitors (Morgensztern et al., 2015). 
Other druggable targets, also mainly in lung ADCs, include ROS1 and RET (ret proto-oncogene) 
translocations and HER2, B-Raf proto-oncogene, serine threonine kinase (BRAF), PIK3CA, and 
catenin (cadherin-associated protein), beta 1 (CTNNB1) mutations (Li et al., 2013). Although 
KRAS mutations are not yet a druggable target, patients carrying mutations in this gene can be 
treated with synthetic lethal approaches such as a combination of mitogen-activated protein 
kinase (MEK) and PIK3CA or AKT1 inhibitors (Yang et al., 2010a). In SCC, fibroblast growth 
factor receptor 1 (FGFR1) and discoidin domain receptor tyrosine kinase 2 (DDR2) have been 
reported as potential biomarkers but only a few clinical trials are ongoing, and diagnostic 
methods still need to be standardised (Drilon et al., 2012). Genetic assessment by PCR and 
next generation sequencing (NGS) platforms are being evaluated in order to identify new 
driver alterations, and also for developing new clinical tools. Molecular classification of lung 
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cancer holds great promise for the advancement and personalisation of cancer treatments, 
with the goal of maximising efficacy and minimising toxicity.  
Apart from the driver mutations mentioned above, it is known that all lung cancers 
carry high numbers of somatic mutations: high levels of inter- and intra-chromosomal 
rearrangements and copy-number alterations compared with other tumour types (Figure 6). In 
fact, lung cancers are among the most mutated types of cancer (Alexandrov et al., 2013). The 
diversity and complexity of the somatic mutational processes underlying carcinogenesis in 
human beings is now being revealed by identifying mutational patterns buried within cancer 
genomes. This diversity of mutation makes it difficult to treat all patients with targeted 
therapies. However, cancer-cell mutations that do not directly contribute to cancer initiation 
and progression (passenger mutations) generate new antigens which play a key part in tumour 
immunity. This fact is a great opportunity for therapies based on potentiating the body's own 
immune system to help fight cancer, also known as immunotherapies. 
 
Figure 6. The prevalence of somatic mutations across human cancer types. Every dot represents a 
sample whereas the red horizontal lines are the median numbers of mutations in the respective cancer 
types. Lung cancer subtypes are among the most mutated human cancer types. Reproduced from 
Alexandrov, 2013. 
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3. THE IMMUNE SYSTEM AND CANCER 
The main functions of the mammalian immune system are to control tissue 
homeostasis, to protect against invading or infectious pathogens, and to eliminate damaged 
cells. It is divided into two major components, innate and adaptive immunity, both of which 
produce an effective immune response through a variety of cells and soluble mediators. The 
innate immune system, which represents the first line of resistance, is composed of 
macrophages, neutrophils, dendritic cells (DCs), mast cells, eosinophils, basophils, natural killer 
(NK) cells, and NK T cells. Macrophages and mast cells release soluble mediators such as 
cytokines, chemokines, matrix metalloproteinases, and reactive oxygen species (ROS), and also 
attract additional leukocytes (de Visser et al., 2006). NK cells play a major role in the rejection 
of tumour cells or virus infected cells, whilst NK T cells are able to detect the presence of 
pathogens and induce DC maturation, functional activation, migration, and antigen 
presentation (Vivier and Anfossi, 2004). The adaptive immune system comprises B and T cells 
that further promote activation of innate immunity and support the expansion and production 
of tumour-specific T cells and antibodies. There are two main T cell subtypes: T helper cells (Th 
or CD4) and cytotoxic T cells (CTL or CD8). These cells express antigen-specific receptors that 
allow a flexible and broad number of responses (Bremnes et al., 2011). 
The immune system plays three important roles in preventing tumours: it protects the 
host from virus-induced tumours by eliminating virus infections; it resolves the elimination of 
pathogens in a prompt manner avoiding the establishment of an inflammatory environment; 
and finally, the immune system eliminates tumour cells which express tumour-specific 
antigens in a process known as immunosurveillance (Vesely et al., 2011). In fact, early research 
showed that the presence of intratumoural T cells is correlated with improved clinical 
outcomes in advanced ovarian carcinomas (Zhang et al., 2003), which was also observed in 
other types of tumours such as NSCLCs (Al-Shibli et al., 2008). Among these intratumoural T 
cells, CD8+ cells are the most important source of anti-tumour activity in vivo. Major 
histocompatibility complex (MHC) class I and B7 are two indispensable signals for activating 
CD8+ T cells. After stimulating and interacting with CD4+ T cells, CD8+ T cells convert into 
cytotoxic lymphocytes (Russell and Ley, 2002). However, when the immune system cannot 
completely eliminate cancer cells, a state of equilibrium is developed whereby the tumour 
does not progress or further metastasise. In this case cancer cells that can resist, avoid, or 
suppress the antitumour immune response are selected for, leading to tumour escape and 
progressive tumour growth (Finn, 2012). 
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Taking all this evidence together, it has become increasingly clear that cancer cells can 
not only avoid immunosurveillance but also exploit native immune mechanisms to their own 
benefit. In fact, three capabilities or characteristics have been defined as essential features of 
cancer: the ability to thrive in a chronically inflamed microenvironment, the ability to evade 
immune recognition, and the ability to regulate and suppress immune activity. The relative 
strength of each of these abilities may vary from one kind of tumour to another (Cavallo et al., 
2011). 
Even in the absence of external inflammatory stimuli, signals driven by oncogenes can 
activate intrinsic pro-inflammatory pathways that accelerate the carcinogenesis process 
(Mantovani et al., 2008). The most important inflammatory pathways that are involved in 
inflammation-induced carcinogenesis converge at the level of transcription factor signal 
transducers. Some examples are activator of transcription 3 (STAT3) and nuclear factor-κB 
(NFκB). By using these pathways, tumours modulate the inflammatory environment by 
secreting soluble growth factors and chemoattractants which stimulate inflammatory-
suppressive cells to counteract anticancer T cell responses (Elinav et al., 2013). As a result of 
this inflammation several types of immune cells accumulate in the tumour microenvironment 
(de Visser et al., 2006) in addition to the cancer cells and their surrounding stroma (the latter 
consisting of fibroblasts, endothelial cells, pericytes, and mesenchymal cells) which are shown 
in Figure 7. It is the expression of immune mediators and modulators, as well as the 
abundance and the activation state of different kinds of cells in the tumour microenvironment 
that define which direction the balance is tipped in, and therefore whether tumour-promoting 
inflammation or antitumour immunity will ensue (Lin and Karin, 2007).  
Another characteristic of cancer cells is that they can avoid immune recognition. 
Because of the increasing instability of their genomes, tumours are able to produce different 
immunogenic clones, and the poorly immunogenic ones escape from immunosurveillance 
(Dunn et al., 2004). One of the mechanisms by which tumour cells escape is the loss or 
alteration of MHC glycoproteins on their cell membrane. Escape can also be facilitated by the 
subversion of cell physiology as a consequence of the overexpression of oncogenes, or/and 
alterations of antigenic peptide-processing machinery (Norell et al., 2006). These processes 
disturb direct T cell tumour antigen recognition and prevent direct priming of an immune 
response against the tumour (Cavallo et al., 2011). Finally, tumour cells can regulate immune 
system activity in order to suppress its response against them and to modulate the different 
immune system mechanisms to their own benefit. 
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Figure 7. Representation of innate and adaptive immune-cell accumulation in the tumour 
microenvironment. Antigens that are present in early neoplastic tissues are transported to lymphoid 
organs by dendritic cells (DCs) that activate adaptive immune responses resulting in both tumour-
promoting and antitumour effects. Activation of B cells and humoural immune responses results in 
chronic activation of innate immune cells in neoplastic tissues. Activated innate immune cells, such as 
mast cells, granulocytes and macrophages, promote tumour development by the release of potent pro-
survival soluble molecules. Inflammatory cells positively influence tissue remodelling and development 
of the angiogenic vasculature by production of pro-angiogenic mediators and extracellular proteases. In 
contrast, activation of adaptive immunity also enhances antitumour responses through T-cell-mediated 
toxicity (by induction of TNF receptor superfamily member 6 [FAS], perforin and/or cytokine pathways) 
in addition to antibody-dependent cell-mediated cytotoxicity and antibody-induced complement-
mediated lysis. Reproduced from de Visser et al., 2006. 
3.1. CANCER IMMUNOREGULATION 
Tumours acquire mechanisms to regulate their immune microenvironment which 
include: the release of a series of factors to subvert normal reaction mechanisms, the 
modulation of co-stimulatory pathways (also known as immunological checkpoints), and the 
induction and attraction of suppressor cells such as MDSCs, tumour-associated macrophages 
(TAMs), DCs, and Tregs. 
3.1.1. IMMUNOSUPPRESSIVE FACTORS 
Immunosuppressive mediators (such as cytokines) released by tumour cells may 
function to suppress DCs, indirectly inhibiting T-cell penetration into the tumour bed or 
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directly suppressing effector T-cell activation while also enhancing the function of Treg cells. 
TGFβ (transforming growth factor β) is one of the most important immunosuppressive 
cytokines produced by tumour cells and infiltrating leukocytes in the tumour 
microenvironment. It has been proven that TGFβ can promote cancer metastasis by enhancing 
tumour cell invasion and inhibiting the function of immune cells (Massague, 2008): TGFβ can 
suppress or alter the activation, maturation, and differentiation of both innate and adaptive 
immune cells, including NK cells, DCs, macrophages, neutrophils, and CD4+ and CD8+ T cells. 
Moreover, TGFβ has an important role in the differentiation and induction of natural and 
induced Tregs, which contributes creating an immuno-tolerant environment (Li et al., 2006). 
However, it is important to note that TGFβ plays a dual role in cancer; this was first shown in a 
set of skin cancer experiments performed in mice which demonstrated that TGFβ expression 
targeted keratinocytes to inhibit benign tumour outgrowth, whereas later it enhances the 
progression of malignancy and promotes benign papillomas towards malignancy (Cui et al., 
1996). It was later demonstrated that TGFβ suppresses tumour initiation and early 
development by inhibiting cell cycle progression, inducing apoptosis, and suppressing the 
expression of growth factors, cytokines, and chemokines (Yang et al., 2010b). 
Another function of TGFβ is the upregulation of IL10 (interleukin 10), which in turn 
enhances TGFβ expression in a positive feedback circuit. IL10 inhibits antigen presentation, 
MHC class II expression, and the upregulation of the co-stimulatory molecules CD80 and CD86 
(Mosser and Zhang, 2008). IL10 suppresses the inflammatory cytokines IL1, IL6, IL12, and 
tumour necrosis factor alpha (TNFα). IL10 seems to act on DCs and macrophages and protects 
tumour cells from CTL-mediated cytotoxicity (Kurte et al., 2004); however, some evidence 
indicates that IL10 may also possess immune stimulating properties. In fact, overexpression of 
IL10 in the tumour microenvironment synergises with other cytokines to promote tumour 
rejection instead of inducing immunosuppression (Lopez et al., 2005). 
Tumours are also capable of expressing immunosuppressive factors other than 
cytokines; Galectins are important immunosuppressive molecules released in the tumour 
microenvironment. Current research indicates that galectins have important roles in cancer: 
they contribute to neoplastic transformation, tumour cell survival, angiogenesis, and tumour 
metastasis. Moreover, they can modulate the immune and inflammatory responses and might 
have a key role helping tumours to escape immune surveillance. The most extensively studied 
galectin in the context of immune response regulation is galectin-1, encoded by the gene 
LGALS1 (lectin galactoside binding soluble 1). Galectin-1 inhibits full T-cell activation, induces 
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the growth arrest and apoptosis of activated T cells, and suppresses the secretion of 
proinflammatory cytokines (Liu and Rabinovich, 2005). Galectins-2 and -9 also seem to play a 
role in tumour immunoregulation (Ito et al., 2012). In fact, Galectin-2 can induce T-cell 
apoptosis and control the secretion of lymphotoxin-α by macrophages (Liu and Rabinovich, 
2005). 
Indoleamine 2,3-dioxygenase (IDO), the key metabolic enzyme implicated in 
tryptophan catabolism, also effects immune response suppression. It produces a decrease in 
tryptophan availability and generates tryptophan metabolites which have negative effects on T 
lymphocytes. IDO activity seems to favour a regulatory phenotype in CD4+ T cells. On the other 
hand, tryptophan catabolism by IDO can act as a negative modulator of tumour growth 
because of the inhibitory effect of interferon gamma (IFNγ) on cancer cell proliferation 
mediated by tryptophan deprivation (Godin-Ethier et al., 2011). However, IDOs role and 
mechanism of action in immune evasion and tumour growth are still poorly understood in 
human cancer. Other factors released by tumour cells that can affect the immune response are 
prostaglandin E2 (PGE2), gangliosides, stromal cell-derived factor 1 (SDF1 or CXCL12), and 
VEGF (Banerjee et al., 2013). 
3.1.2. IMMUNE CHECKPOINTS 
T cell activation requires at least two signals to become fully activated. The first occurs 
after engagement of the T cell antigen-specific receptor (TCR) by MHC, and the second by 
subsequent engagement of co-stimulatory molecules, the T cell co-stimulator CD28 being the 
most potent. It has been demonstrated that tumour cells may upregulate surface ligands 
which act as negative co-stimulatory signals for T cells. Undoubtedly, one of the best-studied 
regulatory signals is CTLA4 which is induced in T cells at the time of their initial antigen 
response. Naïve and memory T cells express high levels of cell surface CD28 but do not express 
CTLA4: it is sequestered in intracellular vesicles and is transported to the cell surface after the 
TCR is triggered by encountering antigen (Figure 8a). The stronger the stimulation through the 
TCR (and CD28), the greater the amount of CTLA4 deposited on the T cell surface (Pardoll, 
2012). CTLA4 counteracts the activity of the CD28 T cell co-stimulatory receptor and binds two 
identical ligands: CD80 (also known as B7.1) and CD86 (also known as B7.2; Carreno et al., 
2000). Moreover, CTLA4 is constitutively expressed on the surface of Tregs (Jain et al., 2010). 
Therefore, CTLA4 functions as a signal dampener to maintain consistent levels of T cell 
activation. Tumour cells and antigen presenting cells (APCs) bind CTLA4 which circumvents 
Introduction 
23 
 
anticancer T cell activity. Allison and colleagues were pioneers in demonstrating that blocking 
CTLA4 signalling may enhance antitumour responses (Leach et al., 1996). The initial studies 
demonstrated significant anti-tumour responses without overt immune toxicities when mice 
bearing partially immunogenic tumours were treated with CTLA4 antibodies as single agents. 
The blockade of CTLA4 physiological functioning in T cells is currently used as a therapeutic 
approach in a variety of human malignancies, particularly in advanced melanoma, with the aim 
of promoting the activation and expansion of antitumour immune cells (Pardoll, 2012). 
Another immune checkpoint receptor, PD1 is emerging as an additional promising 
target; the major role of PD1 is regulation of inflammatory responses in peripheral tissues 
caused by effector T cell antigen recognition. Inflammatory signals in the tissues induce the 
expression of PD1 ligands, which downregulate T cell activity and thus limit collateral tissue 
damage (Figure 8b). Tumour cells are able to express PDL1 and, by doing so, they stop 
anticancer T cell activity (Pardoll, 2012). This receptor is expressed on a large proportion of 
tumour-infiltrating lymphocytes (TILs), including Tregs, whereas PDL1 is commonly 
upregulated on the cell surface of many different human tumours (Zou and Chen, 2008). In 
addition to tumour cells, PDL1 is commonly expressed on myeloid cells in the tumour 
microenvironment. Encouragingly, blocking antibodies against PD1 or PDL1 have been 
demonstrated to have substantial clinical effect in patients with metastatic melanoma, renal 
cell carcinoma, NSCLC, and other tumours. Moreover, preliminary findings raise the possibility 
that PD1 blockade might be less toxic than ipilimumab, although more detailed testing is still 
required (Topalian et al., 2012). 
Other immune checkpoints that are currently being explored are lymphocyte 
activation gene 3 (LAG3; also known as CD223), 2B4 (also known as CD244), B and T lympho-
cyte attenuator (BTLA; also known as CD272), T cell membrane protein 3 (TIM3; also known as 
HAVcr2), adenosine A2a receptor (A2aR), and the family of killer inhibitory receptors. These 
molecules have all been associated with lymphocyte activity inhibition, and in some cases, the 
induction of lymphocyte anergy (Pardoll, 2012). 
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Figure 8. Immune checkpoint mechanisms of producing T cell anergy. a) Cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4, also known as CD152) mechanisms of action in T cell response and; b) 
programmed cell death 1 (PD1) pathway activity on the surface of T cells. Reproduced from Pardoll, 
2012. 
3.2. IMMUNOREGULATORY CELLS 
The contribution of stroma cells in the immunescape, which has been intensively 
studied over the last decade, is represented by its rapid recruitment, expansion, and activation 
of various lymphoid and myeloid origin immunosuppressive cells in the tumour 
microenvironment including Tregs, tumour-associated M2 macrophages, and MDSCs. 
3.2.1. REGULATORY T CELLS 
Tregs are vital for keeping the immune system in check, helping to avoid immune-
mediated pathologies and unrestricted expansion of effector T cell populations. Tregs have 
been the focus of extensive research over the past few years, which have revealed diverse 
roles for these cells in numerous pathologies, including autoimmunity, allergy, microbial 
infection, and cancer. Defects in Treg cell function are an important factor in the development 
of autoimmunity or in the failure to control immunopathology, whereas overactive Treg cell 
function may contribute to the suppression of tumour immunity. 
In 1995, a subset of CD4+ T cells which constitutively express high amounts of IL2 
receptor α-chain (CD25), and which were highly enriched in suppressor activity, were 
identified and termed regulatory T cells (Sakaguchi et al., 1995). CD25 was intended to be used 
as a Treg marker because it allowed their identification for functional analysis following their 
Introduction 
25 
 
isolation from non-immune animals; however, it soon became clear that its utility was limited 
because all activated T cells present CD25 upregulation.  
The biology of Tregs was better understood after the identification and study of 
mutations in the X-chromosome encoded transcription factor FOXP3 (forkhead box P3) in mice 
and in human IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked) 
syndrome patients. Mice and humans with a loss-of-function mutation in the FOXP3 gene are 
afflicted with a fatal, early-onset, T cell-dependent, lymphoproliferative, immune-mediated 
disorder. Interestingly, the disease only affects hemizygous mutant males, because in females 
random X-chromosome inactivation ensures that some T cells express a wild-type FOXP3 allele 
(Bennett et al., 2001; Brunkow et al., 2001). After this discovery, different laboratories 
assessed the stable expression of FOXP3 in mouse CD25+CD4+ Tregs, but not in naïve CD25-
CD4+ T cells or inactivated CD4+ T cells (Hori et al., 2003). 
Initially, it was thought that Tregs were a unique entity that originate in the thymus, 
but this assumption changed with the revelation that naïve CD4+ T cells can be differentiated 
to become FOXP3+ T cells. It is now accepted that the Treg population comprises various 
subsets (Figure 9), those derived from the thymus (or natural Tregs) and those produced in the 
periphery (or induced Tregs). Interestingly, TGFβR signalling appears to be required for most, if 
not all, FOXP3 induction in peripheral CD4+ T cells (Selvaraj and Geiger, 2007). 
a) TRANSCRIPTIONAL CONTROL OF REGULATORY T CELLS: FOXP3 
Extensive studies in mice and humans have revealed the critical importance of FOXP3 
as a master regulator of Treg development and function. The FOXP3 gene, which is highly 
conserved, is located on the X chromosome at Xp11.23 and is subject to X chromosome 
inactivation. The gene contains 11 coding and 3 non-coding exons (Bennett et al., 2001). 
FOXP3 directly or indirectly controls hundreds of genes (approximately 700) and directly binds 
to about 10% of them, acting as an activator or suppressor of their expression (Zheng et al., 
2007). 
FOXP3 dimerises with nuclear factor of activated T cells (NF-AT) leading to suppression 
of IL2, IL4, and IFNγ expression, while inducing CD25, CTLA4, and glucocorticoid-induced TNF 
receptor family-related gene/protein (GITR), among others (Wu et al., 2006). Analysis of the 
transcriptional signatures and functional characteristics of cells expressing either null or 
functional FOXP3 reporter alleles further highlighted some of the features of Tregs: high CD25 
and CTLA4 expression and diminished IL7Ra and immune response-promoting cytokine 
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expression are conferred upon these precursor cells prior to FOXP3 expression, most likely by 
TCR and cytokine signalling, but FOXP3 exaggerates this pre-existing pattern and makes it 
permanent (Zheng et al., 2007). Although FOXP3 is presently considered the most reliable 
(intracellular) phenotypic marker for Tregs, major concerns arose when it became evident that 
FOXP3 expression could be transiently induced in CD4+ and CD8+ effector T cells upon 
stimulation, albeit at lower levels (Roncador et al., 2005). 
 
Figure 9. Differentiation of thymic and induced Tregs. Most FOXP3
+
 thymic Tregs (tTregs) differentiate 
from FOXP3
- 
CD4
+
 thymocytes. The process of tTreg cell differentiation requires strong T cell receptor 
(TCR) stimulation by the self-peptide-MHC complexes presented by thymic epithelial cells (TECs) or 
dendritic cells (DCs); CD28 signalling induced by the CD80 and CD86 ligands expressed on antigen-
presenting cells; and high-affinity IL2 receptor, and other γc cytokine receptor signalling. Foxp3
+
 Tregs 
can also be induced from peripheral naive CD4
+
 T cells (iTregs). In this case, the conditions favouring the 
peripheral induction of FOXP3 include: chronic low-dose antigen stimulation under tolerating 
conditions, suboptimal co-stimulation, and the presence of the immunomodulatory cytokine TGFβ, 
which plays a very important role in this process. Additionally, IL2 and the vitamin A metabolite retinoic 
acid (RA) facilitate the induction of FOXP3 in peripheral naïve CD4
+
 T cells. Reproduced from Josefowicz 
and Rudensky, 2009. 
Although FOXP3 plays a key role in Treg cell development and function, other 
molecular mechanisms are also necessary. Genome-wide comparison of DNA methylation 
status in conventional T cells and Tregs demonstrated that the presence of Treg-specific DNA 
hypomethylation in the genes associated with Treg function is also essential, more specifically, 
a pattern conserved in a non-coding region in the FOXP3 locus, known as CNS2 (Ohkura et al., 
2012). Furthermore, proteomic analysis in Treg cells indicates that FOXP3 forms complexes 
with other factors, including Helios, X-box binding protein 1 (Xbp1), Eos, and GATA-binding 
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factor 1 (GATA1), to activate the expression of most of the genes associated with the Treg-cell 
signature (Fu et al., 2012). Altogether, these findings suggest that the generation of functional 
Tregs requires more than just FOXP3 expression. However, stable expression of this 
transcription factor is critical in Treg development (Josefowicz and Rudensky, 2009). 
b) MOLECULAR MECHANISMS OF REGULATORY T CELL SUPPRESSION 
Defining the mechanisms of Treg function is clearly of crucial importance in order to 
understand their pivotal role in the immune system. From a functional perspective, the various 
potential suppression mechanisms of Treg cells can be grouped into four basic modes of action 
(Vignali et al., 2008): 1) suppression by the release of inhibitory cytokines such as IL10, TGFβ, 
and IL35; 2) induction of cytolysis through the expression of granzyme A and B, which can kill 
either responder T cells or APCs; 3) suppression by metabolic disruption produced by the high 
levels of IL2R expression on Treg cells that deprive effector T cells of IL2, and inhibits their 
proliferation; 4) suppression by targeting DCs, via expression of CTLA4 which binds CD80 
and/or CD86 on DCs, thus inhibiting their maturation and proper function. Tregs could also 
condition DCs to express IDO, which induces the catabolism of tryptophan into pro-apoptotic 
metabolites, resulting in the suppression of effector T cells. Finally, Tregs can also express 
LAG3 which binds to MHC class II molecules, suppressing DC maturation as well as their 
immunostimulatory capacity. 
c) REGULATORY T CELLS IN CANCER 
Shortly after the publication of evidence for the existence of CD4+CD25high Tregs in the 
peripheral blood of healthy individuals (Baecher-Allan et al., 2001), Carl June’s group reported 
the presence of these cells in patients with epithelial malignancies, in particular ovarian and 
NSCLCs. They observed increased levels of CD4+CD25high Tregs in the circulation and also within 
the tumour infiltrating lymphocytes. Upon identification of FOXP3 as a more reliable Treg 
marker, it was demonstrated that CD4+CD25highFOXP3high Tregs were present in the peripheral 
blood, malignant ascites, tumoural tissue, and draining lymph nodes (LNs) of ovarian cancer 
patients. They proposed that the accumulation of these cells was due to the presence of the 
chemokine CCL22, which is secreted by ovarian cancer cells and TAMs, and which binds to the 
CCR4 expressed on Tregs (Curiel et al., 2004). 
Different mechanisms driving Treg cell accumulation within tumours have been 
described. First, it was suggested that Tregs have an enhanced capacity for infiltrating the 
tumour by migration from lymphoid and non-lymphoid organs, mediated by the coordinated 
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action of chemokines secreted by the tumour and their cognate receptors expressed on T cells, 
such as CCL22/CCR4, CXCL12/CXCR4, and CCL5/CCR5 (Oleinika et al., 2013). A second 
mechanism could be through expansion of Tregs within the tumour due to the presence of IL2 
released by effector T cells (Quezada et al., 2011). A third mechanism is the de novo 
conversion of FOXP3– T cells into Tregs due to tumour-cell derived TGFβ (Chen et al., 2003). 
The presence of FOXP3+ lymphocytes has been associated with a poor prognosis in 
cohorts of patients affected by different types of tumours, including ovarian (Curiel et al., 
2004), breast (Bates et al., 2006), NSCLC (Petersen et al., 2006), hepatocellular (Gao et al., 
2007), renal (Griffiths et al., 2007), pancreatic (Hiraoka et al., 2006b), and gastric cancer 
(Perrone et al., 2008). In line with these results, it has been shown that the clinical response to 
chemotherapies is often associated with a reduction in Tregs and the recruitment of 
intratumoural CD8+ T cells in breast cancer (Ladoire et al., 2008). On the contrary, it has been 
reported that intratumoural Treg infiltration in head and neck cancer tumours was correlated 
with better locoregional control and a good prognosis (Badoual et al., 2006; Bron et al., 2013); 
the latter was also observed in colorectal carcinoma (Salama et al., 2009) and bladder cancer 
(Winerdal et al., 2011). Various factors might explain these discrepancies: 1) the fact that 
although Tregs can potentially suppress antitumour immunity and therefore promote cancer 
progression, they also have the ability to dampen inflammation thereby reducing cancer 
progression (Banerjee et al., 2013); 2) the functional heterogeneity displayed by intratumoural 
Tregs depends on the factors they released and their activation markers (Kryczek et al., 2011); 
3) the accumulation of Tregs may reflect the overall level of tumour infiltration by immune 
cells, including effector T cells; 4) the imperfect markers used to phenotype suppressive cells 
or technical differences; and 5) the fact that tumours have different phenotypes, grow in 
different organs, and are associated with unique host factors and, therefore, have unique 
microenvironments (Fridman et al., 2012). Since the relative contribution of different Treg 
populations in tumour immunity and in blocking tumour-associated inflammation is still 
unclear, a key question that arises out of recent work is whether Tregs directly influence 
cancer development and progression, or if they are merely a prognostic feature of malignancy 
(Banerjee et al., 2013). 
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3.2.2. MYELOID-DERIVED SUPPRESSOR CELLS 
Myeloid cells are the most abundant haematopoietic cells in the human body and have 
diverse functions. The three groups of terminally differentiated myeloid cells are macrophages, 
DCs, and granulocytes, which are essential for the normal functions of the innate and adaptive 
immune systems. However, in cancer, myeloid cell differentiation is diverted from its normal 
pathway towards the differentiation of pathological MDSCs. These are immature myeloid cells 
that fail to complete their differentiation under the chronic inflammatory conditions that are 
typical in the tumour microenvironment. These cells impair immunosuppressive functions that 
allow them to efficiently inhibit T-cell mediated anti-tumour reactivity (Ostrand-Rosenberg and 
Sinha, 2009).  
In mice, MDSCs express the Gr1 and CD11b surface markers; the human counterparts of 
these markers are CD97 and ITGAM respectively. They consist of two major subsets: 
granulocytic CD11b+Ly6G+Ly6Clow (G-MDSCs) and monocytic CD11b+Ly6G+/−Ly6Chigh cells (M-
MDSCs) which may differ in their immunosuppressive mechanisms. However, the human 
counterpart situation is much more complicated: The same two subsets can be distinguished 
as Lin−HLA-DR−CD33+ or CD11b+CD14−CD15+ for granulocytic cells and CD14+HLA-DR-/low or 
CD11b+CD14+HLA-DR-/low for monocytic cells (Gabrilovich and Nagaraj, 2009). MDSCs derived 
from bone marrow haematopoietic precursors due to alteration of myelopoiesis by chronic 
inflammatory mediators such as the STAT family of factors (STAT3, STAT6, and STAT1), NF-κB, 
and S100 calcium-binding protein A8. These factors induce strong activation of inducible nitric 
oxide synthase (iNOS) and arginase (ARG)-1, the upregulated production of TGFβ, and the 
expression of cyclin D1, MYC, and survivin (Sonda et al., 2011). 
a) THE MOLECULAR MECHANISMS OF MYELOID-DERIVED SUPPRESSOR 
CELL SUPPRESSION 
 The immunosuppression mechanisms used by MDSCs in tumours are: 1) production of 
nitric oxide (NO) and ROS that produce T cell apoptosis; 2) nitration of chemokines and TCRs, 
thus blocking T cell migration and tumour cell killing; 3) induction of the expression of TGFβ1 
on cell membranes, stimulating anergy of immune effector cells; 4) deprivation of arginine and 
cysteine which are needed for multiple T cell functions; 5) reduction of T cell migration to the 
lymph nodes via the downregulation of L-selectin; and 6) downregulation of TCR ζ-chain 
expression, thus disabling the transmission of activation signals from the cell membrane by T 
cells (Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009). Furthermore, it has 
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also been observed that MDSCs produce NO that is accumulated in the tumour 
microenvironment and stimulates the development of tumour cell chemo resistance by 
inactivation of the caspase cascade (Sebens et al., 2007). Thus, MDSCs play a critical role in the 
development of an immunosuppressive tumour microenvironment. 
b) MDSCS AND CANCER 
It has been reported that chronic inflammatory mediators strongly stimulate MDSC 
expansion, migration into tumour lesions, and their immunosuppressive response. These 
mediators include IL1β, IL4, IL5, IL6, IL10, IL13, TNFα, IFNγ, VEGF, TGFβ, granulocyte-
macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-
CSF), CCL2, CCL4, CCL5, CXCL1, CXCL8, CXCL12, cyclooxygenase-2 (prostaglandin synthase-2; 
COX2), and PGE2 (Gabrilovich et al., 2012). The pattern of mediators involved in MDSC 
recruitment to the tumour seems to be dependent on the tumour type, and is likely specific 
for the particular MDSC subset (Figure 10). It has been reported that the recruitment of the 
monocytic subset occurs via an interaction between CCL2 and its receptors CCR2, CCR4, and 
CCR5. However, migration of the granulocytic subset has been observed to be regulated by 
enhanced CXCR2 ligand production in the tumour milieu (Lesokhin et al., 2012). 
While some aberrant myeloid populations can be detected in virtually every cancer 
type that has been studied, the heterogeneity of MDSCs in human malignancies is striking. To 
characterise them, most researchers agree on general myeloid markers such as CD33 and 
CD11b, but the human MDSC phenotypes described range from CD34+ or Lin-DR-CD33+ myeloid 
precursors to CD15+ granulocyte-like cells and cells resembling monocytes [CD14+ human 
leukocyte antigen-DR [HLA-DR]-/low] (Poschke et al., 2011). It has been observed that levels of 
peripherally circulating CD11b+CD33+HLA-DR-Lin1-/low MDSCs correlate with the clinical stage in 
breast cancer and gastrointestinal malignancies. Moreover, therapy with cytotoxic agents can 
further increase the burden of circulating MDSCs, indicating that these cells might play a role 
in treatment failure (Diaz-Montero et al., 2009). Furthermore, in patients with gastrointestinal 
malignancies CD15+MDSC levels correlated with elevated IL6 plasma levels whereas the CD15- 
MDSC subset revealed a strong correlation with IL10 (Mundy-Bosse et al., 2011). Similarly, 
elevated levels of CD11b+CD33+HLA-DR-Lin1-/low MDSCs may represent an independent 
prognostic factor in pancreatic, oesophageal, and gastric cancers, which also correlates with 
increased Treg numbers, and an increased risk of death (Gabitass et al., 2011).  
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Figure 10. Mechanisms of MDSC-mediated immune suppression in peripheral lymphoid organs and at 
the site of a tumour. a) In peripheral lymphoid organs, MDSCs produce high levels of reactive oxygen 
species (ROS), including peroxynitrite (ONOO-), and upregulate signal transducer and activator of 
transcription 3 (STAT3) activity. This is associated with a moderate increase in arginase 1 (ARG-1) activity 
and low levels of nitric oxide (NO) production. MDSCs can take up, process, and present antigens to 
antigen-specific CD8
+
 T cells, which causes these T cells to become unresponsive to antigen-specific 
stimulation. b) In contrast, MDSCs that migrate to the tumour site upregulate STAT1 activity, and 
produce high levels of inducible nitric oxide synthase (iNOS), NO, and arginase 1; this is associated with 
low levels of ROS. The high levels of ARG-1 and NO that are released by MDSCs inhibit CD8
+
 T-cell 
function in a non-specific manner. MDSCs at the tumour site can also differentiate into tumour-
associated macrophages (TAMs). Reproduced from Gabrilovich and Nagaraj, 2009. 
3.2.3. TUMOUR-ASSOCIATED MACROPHAGES 
Macrophages display phenotypic plasticity, and therefore, they are able to perform 
and participate in a diverse range of functions such as inflammation, tissue remodelling, 
antimicrobial activity, immunoregulation, and tumour promotion, depending on the signals 
they receive from their microenvironment. Macrophages have two main phenotypes: classical 
activation that is promoted by microbial stimuli like lipopolysaccharides (LPS) and Th1 
cytokines including IFNγ; and the alternative activation drive by Th2 cytokines such as IL4 and 
IL13. It has also been proposed that macrophages could be classified into M1 or M2, 
corresponding to their Th1 and Th2 responses. A polarised macrophage phenotype that has 
received a great deal of attention in the literature is the tumour-associated macrophages 
which are often considered to be synonymous with M2 macrophages (Figure 11; Lawrence and 
Natoli, 2011). 
Different mechanisms have been postulated for the differentiation of blood monocytes 
into TAMS, including the abundant release of colony stimulating factor 1 (CSF1) by tumours 
and their surrounding stroma. IL34, a ligand for CSF1R, was recently shown to be expressed by 
breast carcinoma epithelial cells following cytotoxic therapy and was also implicated in TAM 
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recruitment (DeNardo et al., 2011). Early studies linked the origin of TAMs to “tumour-derived 
chemotactic factors” (later characterised as CCL2), which recruit these cells to tumour tissues. 
In fact, studies using overexpression of CCL2 and transgenic modulation of CSF1 (using CSF1R 
knockouts or siRNA) indicated a functional relationship between macrophage infiltration and 
tumour progression (Aharinejad et al., 2007). Other chemokines, such as CCL3, CCL4, CCL5, 
CCL7, CCL8, CXCL12, VEGF, platelet-derived growth factor (PDGF), and IL10, are also reported 
to promote macrophage recruitment  to the tumour microenvironment (Murdoch et al., 2004). 
 
Figure 11. The yin-yang of myelomonocytic cells in tumour progression. Myelomonocytic cells can have 
either beneficial or pathological roles in cancer depending on the cellular and tissue environment. Red, 
M1 polarisation; green, M2 or M2-like polarisation; red and green shading, functional outputs for M1 
and M2 macrophages, respectively; black lettering in cells, salient features of M1 and M2 macrophages; 
arrows, crosstalk between macrophage and lymphoid cells. TAM, tumour associated macrophage. 
Reproduced from Biswas et al., 2010. 
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a) THE MOLECULAR MECHANISMS OF TUMOUR-ASSOCIATED 
MACROPHAGES 
Since the formal demonstration in the 1970s, by isolation and transplantation, that 
TAMs are bona fide host cells rather than cancer cells in disguise, considerable progress has 
been made in defining their function and significance in tumours. It has been demonstrated 
that macrophages promote cancer-related inflammation through the release of inflammatory 
mediators like TNF, IL6, and IL1β and they are believed to mediate DNA damage, oncogenic 
transformation, and cancer-cell survival. They also facilitate angiogenesis, invasion, and 
metastasis by the expression of a variety of pro-angiogenic factors such as VEGFA, epidermal 
growth factor (EGF), and CXCL8. Furthermore, TAMs also seem to interact with cancer stem 
cells (Biswas et al., 2013).  
Interestingly, TAMs display a pivotal role in immunoregulation. Early on, some studies 
demonstrated that macrophages from tumour-bearing animals often had an 
immunosuppressive phenotype. For example, macrophages from different murine tumours 
(such as mammary carcinoma, chemically induced fibrosarcoma, ovarian carcinoma, and Lewis 
lung carcinoma) expressed reduced levels of the pro-inflammatory cytokine IL12, while 
displaying elevated expression of the anti-inflammatory cytokine IL10 (Torroella-Kouri et al., 
2005). It has also been suggested that the IL12low/IL10high characteristic of TAMs, together with 
the upregulation of TGFβ and CCL22, alter T-cell response in favour of the tumour. Various Th2 
cytokines like IL4, IL13, and IL10 polarise TAMs into a M2-like phenotype, as for example, in 
the mammary carcinoma model (DeNardo et al., 2011). It is also interesting that IL10 derived 
from tumour-infiltrating Tregs may trigger PDL1 activation on TAMs which favours the 
inhibition of tumour-specific T-cell immunity (Kuang et al., 2009). 
b) TUMOUR-ASSOCIATED MACROPHAGES: CLINICAL VALUE IN CANCER 
Some evidence from epidemiological studies support the role of TAMs in human 
cancer, showing that an increased number of TAMs correlated with poor prognosis in many 
cancers such breast, bladder, and prostate, but not in others like gastric and colon cancer. 
Most of these studies were performed using macrophage markers like CD68 and CD163 in 
human sections (Biswas et al., 2013). A macrophage-specific gene signature and the presence 
of CD68+ TAMs have also been reported to predict treatment outcome in classic Hodgkin’s 
Lymphoma (Steidl et al., 2010). A recent meta-analysis summarised the current prognostic 
value of the presence of macrophages, which was associated with decreased survival in 
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endometrial, prostate, urothelial bladder, ovary, gastric, and oral carcinomas. Interestingly, 
TAM infiltration was associated with improved OS in colorectal cancer patients (Zhang et al., 
2012). 
In lung cancer a significant portion of the available evidence points to a positive 
correlation between TAM infiltration and a good prognosis. In a study in patients with resected 
NSCLCs, an increased tumour islet CD68+ macrophage density and tumour islet/stromal 
macrophage ratio were significant independent predictors of increased survival (Welsh et al., 
2005). On the other hand, substantial evidence correlating TAMs with poor prognosis in 
human lung cancer also exists. For instance, Takanami et al. found significantly lower 5-year 
survival rates in ADC patients with high CD68+ TAM densities (Takanami et al., 1999). This work 
was furthered by Chen et al. who found that CD68+ TAM density correlated positively with 
tumour IL8 mRNA expression and intratumour microvessel counts, but negatively with 
prognosis in patients with NSCLC (Chen et al., 2005).  
4. BIOMARKERS 
According to the National Cancer Institute (NCI), a biomarker is “a biological molecule 
found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or 
of a condition or disease”. There are a tremendous variety of biomarkers, which can include 
proteins, nucleic acids, antibodies, and peptides, among other categories. Furthermore, a 
biomarker can be a set of alterations, such as gene expression profiles, proteomics, and 
metabolomic signatures. There are different types of biomarkers: 1) diagnostic biomarkers, 
which can be used to screen or detect otherwise healthy patients for malignancy; 2) prognostic 
biomarkers, which determine the outcome of the disease independently of treatment; and 3) 
predictive biomarkers which determine which treatment is likely to be most effective or, in 
other words the likelihood of response to a specific treatment. 
Traditionally, the clinicopathological characteristics of a tumour have been used to 
assess prognosis. The search for a prognostic and predictive biomarker has to take two key 
points into consideration: the strength of evidence to support its use and the depth of 
information provided by a biomarker which adds to what is already known about the disease 
based on clinical parameters. For instance, there are a number of gene expression signatures, 
which have been developed in breast cancer that can be used to estimate prognosis for an 
individual patient (Van't Veer et al., 2005). On the other hand, an example of predictive 
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biomarkers is the determination of KRAS mutations in colorectal cancer, which correlates to 
poor responses to EGFR TKI treatments (Allegra et al., 2009). 
Over the last decade, a large amount of research has been performed in order to 
discover and validate biomarkers in NSCLC. Some results from these studies have been 
adopted in current clinical practice, although a plethora of potential biomarkers could have not 
yet been validated. Among these validated biomarkers, is the activation EGFR mutations, 
which have become predictive biomarkers for TKI therapy (Paez et al., 2004), or the presence 
of ALK translocations, which are predictive biomarkers for ALK inhibitor therapy (Peters et al., 
2013). Apart from these, there are several potential biomarkers still being researched which 
have been proposed as possible tools for the future management of NSCLC, especially early-
stage NSCLC. The tumour suppressor gene p53, which is frequently altered in NSCLC patients, 
is a well-established poor-prognosis biomarker in many tumours, although its prognostic role 
in NSCLC is still controversial (Graziano et al., 2010). The prognostic significance of KRAS also 
remains controversial due to discrepancies in the results reported so far. Some studies seem to 
show that KRAS mutations, especially at codon 12, are associated with worse progression free 
survival (PFS) and OS (Vega et al., 1996), while others claim that the presence or absence of 
mutations in codon 12 of KRAS do not confer a survival disadvantage (Shepherd et al., 2013). 
Other individual biomarkers that have been suggested as prognostic or predictive biomarkers 
in NSCLC are Her2, excision repair cross-complementation group 1 (ERCC1), ribonucleotide 
reductase M1 (RRM1), and breast cancer 1 (BRCA; Burotto et al., 2014). 
However, not only individual markers but also gene signatures have been postulated 
as useful biomarkers in NSCLC. Several authors have attempted to identify prognostic gene 
signatures based on gene expression levels by using several platforms such as microarrays and 
quantitative real time PCR (RTqPCR). For instance, Chen et al. identified a five-gene signature 
associated with an increased risk of death (Chen et al., 2007) and, more recently, Kratz et al. 
reported a 14-gene prognostic signature using RTqPCR in a large cohort of non-squamous 
NSCLCs (Kratz et al., 2012). Our group has recently reported a gene expression signature 
comprising the combination of three angiogenic factors (VEGFA/VEGFB/VEGFD) which is 
associated with a worse outcome and which was an independent prognostic biomarker in 
resectable NSCLCs (Sanmartin et al., 2014). 
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4.1. IMMUNE SYSTEM-RELATED BIOMARKERS IN LUNG CANCER 
In NSCLC several attempts have been made to evaluate the prognostic and predictive 
role of immune microenvironment markers. Furthermore, they have acquired special 
importance due to the increasingly important role of immunotherapeutic approaches in the 
treatment of solid tumours. 
Previous studies have demonstrated the prognostic importance of tumour infiltrating 
cells and their location. On one hand, it has been observed that the presence of antitumour 
cells such as CD4+ and CD8+ T lymphocytes and M1 macrophages predict prolonged patient 
survival (Al-Shibli et al., 2008). On the other, the presence of immunoregulatory cells such as 
Tregs, MDSCs, and TAMs has generally been associated with poor clinical outcome, although 
there are discrepancies between the different studies. For instance, patients with tumours 
infiltrated by three or more Tregs in 10 high-power fields (HPF) have significantly worse 
recurrence-free survival (RFS), especially in stages I and II of the disease (Shimizu et al., 2010). 
Regulatory signals through molecules like CTLA4 and PD1/PDL1 are also of great importance; in 
fact, CTLA4 overexpression has been reported to be an independent favourable prognostic 
factor (Salvi et al., 2012). As for PDL1, Velcheti et al. have recently demonstrated that the 
expression of PDL1 was associated with better OS independently of other factors (Velcheti et 
al., 2014). 
Altogether, the data obtained so far indicates that immune system-related biomarkers, 
and more specifically those involved in immunoregulation, may become useful in the 
development of the next generation of prognostic and predictive biomarkers in NSCLC. 
Therefore it is important to continue searching for, studying, and validating new 
immunoregulation biomarkers using feasible techniques such as RTqPCR and 
immunohistochemistry (IHC), before these biomarkers can become useful oncological clinical 
tools. 
  
 
 
 
 
 
 
 
 
 
 
II. OBJECTIVES 
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NSCLC is a heterogeneous and etiopathologically complex disease. Five-year survival 
remains poor, mainly because these tumours may have already developed regional or distant 
metastases at the time of diagnosis. Moreover, these patients have strikingly different 
outcomes which highlight the importance of establishing new prognostic biomarkers that 
allow better patient stratification. Given that we are now in the era of precision oncology, the 
objective of this thesis is to find new immunoregulatory biomarkers that could provide 
relevant information on the immunological features of the tumour microenvironment and 
their possible clinical translation in NSCLC. 
The specific aims of this study are: 
1. To analyse biomarkers related to immunoregulation by performing RTqPCR on tumour 
samples from resected NSCLCs. 
2. To determine the presence of infiltrating CD4+, CD8+, and FOXP3+ lymphocytes in the 
tumour and stroma by immunohistochemistry. 
3. To analyse biomarkers related to immunoregulation by performing RTqPCR on blood 
samples from advanced NSCLCs and to determine their diagnostic and prognostic 
value. 
4. To integrate the gene expression analysis with data about the levels of infiltrating 
immune cells to gain new insights into their role in the tumour microenvironment. 
5. To find new immune-related profiles and signatures and to evaluate their possible 
roles as biomarkers for better NSCLC patient stratification. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
III. MATERIALS & 
METHODS 
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1. PATIENTS AND SAMPLES 
1.1. PATIENTS INCLUDED IN THE STUDY 
1.1.1. EARLY STAGE NON-SMALL CELL LUNG CARCINOMA PATIENTS 
In this study 178 patients from Consorcio Hospital General Universitario de Valencia 
and 20 from Hospital Clínico Universitario de Valencia with NSCLC were included between 
2004 and 2013. Patients that met the eligibility criteria had resected non-pre-treated stage I to 
IIIA cancer (according to the American Joint Committee on Cancer staging manual) with a 
histological diagnosis of NSCLC. The study was conducted in accordance with the Declaration 
of Helsinki, and the institutional ethical review board approved the protocol. 
1.1.2. ADVANCED STAGE NON-SMALL CELL LUNG CARCINOMA PATIENTS  
Forty-nine samples from patients enrolled in a multicentre study coordinated by the 
Spanish Lung Cancer Group were retrospectively analysed. The clinical study was carried out 
between February 2003 and January 2005. Eligibility criteria were: the diagnosis of stage IIIB 
disease with pleural effusion or stage IV NSCLC. Patients were treated with cisplatin (75 
mg/m2) and docetaxel (75 mg/m2) on day 1 every 3 weeks and then the objective responses 
were evaluated using the Response Evaluation Criteria for Solid Tumour (RECIST) criteria 
(Therasse et al., 2000). All individuals provided informed consent. The study was conducted in 
accordance with the Declaration of Helsinki and the institutional ethical review board 
approved the protocol. 
1.1.3. CONTROL GROUP 
The control group consisted of 54 anonymous, aged- and gender-matched, healthy 
volunteers without any acute or chronic inflammatory conditions. Control samples were taken 
at the same time points as the patient samples at the Consorcio Hospital General Universitario 
de Valencia. 
1.2. SAMPLES 
A total of 178 pairs of patient tumour and adjacent normal lung tissue specimens were 
obtained at the time of surgery and immediately separated by a pathologist. Tissue samples 
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were preserved in RNALater® (Applied Biosystems, USA) to avoid RNA degradation, and were 
fresh-frozen at -80° C until their analysis. Furthermore, 102 formalin-fixed, paraffin-embedded 
(FFPE) samples from the same cohort of patients were provided by the Pathology Service at 
the Consorcio Hospital General Universitario de Valencia as well as 20 FFPE samples from the 
Pathology Service at the Hospital Clínico Universitario de Valencia. A pathology report was 
available for all the samples, enabling their characterisation. We included the different NSCLC 
histology subtypes in this study.  
Peripheral blood samples (2.5 ml) from 49 advanced stage NSCLC patients and 54 
controls were obtained in PAXgene™ Blood RNA (PreAnalytiX, Switzerland) tubes and were 
stored at -80° C until they were used. These specialised tubes contain an additive that 
stabilises the gene transcription profile by reducing RNA degradation and minimising gene 
induction. Samples from patients enrolled in this multicentre study were obtained on two 
occasions: before the treatment, and after three cycles of chemotherapy with docetaxel and 
cisplatin. 
2. HISTOPATHOLOGICAL METHODS 
The histopathological study was performed using lung tumour tissue fixed in 10% 
formaldehyde and embedded in paraffin. Each FFPE sample was cut with different section 
thicknesses using a Leica RM 2135 Microtome: a) 5 μm sections each for non-treated slides for 
haematoxylin and eosin staining (HE) and for Dako charged slides (Code K8020, Dako, Canada) 
for IHC; and b) 10 μm sections for membrane slides (PEN-Membrane 2.0 μm; Leica, Germany) 
for microdissection. 
2.1. HAEMATOXYLIN AND EOSIN STAINING 
HE staining is the most common staining technique used in histology. Haematoxylin 
stains the nucleus of the cell blue and the eosin stains the cytoplasm pink. HE staining was 
used to assess the morphology of the tissue studied, which enabled for further analysis steps 
as described in the sections below. HE was performed on 5 μm sections for non-treated slides 
and 10 μm sections in membrane-slides. Briefly, deparaffinization was performed by 
incubating the slides at 60° C for 20 minutes and then submerging in xylene. The slides were 
hydrated with ethanol (absolute/96°/80°/70°) and rinsed with water. They were then stained 
with haematoxylin, decolourised with acid chloride, and immersed in lithium carbonate. The 
slides were counterstained with eosin, dehydrated with ethanol (96°/absolute) and cleared 
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with xylene. Finally, the 5μm sections were mounted with a cover using DPX Mountant for 
histology (Sigma, USA), whereas the 10μm sections were left uncovered. 
2.2. LASER-CAPTURE MICRODISSECTION 
Laser-capture microdissection (LCM) was performed in order to separately collect 
tumour and stroma tissue areas from FFPE tumour specimens. For this purpose, a Leica Laser 
Microdissection System LMD6500 was used with the support of a Hitachi HV-D20 camera. This 
system uses a laser to isolate a specific region in the tissue sample and transfers the area of 
interest into devices by gravity (Figure 12). Five micrometre HE sections were used to assess 
the morphology of the tissue, and to visually select the different areas (tumour vs. stroma) to 
be microdissected with the help of the computer. These areas were then translated onto the 
10 μm membrane-slide sections where they were microdissected. An area of at least 1·107 μm2 
was microdissected from the tumour and stroma compartments and collected on the lids of 
separate 0.2 ml tubes containing 30 μl of Digestion Buffer from the RecoverAllTM Total Nucleic 
Acid Isolation Kit for FFPE (Qiagen, Germany). 
 
Figure 12. Representation of the laser capture microdissection and the recollection of the dissected 
areas. 
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2.3. IMMUNOHISTOCHEMISTRY 
IHC is a method that allows the location of proteins (antigens) in tissue sections to be 
identified by the union of specific antibodies. The antibody-antigen interaction is then 
visualised by a chromogenic reaction, in which an enzyme conjugated to the antibody cleaves 
the substrate in order to produce a coloured and insoluble precipitate that can be visualised 
using a microscope. Depending on the system used and the type of tissue samples, the IHC 
technique requires specific optimisation. 
The pivotal reagent common to all IHC techniques is the antibody, which can be 
divided according to clonality: antibodies are either polyclonal or monoclonal. Polyclonal 
antibodies are directed against one antigen, but may bind different epitopes. This type of 
antibody is generated by different B-cell clones in an animal; hence they have slightly different 
specificities and affinities. On the other hand, monoclonal antibodies are homogeneous 
populations of immunoglobulins which are directed against one epitope. They are generated 
by a single B-cell clone from one animal and are therefore immunochemically similar. 
Polyclonal antibodies are more robust in antigen binding because they can identify several 
epitopes of the antigen and consequently false negative results are infrequent. However, 
monoclonal antibodies are more specific, and false positive results are less frequent. 
In this study, the expression of three proteins (FOXP3, CD4, and CD8) was evaluated. 
For this purpose, we used a Dako Autostainer Link 48, which is a compact, bench-top, open 
system that allows decoupled pre-treatment, and in which up to 48 IHC slides can be run at the 
same time. The Dako EnVision™ FLEX detection system was used, which consists of a dextran 
backbone to which a large number of horseradish peroxidase (HRP) molecules and secondary 
antibody molecules have been coupled. This system allows the detection of mouse monoclonal 
antibodies and rabbit polyclonal antibodies. 
2.3.1. IMMUNOHISTOCHEMISTRY PROTOCOL 
One 5µm section on Dako charged slides was analysed for each sample and antibody. 
The protocol, which is explained below, was performed with three different antibodies 
(detailed in Table 2). First, the sections were dried at 60° C for 30 minutes prior to IHC and 
loaded into the PT Link instrument where the antigen retrieval/dewaxing process took place. 
The protocol comprised the following steps: temperature increase to 97° C over a period of 10 
minutes; incubation at 97° C for 20 minutes with high pH EnVision™ FLEX Target Retrieval 
Solution (Dako); cooling for an additional 10 minutes; and, finally, section transfer to an 
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Autostainer Link 48 instrument. The immunostaining was done with Dako FLEX Ready to-Use 
format for CD4 and CD8, and with a primary antibody diluted at 1:300 with Dako Antibody 
Diluent (Dako) for FOXP3. The protocol was the following: incubation with peroxidase blocking 
reagent for 10 minutes; incubation with the primary antibody for 20-30 minutes, incubation in 
the detection system for 20 minutes, and finally incubation with the chromogen (3,3’-
diaminobenzidine, DAB) for 10 minutes. At the end of the run, the slides were flooded with 
distilled water and then manually counterstained with haematoxylin, dehydrated, and 
coverslipped. 
Table 2. Characteristics of the antibodies and conditions used to detect each protein. 
Antigen Antibody type Company and clone Incubation time 
FOXP3 Monoclonal Mouse Abcam, 236A/E7 30 minutes 
CD4 Monoclonal Mouse Dako, 4B12 20 minutes 
CD8 Monoclonal Mouse Dako, C8/144B 20 minutes 
2.3.2. IMMUNOHISTOCHEMISTRY CONTROLS 
As in many other biological experiments, IHC requires positive and negative controls to 
assess the experimental quality. Each run should include at least a positive and a negative 
control. The positive control is usually a section of tissue which expresses the antigen, which is 
fixed and processed in a similar manner to the samples analysed. The negative control refers 
to two possible options: a section treated in the same way as the samples analysed but 
omitting the primary antibody, or a section of a tissue that it is known not to express the 
antigen. 
In this study we included two controls in each run. Human normal tonsil tissue was 
used as a positive control for the three antibodies, as recommended on the data sheets. 
Controls were fixed and processed in the same way as the rest of the samples. As a negative 
control, one of the samples included in the run was duplicated, and one, but not the other, 
was incubated with the primary antibody. 
2.3.3. MICROSCOPE EVALUATION AND SCORING 
The slides were independently examined by one experienced pathologist and one 
investigator, both blinded to the case. Before initiating the scoring, controls were reviewed for 
quality assurance; the compartments for scoring, as well as the semiquantitative scale to be 
used, were defined. First, each sample was semiquantitatively scored for the degree of 
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immune-cell infiltration into the tumour nest and tumour-associated stroma (0 = negative, 1 = 
weak, 2 = intermediate, and 3 = strong). 
To evaluate FOXP3 immunostaining, the percentage of nuclear-stained lymphocytes 
present in tumour and stroma was defined and graded on a scale of 0-3 according to the 
percentage of positive lymphocyte cells: 0 = no staining, 1 = less than 10% positive, 2 = 10-33% 
positive, 3 = 33% or more positive. Furthermore, in 10 tumour and stroma area high power 
fields (HPFs; magnification = X400) the absolute number of FOXP3+ lymphocytes was 
determined and then averaged. CD4+ and CD8+ lymphocytes were also counted in 10 HPFs for 
both tumour and stroma areas and were then averaged.  
3. MOLECULAR BIOLOGY METHODS 
RNA was isolated from fresh-frozen tissue, samples isolated from FFPE slides, and 
peripheral blood in order to further perform gene expression analyses. Additionally, genomic 
DNA was also isolated to assess the most common mutations in lung cancer patients. 
3.1. NUCLEIC ACID ISOLATION 
3.1.1. RNA AND DNA ISOLATION FROM FRESH-FROZEN TISSUE SAMPLES 
RNA and DNA were isolated from 178 tumoural and normal tissue samples using Tri 
Reagent® (Invitrogen, USA) according to the manufacturer’s instructions. Briefly, a piece of 10-
20 mg of tissue was dissected and 1 ml of Tri Reagent® was added. Samples were 
homogenised using TissueLyser (Qiagen) and chloroform was added in order to separate the 
aqueous phase containing the RNA. Isopropanol was used to precipitate the nucleic acids and 
ethanol was used for washing. Messenger RNA was redissolved in nuclease free (NF) water and 
stored at -80° C until further analysis. The DNA interphase was recollected in absolute ethanol 
and was washed first with buffer (10% ethanol/0.1 M sodium citrate) and then with 75% 
ethanol. It was redissolved in NF water and stored at -80° C until further analysis.  
RNA and DNA quantification was performed using a nano-spectrophotometer (Nano 
Drop 2000C, Thermo Fisher Scientific, USA). RNA integrity and size was assessed using an 
Agilent RNA 600 Nano Bioanalyzer with a microfluidics-based platform (Agilent Technologies, 
USA). 
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3.1.2. RNA ISOLATION FROM MICRODISSECTED FORMALIN-FIXED PARAFFIN-
EMBEDDED SAMPLES 
RNA was isolated from the tumour and stroma areas microdissected from FFPE 
sections using the RecoverAllTM Total Nucleic Acid Isolation Kit (Qiagen) following the 
manufacturer’s recommendations. Briefly, samples were incubated with the digestion buffer 
for 3-4 hours at 50° C and then for 15 minutes at 80° C. RNA was purified using ethanol and the 
buffers provided with a glass fibre filter column, followed by DNase treatment for 30 minutes 
at room temperature. RNA was eluted into NF water that had been previously heated to 50° C. 
Finally, the elution was incubated at 70° C for 20 minutes in order to revert the cross-linking 
produced by the formaldehyde. As described above, RNA quantification was performed by 
nano-spectrophotometry and the samples were stored at -80° C until further analysis. 
3.1.3. RNA ISOLATION FROM PERIPHERAL BLOOD 
Peripheral blood was collected in PAXgene™ Blood RNA (PreAnalytiX) tubes. RNA 
isolation from these samples was carried out using the PAXgene™ Blood RNA kit following the 
manufacturer’s recommendations. Briefly, the purification began with a centrifugation step to 
pellet the nucleic acids in the tube. The pellet was then washed and redissolved in NF water 
followed by proteinase k incubation. Ethanol was added to adjust the binding conditions, and 
the lysate was applied to a PAXgene RNA spin column. This column was centrifuged so the RNA 
could selectively bind to a silica membrane and allowing efficient subsequent washing. The 
membrane was also treated with DNase I to remove any bound DNA, and finally the RNA was 
eluted into a buffer and heat-denatured. Again, the RNA was quantified using nano-
spectrophotometry and stored at -80° C until further analysis. 
3.2. DETECTION OF EGFR MUTATIONS 
The theraScreen® EGFR RGQ PCR (Qiagen) kit was used to analyse the EGFR mutations. 
This kit allows 29 somatic mutations in the EGFR gene to be detected in exons 18-21 (Table 3) 
by RTqPCR combined with ARMS® and Scorpions® technology. This method is highly selective 
and, depending on the total amount of DNA present, enables detection of a low percentage of 
the mutant gene in a background of wild-type genomic DNA. 
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Table 3. EGFR mutations detected using theraScreen kit. 
EXON MUTATION 
19 19 deletions* 
20 T790M 
21 L858R 
21 L861Q 
18 G719X (G719S, G719A and G719C)* 
20 S768I 
20 3 insertions * 
* The kit does not distinguish between them. 
Each reaction was performed in 96-well plates with a reaction volume of 12.5 μl 
comprising 9.75 μl reaction mix (primers, probes, dNTPs and reaction buffer containing Cl2Mg), 
0.25 μl Taq DNA Polymerase, and 2.5 μl DNA (2-10 ng/μl) isolated from fresh-frozen lung 
cancer specimens. A positive and negative control (provided by the manufacturer) was 
included in each run. The reaction was performed using a LightCycler 480 II (Roche, 
Switzerland) thermocycler following the conditions in Table 4. 
Table 4. TheraScreen® EGFR RGQ PCR cycling parameters. 
Cycles Time Temperature 
1 15 minutes 95° C 
40 
30 seconds 
60 seconds 
95° C 
60° C 
3.3. DETECTION OF KRAS MUTATIONS 
The analysis of KRAS mutations was carried out using a theraScreen® KRAS Pyro® kit 
(Qiagen). This kit is used for quantitative detection of mutations in codons 12, 13, and 61 of 
the human KRAS gene by pyrosequencing. Codons 12/13 and codon 61 were amplified by PCR 
using 5 μl of template DNA (10 ng of genomic DNA), 12.5 μl of PyroMark® PCR Master Mix 2x, 
2.5 μl of Coral Load Concentrate 10x, 4 μl of NF water, and 1 μl of KRAS 12/13 or 61 PCR 
primers. The reactions took place in a MasterCycler® thermocycler (Eppendorf, Germany) 
following the conditions described in Table 5. 
The amplicons were immobilised on Streptavidin Sepharose® High Performance beads 
to prepare the single-stranded DNA and anneal the sequencing primers to it using a PyroMark 
Q24 plate and a vacuum workstation. PyroMark Gold Q24 reagents (enzyme mixture, substrate 
mixture, and nucleotides) were then prepared and loaded into a cartridge so they could be 
dispensed during the sequencing process. Finally, the plate and the cartridge were loaded into 
the PyroMark Q24 System and the sequencing process was started. The sequences were 
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analysed using software provided by the manufacturer. In each run, two controls were 
included: unmethylated control DNA which worked as a positive control for PCR and 
sequencing reactions, and a negative control (without template DNA). 
Table 5. TheraScreen® KRAS Pyro® PCR cycling parameters. 
Phases Time Temperature 
Initial activation step 15 minutes 95° C 
3-step cycling: 
Denaturation 
Annealing 
Extension 
Number of cycles 
 
20 seconds 
30 seconds 
20 seconds 
42 
 
95°  C 
53° C 
72° C 
Final extension 5 minutes 72° C 
 
This kit allowed the most frequent mutations at codons 12, 13, and 61 to be detected. 
The nucleotide dispensation order for sequencing codons 12/13 was TACGACTCAGATCGTAG, 
and for codon 61 it was GCTCAGTCAGACT. The analysis sequence for codons 12/13 was 
GNTGRCGTAGGC, which allowed the most frequent mutations in codon 12, nucleotide 35 
(second position) to be detected. To analyse if the mutation was present in nucleotide 34 (first 
position), the analysis sequence was changed into NGTGRCGTAGGC. In the case of exon 61, the 
analysis sequence was CTCDTGACCTG, which represents the most frequent mutation in this 
codon, detected in nucleotide 183 (third position). To analyse if the mutation was present in 
nucleotide 182 (second position) the analysis sequence was changed into CTCTHGACCTG, and 
to analyse if it was present in nucleotide 181 (first position), the sequence was CTCTTSACCTG. 
The expected histograms for each sequence are represented in Figure 13. 
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Figure 13. Representation of the histograms for the codons and nucleotides according to the 
sequences for analysis. 
3.4. REVERSE TRANSCRIPTION 
Reverse transcription was performed in order to transform RNA into complementary 
DNA (cDNA), which was required for the subsequent analyses, by using a High Capacity cDNA 
Reverse Transcription Kit® (Applied Biosystems). The total quantity of RNA included in each 
reaction depended on the initial samples and isolated RNA: from fresh-frozen tissue the RNA 
input was of 1000 ng, from microdissected samples it was 100 ng, and from peripheral blood it 
was 500 ng. Each reaction comprised 2 μl of reverse transcription (RT) buffer, 0.8 μl of dNTP 
mix, 2 μl of RT random primers, 1μl MultiScribe™ Reverse Transcriptase, 1μl RNase inhibitor, 
and RNA, made up to a total volume of 20 μl with NF water. The reactions took place in a 
MasterCycler® thermocycler (Eppendorf) following the conditions described in Table 6 and the 
resulting cDNA was stored at -80° C until further analysis. 
Table 6. Cycling program for reverse transcription reaction. 
Phase Time Temperature 
1 10 minutes 25° C 
2 2 hours 37° C 
2 5 seconds 85° C 
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3.5. PREAMPLIFICATION 
Preamplification was performed using a TaqMan® PreAmp Master Mix Kit to increase 
the quantity of specific cDNA targets. This was necessary due to the low initial quantity of RNA 
obtained from microdissected samples and the large number of genes to be analysed. This kit 
enables multiplex preamplification of up to 100 targets at a time and provides unbiased 
amplification. First, a TaqMan assay pool was prepared by mixing 20x TaqMan® Gene 
Expression Assay mix for the genes of interest which were then diluted with 1x Tris-EDTA (TE) 
buffer so that each assay was at a final concentration of 0.2x. Each reaction comprised: 20μl of 
Master Mix PreAmp 2x, 10 μl of assay pool, and 10 μl of sample. Ten preamplification cycles 
were performed and the reaction took place in the MasterCycler® thermocycler (Eppendorf) 
following the cycling conditions described in Table 7. After preamplification, samples were 
diluted 1:5 with 1x TE buffer. 
The uniformity of the preamplification process was assessed in order to check whether 
all the amplicons were amplified uniformly without bias, using preamplified human reference 
cDNA (Clontech®, USA) preamplified and at a concentration of 0.3 ng/μl. A conventional 
RTqPCR run was carried out and used for relative quantification to determine their ΔΔCt values 
between 0.3 ng/μl of cDNA and the preamplified cDNA as follows: 
1. ∆CT (cDNA) = avg. CT (Target X) – avg. CT (Uniformity ref. gene) 
2. ∆CT (Preamp) = avg. CT (Target X) – avg. CT (Uniformity ref. gene) 
3. ∆∆CT = ∆CT (Preamp) – ∆CT (cDNA) 
A ∆∆CT value close to zero indicates adequate preamplification uniformity. Typically, 90% of 
targets produce ∆∆CT values within ± 1.5 of zero. 
Table 7. Cycling program for preamplification reaction. 
Phases Time Temperature 
Enzyme activation 10 minutes 95° C 
Preamplification PCR  
(10 cycles) 
Denature 
Anneal/Extend 
 
 
15 seconds 
4 minutes 
 
 
95° C 
60° C 
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3.6. QUANTITATIVE REAL TIME PCR 
Target gene quantification was performed by RTqPCR using hydrolysis probes labelled 
with a reporter dye linked to the 5’ end of the probe (TaqMan®, Applied Biosystems). This 
system also includes a non-fluorescent quencher (NFQ) at the 3’ end of the probe and a Minor 
Grove Binder (MGB) attached to the NFQ which increases the melting temperature (Tm) 
without increasing the length of the probe (Figure 14). 
In this study we analysed a total of 46 genes that were selected according to their 
relevance to the biology of tumour immunoregulation (Table 8). The relevance of these genes 
was established from a PubMed database search, which revealed published information 
demonstrating or suggesting a role for these genes in normal immune reaction mechanisms 
against tumours, co-stimulatory pathway modulation (also known as immune checkpoints), 
induction and attraction of suppressor cells (such as MDSCs, TAMs, and other APCs), and Tregs.  
Gene expression levels were assessed using TaqMan® Gene Expression Assays (Applied 
Biosystems) which are described in Table 8. Different endogenous gene controls (Table 9) were 
tested in fresh-frozen, microdissected, and peripheral blood samples in order to evaluate the 
best internal control for each case using GeNorm software. This software automatically 
calculates the gene-stability measurement ‘M’ for all control genes and allows the worst-
scoring housekeeping genes to be eliminated (Vandesompele et al., 2002). 
 
Figure 14. TaqMan® qPCR reaction steps (figure reproduced from Life Technologies). 
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Table 8. Genes analysed in this study, their description and TaqMan® assays used for RTqPCR. 
Gen Description Assay 
Amplicon 
length 
CCL2 Chemokine ligand 2 Hs00234140_m1 101 
CCL22 Chemokine ligand 22 Hs99999075_m1 65 
CCL5 Chemokine ligand 5 Hs00174575_m1 63 
CD1C CD1c molecule Hs00233509_m1 71 
CD209 CD209 molecule Hs00253550_m1 83 
CD33 CD33 molecule Hs01076284_m1 79 
CD34 CD34 molecule Hs00156373_m1 63 
CD4 CD4 molecule Hs00181217_m1 60 
CD40 CD40 molecule Hs00386850_m1 64 
CD40LG CD40 ligand Hs00163934_m1 81 
CD44 CD44 molecule Hs01075861_m1 70 
CD80 CD80 molecule Hs99999103_m1 70 
CD86 CD86 molecule Hs01567025_m1 74 
CD8 CD8A molecule Hs00233520_m1 58 
CD97  (TM7LN1) C97 molecule Hs00173542_m1 72 
CLEC4C 
C-type lectin domain family 4, 
member C 
Hs01092462_m1 72 
CSF1R (CD115) 
Colony stimulating factor 1 
receptor 
Hs00911250_m1 74 
CSF3R (CD114) 
Colony stimulating factor 3 
receptor (granulocyte) 
Hs01114427_m1 83 
CTLA4 
Cytotoxic T-lymphocyte-
associated protein 4 
Hs01011591_m1 79 
CXCL12 (SDF-1 ) Chemokine ligand 12 Hs00171022_m1 77 
CXCR4 Chemokine receptor 4 Hs00237052_m1 78 
FOXP3 Forkhead box P3 Hs00203958_m1 64 
IDO1 Indolamine-1 Hs00984148_m1 66 
IFNG Interferon gamma Hs00989291_m1 73 
IL10 Interleukin 10 Hs00961622_m1 74 
IL12B Interleukin 12B (p40) Hs01011518_m1 72 
IL13 Interleukin 13 Hs99999038_m1 68 
IL23A Interleukin 23A Hs00413259_m1 53 
IL2RA (CD25) Interleukin 2 receptor alpha Hs00166229_m1 67 
IL4 Interleukin 4 Hs00174122_m1 70 
IL4R Interleukin 4 receptor alpha Hs00166237_m1 70 
IL7RA (CD127) Interleukin 7 receptor alpha Hs00233682_m1 68 
IL8  (CXCL8) Interleukin 8 Hs99999034_m1 81 
ITGAM (CD11b) 
Integrin, alpha M (complement 
component 3 receptor 3 
subunit) 
Hs00355885_m1 60 
ITGB2 (CD18) 
Integrin, beta 2 (complement 
component 3 receptor 3 and 4 
subunit) 
Hs00164957_m1 76 
LAG3 Lymphocyte-activation gene 3 Hs00158563_m1 60 
LGALS1 (Galectina-1) 
Lectin, galactoside-binding, 
soluble, 1 
Hs00355202_m1 63 
LGALS2 (Galectina-2) 
Lectin, galactoside-binding, 
soluble, 2 
Hs00197810_m1 73 
MMP2 Matrix metallopeptidase 2 Hs01548727_m1 65 
NRP1 Neuropilin 1 Hs00826125_m1 60 
PD1 (PDC1) Programmed cell death 1 Hs01550088_m1 127 
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PDL1 (CD274) Programmed cell death 1 ligand Hs01125301_m1 89 
TGFB1 
Transforming growth factor, 
beta 1 
Hs00171257_m1 63 
THBD Thrombomodulin Hs00264920_s1 91 
TNF Tumour necrosis factor Hs00174128_m1 80 
TNFRSF18 (GITR) 
Tumour necrosis factor receptor 
superfamily, member 18 
Hs00188346_m1 76 
 
Table 9. Endogenous gene TaqMan® assays used to normalisation the results. 
Gen UniGene Description Assay 
Amplicon  
length 
ACTB Hs.520640 Actin, beta Hs01060665_g1 63 
GAPDH Hs.544577 
Glyceraldehyde-3-
phosphate dehydrogenase 
Hs03929097_g1 58 
GUSB Hs.255230 Glucuronidase, beta Hs01558067_m1 71 
HPRT1 Hs.412707 
Hypoxanthine 
phosphoribosyltransferase 1 
Hs01003267_m1 72 
CDKN1B Hs.238990 
Cyclin-dependent kinase 
inhibitor 
Hs00153277_m1 71 
 
Each reaction was performed twice in 384-well plates with a final volume of 5 μl 
comprising: 2.5 μl of TaqMan® Gene Expression Master Mix (Applied Biosystems), 1.25 of NF 
water, 0.25 μl of TaqMan® Gene Expression Assay mix (Applied Biosystems), and 1 μl of cDNA. 
Non-template controls (NTCs) were included in each run, as well as positive reference controls: 
the NCI-H23 cell line from NSCLC (ATCC Number: CRL-5800TM) and T lymphocyte Jurkat cells 
(ATCC Number: TIB-152TM), in addition to a commercially available reference cDNA 
(Clontech). The reactions took place in a 7900HT Fast Real-Time PCR thermocycler system 
(Applied Biosystems) following the cycling conditions described in Table 10. 
The efficiency of each TaqMan® assay was evaluated by carrying out serial dilutions (50 
ng/μl, 5 ng/μl, 0.5 ng/μl, 0.05 ng/μl, and 0.005 ng/μl) using the cDNA as a template. The 
efficiency was calculated by using the following equation: E = 10-1/slope and the results indicated 
that almost all the assays used were adequately efficient (Supplementary Table 1). However, 
the efficiency of IL4 and CLEC4C could not be assessed. 
Table 10. Cycling program for RTqPCR. 
 Step Time Temperature 
Pre-PCR 
UNG incubation 
Taq activation 
2 min 
10 min 
50° C 
95° C 
PCR 
(40 cycles) 
Denature 
Anneal/Extend 
15 sec 
1min 
95° C 
60° C 
The step at 50° C is required for optimal UNG enzyme activity. The step at 95° C is required to activate 
the AmpliTaq Gold enzyme. 
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Relative gene expression levels were expressed as the ratio of target gene expression 
to reference gene expression by using the Pfaffl formula (Pfaffl, 2001). Relative quantification 
determines the changes in steady-state mRNA levels of a target gene across multiple samples 
and expresses it relative to the levels of control RNA. The expression is normalised against a 
reference gene, which is often a housekeeping gene. 
3.7. DATA ANALYSIS 
Non-supervised hierarchical analysis was carried out with Cluster software (version 
3.0) and visualised with Tree View software version 1.0.6 which can be found at 
http://rana.lbl.gov/EisenSoftware.htm (Eisen et al., 1998). All analyses were carried out on 
normalised and log2-transformed dataset values. Uncentered correlation was used as the 
similarity metric and average linkage was used as the clustering method. 
First, we evaluated if the variables followed a normal distribution by using the 
Kolmogorov-Smirnov test. Because the variables did not follow a normal distribution, statistical 
analyses were conducted by nonparametric tests. Continuous variables were compared using 
non-parametric Mann Whitney U and Kruskall Wallis tests. Spearman’s rank was used to test 
for correlations between continuous variables, and associations between dichotomised 
variables were evaluated using the Chi-square test. In order to represent gene expression data 
in a heat-map we used Genesis software [Institute for Genomics and Bioinformatics, Gratz, 
Austria] (Sturn et al., 2002). 
The performance of each parameter (i.e. its ability to predict the disease vs. control 
status) was evaluated using a receiver operating characteristic (ROC) curve, and the area under 
the curve (AUC) was measured. Differences between ROC curves were estimated according to 
De Long methods (DeLong et al., 1988). Confidence intervals for the AUC were calculated 
according to Hanley and McNeil (Hanley and McNeil, 1982). The best cut-off value was 
selected using the Youden index. 
OS and PFS were calculated from the date of surgery to the end point of the study or 
to the last recorded follow-up and patient progression was assessed following the Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria (Therasse et al., 2000). The survival 
analysis was performed using a univariate Cox regression method using clinicopathological 
variables and dichotomised gene expression markers. Survival curves were created using the 
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Kaplan-Meier method, and the statistical significance between survival curves was assessed 
using the log-rank test. 
Combined markers were also analysed in order to find expression profiles with a 
prognostic value. The combinations were performed according to the biological functions of 
the genes analysed or the processes in which their products are involved. The markers were 
combined in order to interrogate their possible prognostic value, even though these markers 
did not significantly independently correlate with survival rates.  
Furthermore, we also calculated the gene expression scores based on multi-gene 
signatures, which can provide more accurate predictions than a model, using single genes. For 
this purpose, we constructed a gene expression score using a method previously reported by 
Lossos et al. (Lossos et al., 2004). All the genes analysed were included, and expression values 
were introduced as continuous variables. First, univariate COX regression analysis was 
performed to identify which genes were moderately associated with OS, which were those 
that had a |Z-score| higher than 1.5 (p < 0.13). Z-scores are defined as the regression 
coefficient (b) obtained from univariate Cox regression, divided by their standard error. The 
selected genes were included in a multivariate model and regression coefficients from this 
model were multiplied by the gene expression values and summed to build the expression 
score. For multivariate regression models, missing values for genes were replaced with the 
average values (Schetter et al., 2009). 
Finally, to assess the independent value of the tested biomarkers, a Cox proportional 
hazard model for multivariate analyses was used. All significant variables (both biomarker and 
clinicopathological markers) from the univariate analyses were entered into the multivariate 
analyses in a forward stepwise Cox regression analysis.  
A p < 0.05 was considered statistically significant for all analyses. The statistical 
analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 
15.0 (Chicago, IL). Finally, GraphPad Prism v5.0 (GraphPad Software Inc.) was used in order to 
build some of the graphics presented here.  
 
  
 
 
 
 
 
 
 
 
 
 
IV. RESULTS & 
DISCUSSION 
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STUDY I: BIOMARKERS IN RESECTED NON-SMALL CELL LUNG 
CARCINOMAS 
A) IMMUNOREGULATION GENE EXPRESSION BIOMARKERS 
1. ANALYSIS IN FRESH-FROZEN SAMPLES 
The immunoregulatory biomarkers expressed in NSCLC patient biopsies, based on 
mRNA expression levels, were analysed in the tumours and compared with normal lung tissue 
both obtained from surgeries. 
1.1. PATIENT CHARACTERISTICS  
This retrospective study included 178 patients with NSCLCs who underwent resection 
at Consorcio Hospital General Universitario de Valencia. Fresh frozen tumour and adjacent 
normal lung tissue specimens were used. The most relevant demographic and 
clinicopathological characteristics of the cohort are shown in Table 11. The median patient age 
was 65 years [range: 26-85], 86.5% were male, and 47.2% had SCCs. Moreover, 59% of the 
patients were diagnosed at stage I of the disease and 66.3% presented a PS of 0. 
Table 11. Clinicopathological characteristics of the patients included in the study. 
Characteristics N % 
Age at surgery (median, range): 65 [26-85] 
Gender   
Male 154 86.5 
Female 24 13.5 
Stage   
I 105 59 
II 35 19.7 
IIIA 38 21.3 
Histology   
SCC 84 47.2 
ADC 74 41.6 
Others 20 11.2 
Performance Status   
0 118 66.3 
1-2 60 33.7 
Differentiation grade   
Poor 43 24.2 
Moderate 77 43.3 
Well 31 17.4 
NS 27 15.2 
Smoking Status   
Current 86 48.3 
Former 72 40.4 
Never 20 11.3 
ADC, adenocarcinoma; SCC, squamous cell carcinoma; NS, not specified. 
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1.1.1.  EGFR AND KRAS MUTATIONAL ANALYSIS 
KRAS mutational analysis was performed in 173 patients; 151 (87.3%) were wild type 
and 22 (12.7%) presented one of the possible mutations. Most of the patients with mutations 
were male (77.3%) and had ADC histology (77.3%; Table 12). This is similar to other study 
cohorts, which have also reported that the percentages of mutations in the KRAS gene were 
higher in men and in ADC patients (Schmid et al., 2009; Tam et al., 2006). Moreover, the most 
frequent mutation was 12ASP, which was present in 36.4% of our cases (Table 13). 
EGFR mutational analysis was performed in 64 patients; 54 (84.4%) were wild type and 
10 (15.6%) presented a mutation. Most of the patients with these mutations were women 
(70%), with an ADC histology (90%), who had never been smokers (60%; Table 12). These 
percentages were also in agreement with previously reported data, including multicentric 
studies (Molina et al., 2008; Rosell et al., 2009). In our cohort, exon 21 was the most frequently 
mutated (60%), in particular the mutation L858R stood out; this is a single nucleotide point 
mutation leading to a single amino acid change from leucine to arginine in codon 858 (Table 
13). 
Table 12. Frequency of EGFR and KRAS mutations according to the patient characteristics. 
 EGFR KRAS 
Characteristics Analysed 
patients 
N (%) 
Mutated 
patients 
N (%) 
Analysed 
patients 
N (%) 
Mutated 
patients 
N (%) 
Total 64 10 173 22 
Gender     
Male 49 (76.6%) 3 (30%) 149 (86.1%) 17 (77.3%) 
Female 15 (23.4%) 7 (70%) 24 (13.2%) 5 (22.7%) 
Stage     
I 36 (56.3%) 7 (70%) 101 (58.4%) 16 (72.7%) 
II 17 (26.6%) 1 (10%) 35 (20.2%) 5 (22.7%) 
IIIA 11 (17.2%) 2 (20%) 37 (21.4%) 1 (4.5%) 
Histology     
SCC 9 (14.1%) 1 (10%) 80 (46.2%) 3 (13.6%) 
ADC 44 (68.6%) 9 (90%) 73 (42.2%) 17 (77.3%) 
Others 11 (17.1%) - 20 (11.6%) 2 (9.1%) 
Age (years)     
≤ 65 37 (57.8%) 5 (50%) 93 (53.8%) 11 (50%) 
> 65 27 (42.2%) 5 (50%) 80 (46.2%) 11 (50%) 
Smoking Status     
Current 29 (45.3%) 2 (20%) 85 (49.1%) 8 (36.4%) 
Former 21 (32.8%) 2 (20%) 68 (39.3%) 7 (31.8%) 
Never 14 (21.9%) 6 (60%) 20 (11.6%) 7 (31.8%) 
ADC, adenocarcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor. 
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Table 13. Frequency of the different mutations detected for EGFR and KRAS. 
Type of mutation N % 
EGFR   
Del. 19 1 10 
Exon 20 3 30 
Exon 21 6 60 
KRAS   
12ASP 8 36.4 
12CYS 6 27.3 
12VAL 7 31.8 
12SER 1 4.5 
EGFR, epidermal growth factor receptor. 
1.2. GENE EXPRESSION ANALYSIS 
1.2.1. RNA QUANTIFICATION AND QUALITY ASSESSMENT 
For relative gene expression determination 178 samples from tumour and adjacent 
normal lung tissues were analysed. RNA was isolated from small pieces of tissue 
(approximately 10-20 mg). An optimal RNA concentration was obtained from all the samples; 
the median for normal adjacent tissues was 385 [76.8 - 3642] ng/μl and was 1340 [92-5779] 
ng/μl for tumour tissues. 
The quality and integrity of the RNA extracted was evaluated by capillary 
electrophoresis which is widely used for detecting the presence or absence of RNA 
degradation products. Depending on the entire electrophoretic trace of the RNA sample this 
method provides an RNA integrity number (RIN) which is calculated by a software algorithm. 
All the samples presented an adequate quality and integrity because their RIN was superior to 
7, the 18S and 28S peaks were clear and defined, and there was low molecular-weight noise 
(Figure 15). 
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Figure 15. Example of an electropherogram provided by Agilent software after a capillary 
electrophoresis run. This figure represents a good-quality tumour sample electropherogram in which 
the 18S and 28S peaks are clear and defined, there is low molecular-weight noise, and the RNA integrity 
number (RIN) is over 7.  
1.2.2. RELATIVE IMMUNOREGULATORY GENE MESSENGER RNA EXPRESSION 
Relative gene expression analysis of genes of relevance to tumour immunoregulation 
was performed in this part of the study. The 20 genes were: CCL2, CCL22, CD1C, CD127, 
CD209, CD25, CD4, CD8, CLEC4, CTLA4, FOXP3, IDO1, IL10, IL23A, LGALS1, LGALS2, NRP1, PD1, 
PDL1, and TGFB1. Relative gene expression levels were based on the expression of the 20 
target genes analysed in tumour tissues versus their expression in normal adjacent tissue; 
these were normalised against endogenous genes and were calculated using the Pfaffl 
mathematical formula.  
The expression of five endogenous genes (ACTB, GAPDH, GUSB, HPRT1, and CDKN1B) 
was tested in a subset comprising approximately 30% of the samples in order to establish the 
best internal control. For this purpose, we used GeNorm software (see materials and 
methods), which indicated that the most stable option was the ACTB, GUSB, and CDKN1B 
combination. Following the procedure proposed by Vandesompele et al., a normalisation 
factor based on the expression of these three endogenous genes was calculated using the 
geometric mean (Vandesompele et al., 2002).  
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A gene was considered to be overexpressed in tumour samples compared to normal 
tissue when the median of the relative gene expression or fold-change was above 2, and it was 
considered to be downregulated when the fold-change was below 0.5. Using this criteria, we 
found that FOXP3 (3.87X) and CD25 (2.66X) were overexpressed, whilst CD1C (0.42X), CD127 
(0.40X), PDL1 (0.38X), and CCL2 (0.25X) were downregulated in the tumour. To better visualise 
these results, they were log2-normalised and their mean was represented (Figure 16). 
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Figure 16. Relative mRNA expression levels of the 20 genes analysed. In this graphic the log2-
tranformed relative gene expression mean is represented for each gene. The results represented are the 
mean ± SEM. 
FOXP3 was found to be the most overexpressed gene. FOXP3 is a master Treg 
regulator and is one of the most reliable markers for the identification of these cells. However, 
FOXP3 expression is also transiently induced in CD4+ and CD8+ T cells upon stimulation 
(Roncador et al., 2005) and interestingly, its expression in tumour cells has been reported in 
different types of cancers (Triulzi et al., 2013). The overexpression of the non-selective 
biomarker CD25 in tumour compared to normal tissue could indicate strong infiltration by 
different types of immune cells. CD25 is the alpha chain of the IL2 receptor, which becomes 
rapidly expressed upon activation of conventional T cells, Tregs, and NK cells, as well as B cells 
and myeloid precursors (Becknell and Caligiuri, 2005). 
On the other hand, some genes were found to be downregulated. One of these genes 
was CCL2, which encodes a chemokine that recruits and activates monocytes during 
inflammatory responses and which has been reported to induce prostate cancer cell 
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proliferation (Zhang et al., 2010). Other genes found to be downregulated were PDL1, which 
binds to PD1 and has a role in suppressing T cells (Zou and Chen, 2008); CD127, that stands for 
the interleukin-7 receptor-α and is expressed on various cell types, including naïve and 
memory T cells (Gregory et al., 2007); and CD1C, which is expressed on a subset of myeloid 
DCs (Dzionek et al., 2000). 
1.2.3. UNSUPERVISED CLUSTERING ANALYSIS 
Unsupervised hierarchical clustering analysis was used to group patients and genes 
based on the similarity of their expression patterns. Patients were classified into a cluster tree 
with two major subgroups: Cluster I (n = 78) and Cluster II (n = 76). Patients in Cluster I had 
lower expression levels of most of the genes analysed, whilst Cluster II comprised patients with 
higher gene expression levels (Figure 17). 
 
Figure 17. Hierarchical clustering based on gene expression. Patients in the original cohort were 
clustered into a hierarchical tree based on gene expression. The clustering analysis separated patients 
into two distinct groups. Red indicates high expression and green indicates low expression levels. 
Genes were also grouped into two clusters: the first was mainly composed of genes 
related to conventional and regulatory T cells (CD4, CD8, CD127, FOXP3, CD25, and CTLA4) and 
the second comprising genes involved in different immunoregulatory processes (IL10, CCL2, 
NRP1, LGALS1, LGALS2, CD1C, and CD209). Three genes (PDL1, CCL22, and IDO1) did not fit 
into these two clusters so we decided to run a second clustering without them. In this new 
tree the patients, as well as the genes, were classified into two main clusters. In this case, in 
Cluster I (n = 70) most of the genes were downregulated, and in Cluster II (n = 84) most of the 
genes were overexpressed (Figure 18). 
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Figure 18. Hierarchical cluster based on selected gene expression. Patients in the original cohort were 
clustered into a hierarchical tree based on the expression of 15 genes. The clustering separated the 
patients into two distinct groups. Red indicates high expression and green indicates low expression 
levels. 
Hierarchical clustering is a powerful bioinformatics method, which analyses multiple 
factors in order to classify tumours by their similarities. The strategy of unsupervised 
hierarchical patient classification according to the expression patterns of genes related to 
tumour immunology was previously reported for other types of tumours such as 
hepatocellular carcinoma (Gao et al., 2011) as well as in lung ADCs (Seike et al., 2007). In this 
study, a 15-cytokine gene expression profile in noncancerous lung tissue and corresponding 
lung tumour tissues from 80 lung ADC patients was analysed. These data were used to 
construct a classification algorithm based on the analysis of noncancerous and tumour tissues 
to predict the prognosis of lung ADC patients with stage I disease. Thus, the principal objective 
of this clustering analysis was to find groups of patients with specific characteristics, like for 
instance, those with specific histology or survival groups based on the mRNA levels detected in 
the tumour microenvironment. 
1.3. CORRELATION OF BIOMARKERS WITH CLINICOPATHOLOGICAL 
VARIABLES 
Non-parametric tests such as the Mann-Whitney U, Kruskal Wallis, and Chi-square 
tests were carried out in order to investigate the association of the immunoregulatory markers 
with clinicopathological characteristics. 
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The Mann-Whitney U test revealed significant differences between histology (SCC vs. 
non-squamous), and TGFB1 (p = 0.020) and NRP1 (p = 0.022) expression (Figure 19a). TGFB1 
expression was higher in patients with SCC histology and, in the case of NRP1, the expression 
was higher in non-squamous patients. The first observation seems to be in line with a previous 
study reporting that TGFB1 plays a very important role in SCC carcinoma because it induces 
angiogenesis, inflammation, and epithelial-mesenchymal transition (EMT; Han and Wang, 
2011). To the best of our knowledge no association between NRP1 and non-squamous 
histology has previously been reported. 
Moreover, higher levels of PDL1 (p = 0.018) and LGALS2 (p = 0.023; Figure 19b) were 
found to be associated with the absence of lymph node involvement, whilst higher levels of 
FOXP3 (p = 0.045) and PD1 (p = 0.029) correlated with tumour size. These correlations could be 
explained by the fact that larger tumours attract a greater number of immune cells including 
cells expressing PD1, such as T lymphocytes and, in the case of FOXP3, Tregs. An association 
between KRAS status and FOXP3 (p = 0.007), IL10 (p = 0.030), PD1 (p = 0.028), PDL1 (p = 0.036), 
and IL23A (p = 0.029) was also observed, and the expression of these genes was higher in 
patients with a wild type (WT) KRAS phenotype.  
 
Figure 19. These figures represent two examples of correlation between clinicopathological variables 
and gene expression markers. a) Representation of NRP1 expression according to histology and, b) 
representation of LGALS2 according to lymph node involvement. Error bars represent the 95% 
confidence interval (CI) of the mean. 
Gene expression levels were then dichotomised according to their medians into high 
and low expression levels, thus converting them into qualitative variables. Correlations 
between them and clinicopathological variables were then assessed using the Chi-square test. 
We found that LGALS2 correlates with lymph node involvement (p = 0.006; Figure 20a) and 
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that tumour size correlated with FOXP3 (p = 0.042), but in addition it also correlated with CD8 
(p = 0.036) and CCL2 (p = 0.005; Figure 20b). Moreover, CD4 (p = 0.006), FOXP3 (p = 0.04), PD1 
(p = 0.038), and IL23A (p = 0.006) correlated with KRAS status (Figure 20c). 
 
Figure 20. Histograms showing the associations between clinicopathological variables and gene 
expression markers. Statistically significant associations of dichotomised gene expression values with a) 
lymph node involvement, b) tumour size and c) KRAS status. Histograms show the percentage of 
patients. The p-value was obtained using the Chi-square test. 
Chi-square test showed that there were significantly more patients with stage I (p = 
0.017), absence of LN involvement (p = 0.016), and wild type KRAS phenotype (p = 0.011) in 
Cluster II than in Cluster I. These correlations may indicate that patients in Cluster II, which 
comprises patients expressing higher levels of tumour immune-related genes compared to 
normal tissue, presented a less aggressive type of NSCLC. 
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1.4. BIOMARKER SURVIVAL ANALYSIS 
1.4.1. CLINICOPATHOLOGICAL VARIABLES 
Of the 178 resected NSCLC patients included in this part of the study, 80 (45%) 
relapsed and 76 (42.7%) died during the follow-up. The median follow-up was of 81.23 months 
[Range: 1-113]. The prognostic value of the different clinicopathological variables was assessed 
using the univariate Cox regression method for OS and PFS, and are shown in Table 14 along 
with the hazard ratios and p-value for each variable. 
Table 14. Results from survival analysis based on clinicopathological variables for the entire cohort. 
 OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
Gender 
Male vs. Female 2.499 0.909-6.875 0.076 1.638 0.791-3.391 0.184 
Age (years) 
>65 vs. ≤ 65 1.290 0.792-2.100 0.065 1.207 0.792-1.841 0.382 
Stage 
II/IIIA vs. I 1.081 0.662-1.768 0.755 1.258 0.824-1.920 0.288 
Histology 
ADC vs. SCC vs. Others 1.038 0.702-1.536 0.850 1.141 0.813-1.601 0.446 
Tumour size 
>3.5 cm vs. ≤ 3.5 cm 1.503 0.910-2.484 0.111 1.478 0.962-2.271 0.075 
LN involvement 
Yes vs. No 1.502 0.892-2.529 0.126 1.635 1.046-2.556 0.031* 
PS 
1/2 vs. 0 1.405 0.829-2.382 0.206 1.457 0.924-2.296 0.105 
Differentiation grade 
Poor vs. Well/Moderate 0.943 0.546-1.756 0.979 1.009 0.614-1.659 0.972 
Smoking status 
Former/Current vs. Never 1.835 0.667-5.048 0.240 0.844 0.352-2.024 0.353 
EGFR 
Wild type vs. Mutated 0.477 0.144-1.576 0.225 2.499 0.909-6.875 0.704 
KRAS 
Mutated vs. Wild type 1.970 1.024-3.790 0.042* 1.886 1.038-3.429 0.037* 
CI, confidence interval; EGFR; epidermal growth factor receptor; HR, hazard ratio; LN, lymph node; OS, 
overall survival; PFS, progression free survival; PS, performance status. The results were obtained using 
the univariate Cox regression method.*p < 0.05. 
Significant results obtained from the univariate COX regression method were also 
analysed using the Kaplan-Meier method (long-rank) in order to obtain the survival plots. This 
univariate analysis of clinicopathological variables showed that patients with the KRAS 
mutation had a worse OS (p = 0.038) and a shorter PFS (p = 0.034; Figure 21), which agrees 
with previously published results (Meng et al., 2013). Also, as previously reported (Suzuki et 
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al., 2013), LN involvement was significantly associated with PFS (p = 0.029). No other 
clinicopathological variables appeared to have any prognostic value. 
 
Figure 21. Kaplan-Meier plots according to KRAS status. a) Analysis for OS, and b) PFS. Blue line 
represents KRAS wild type patients, whilst green line represents mutated patients. P-values from the 
Kaplan-Meier test. 
ANALYSIS ACCORDING TO HISTOLOGY 
The prognostic value of clinicopathological variables was also assessed according to 
histology. The ADC subgroup comprised 78 patients (including ADCs and adenosquamous 
histology): of these, 33 (42.3%) relapsed and 33 (42.3%) died. In the univariate analysis, only 
LN involvement was associated with PFS (p = 0.038; Table 15). The SCC subgroup comprised 84 
patients; 40 (47.6%) relapsed and 36 (42.9%) died. In contrast to the findings in ADC patients, 
no significant association was found between the clinicopathological variables and OS or PFS in 
SCC patients (data not shown). 
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Table 15. Results from survival analysis based on clinicopathological variables for ADC patients.  
V.  OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
Gender 
Male vs. Female 3.215 0.963-10.728 0.058 1.956 0.860 -4.449 0.110 
Age (years) 
>65 vs. ≤ 65 1.619 0.741-3.537 0.227 1.205 0.636-2.284 0.567 
Stage 
II/IIIA vs. I 0.967 0.430-2.174 0.935 1.265 0.653-2.451 0.487 
Tumour size 
>3.5 cm vs. ≤ 3.5 cm 1.925 0.872-4.248 0.105 1.812 0.948-3.464 0.072 
LN involvement 
Yes vs. No 1.786 0.707-4.511 0.220 2.428 1.153-5.113 0.020* 
PS 
1/2 vs. 0 1.364 0.541-3.442 0.511 1.698 0.816-3.534 0.157 
EGFR 
Wild type vs. Mutated 0.339 0.079-1.461 0.147 20.819 0.309-2.168 0.688 
KRAS 
Mutated vs. Wild type 2.146 0.947-4.864 0.067 1.976 0.971-4.020 0.060 
CI, confidence interval; HR, hazard ratio; LN, lymph node; OS, overall survival; PFS, progression free 
survival; PS, performance status; EGFR; epidermal growth factor receptor. The results were obtained 
using the univariate Cox regression method. *p < 0.05. 
1.4.2. HIERARCHICAL CLUSTERS 
We then carried out univariate Kaplan-Meier survival analysis using the two major 
clusters obtained from the second unsupervised clustering (where some genes were 
excluded). This showed that patients in Cluster II had better OS (not reached (NR) vs. 46.6 
months, p = 0.040) and longer PFS (81.2 vs. 26.2 months, p = 0.027) than patients in Cluster I 
(Figure 22a-b). We also analysed their prognostic value according to histology, and observed 
that ADC patients classified in Cluster II had a significantly better OS (NR vs. 42.9 months, p = 
0.034) and PFS (81.2 vs. 17.8 months, p = 0.005) than patients in Cluster I. 
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Figure 22. Kaplan-Meier plots for OS and PFS according to the clustering classification of patients. a) 
OS and, b) PFS. Blue line represents patients classified in Cluster I, whilst green line represents patients 
in Cluster II. P-values were calculated using the Kaplan-Meier test. 
Molecular profiling based on mRNA microarrays or RTqPCR data has been extensively 
studied in lung tumour tissues. Some of these studies found significant associations between 
specific clusters of patients and their survival or metastasis (Beer et al., 2002; Bhattacharjee et 
al., 2001). Hierarchical clustering of immune-related genes performed in different types of 
cancer have demonstrated that clusters with an over-representation of genes related to 
cellular immunity are, in general, associated with a better outcome (Fehlker et al., 2014; Seike 
et al., 2007). In our study, unsupervised clustering analysis of immune-related genes in NSCLC 
samples indicated that the group of patients with the highest expression levels of immune-
related genes had better outcomes than the other group, although most of these genes are 
involved in immunoregulatory processes. This might point towards a beneficial impact of an 
active immune response within the tumour microenvironment of NSCLCs. 
This is not the first study to observe that patients with higher expression of genes 
related to immunoregulation have better survival rates. In fact, in breast cancer, a molecular 
signature (obtained from microarray data analysis) which was associated with relapse-free 
patients had a higher representation of genes involved in B cell development and antigen 
presentation, but also of genes involved in T-cell apoptosis, CTLA4 signalling, or activation of 
IL23R, which are all pathways involved in the negative regulation of effector T cells (Ascierto et 
al., 2012). In a recent study, the expression of immunosuppressive factors such as PD1, PDL1, 
CTLA4, and FOXP3 measured in 481 breast tumours, were highly significant predictors of 
therapy response and improved outcome (Denkert et al., 2014). 
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Although it is of interest that the unsupervised cluster analysis of immune-related 
genes was able to identify a group of patients with a better prognosis, hierarchical clustering 
can only be applied retrospectively and cannot be used to predict a patient’s future outcome. 
Therefore, next we investigated the prognostic value of genes analysed individually or as small 
groups. 
1.4.3. INDIVIDUAL BIOMARKERS 
The prognostic value of the different immune biomarkers was assessed using the 
univariate Cox regression method for OS and PFS. Gene expression levels were dichotomised 
according to their median. Results obtained in the univariate analysis are shown in Table 16. 
Table 16. Results from survival analysis based on gene expression biomarkers in the entire cohort. 
VI.  OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
FOXP3  
High vs. Low 0.728 0.443-1.198 0.212 0.607 0.392-0.940 0.025* 
CD4  
High vs. Low 0.670 0.406-1.106 0.117 0.641 0.414-0.992 0.046* 
CD8  
High vs. Low 0.750 0.456-1.234 0.258 0.693 0.447-1.075 0.101 
CD25 
 High vs. Low 0.584 0.353-0.967 0.036* 0.702 0.450-1.083 0.110 
CD127  
High vs. Low 0.700 0.425-1.153 0.161 0.543 0.349-0.844 0.007* 
CTLA4  
High vs. Low 0.639 0.385-1.060 0.083 0.655 0.421-1.018 0.060 
IL10  
High vs. Low 0.674 0.409-1.110 0.121 0.847 0.549-1.308 0.455 
TGFB1  
High vs. Low 1.177 0.715-1.937 0.521 1.096 0.711-1.690 0.677 
PD1  
High vs. Low 0.657 0.399-1.082 0.099 0.731 0.473-1.129 0.157 
PDL1 
 High vs. Low 0.92 0.564-1.517 0.757 0.882 0.570-1.365 0.573 
NRP1  
High vs. Low 1.058 0.634-1.764 0.830 1.057 0.678-1.649 0.806 
IL23A  
High vs. Low 0.390 0.215-0.708 0.002* 0.480 0.294-0.783 0.003* 
CCL2  
High vs. Low 0.801 0.483-1.329 0.391 0.794 0.512-1.232 0.304 
CCL22  
High vs. Low 0.957 0.574-1.595 0.867 0.966 0.619-1.507 0.879 
CD1C  
High vs. Low 0.755 0.453-1.258 0.281 0.924 0.593-1.438 0.725 
CD209  
High vs. Low 0.684 0.409-1.144 0.148 0.931 0.598-1.448 0.750 
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IDO1  
High vs. Low 0.800 0.479-1.336 0.394 0.824 0.526-1.291 0.399 
LGALS1  
High vs. Low 1.072 0.642-1.789 0.791 1.173 0.752-1.831 0.481 
LGALS2  
High vs. Low 0.495 0.293-0.837 0.009* 0.485 0.306-0.768 0.002* 
CLEC4  
High vs. Low 0.684 0.386-1.212 0.194 0.745 0.439-1.264 0.275 
Gene expression levels dichotomised as high and low according to their medians. The results 
were obtained using the univariate Cox regression method. CI, confidence interval; HR, hazard 
ratio; OS, overall survival; PFS, progression free survival; *p < 0.05. 
Univariate Cox regression analysis found that high levels of IL23A were associated with 
OS [HR, 0.390; 95% CI, 0.215-0.708; p = 0.002] and PFS [HR, 0.480; 95% CI, 0.294-0.783; p = 
0.003]. Kaplan-Meier analysis was carried out in order to obtain the survival plots and it 
indicated that patients with high levels of IL23A did not reach the survival median for OS (p = 
0.001), and that the median PFS was higher than for the other group (81.2 vs. 23.4 months, p = 
0.003; Figure 23a-b). IL23 is a heterodimeric cytokine composed of the p40 subunit, expressed 
by IL12 gene, and the p19 subunits, expressed by IL23A gene (Oppmann et al., 2000). In T cells, 
IL23 induces activation of STAT family members, but it is predominantly produced by activated 
myeloid dendritic cells and by type 1 macrophages (Parham et al., 2002). This cytokine is now 
considered the master switch in several T cell-mediated inflammatory disorders, but the 
antitumour activity of IL23 is controversial. On the one hand, it has been shown that pro-
inflammatory cytokines, including IL17A, IL6, and IL23 can impair CD8+ T cell-mediated immune 
surveillance and promote tumour neovascularisation (Langowski et al., 2006). But on the other 
hand, other groups have reported that IL23 exerts antitumour activity by stimulating T cells 
and natural killer (NK) cells (Kaiga et al., 2007). Its prognostic value was studied in ovarian 
cancer, and an improved OS was observed in patients with high p19 mRNA expression 
(expressed by the IL23A gene; Wolf et al., 2010). In lung cancer, a recent study in NSCLC 
tumour samples and cell lines reported that gemcitabine, a chemotherapy drug indicated for 
first-line treatment of NSCLC, induced IL23A expression and that it was found to induce NSCLC 
cell line proliferation. However, they failed to correlate IL23A expression with NSCLC patient 
prognosis (Baird et al., 2013). 
Another gene that correlated with better OS [HR, 0.495; 95% CI, 0.293-0.837; p = 
0.009] and longer PFS [HR, 0.485; 95% CI, 0.306-0.768; p = 0.002] was LGALS2, which encodes 
galectin-2. The median survival for patients with high levels of LGALS2 was, again, not reached 
at the end of the study for either OS or PFS (Figure 23c-d). In contrast to galectin-1 and 
galectin-3, relatively few studies have examined the expression of galectin-2 in animals and 
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human tumours. Galectins are members of a highly conserved family of β-galactoside-binding 
lectins, which have a broad variety of functions including immune function regulation. The 
most extensively-studied galectin function is their regulation of apoptosis. Furthermore, 
galectin-1 functions as a soluble mediator used by tumour cells to evade the immune response 
(Liu and Rabinovich, 2005). Galectin-2 can induce T-cell apoptosis and control the secretion of 
lymphotoxin-α by macrophages (Ozaki et al., 2004). Similar to our findings that lower LGALS2 
expression is associated with a worse outcome, in gastric cancer, it has been reported that 
decreased galectin-2 expression is associated with LN involvement and advanced clinical stage 
(Jung et al., 2012). 
Furthermore, higher levels of FOXP3 were correlated with longer PFS [HR, 0.607; 95% 
CI, 0.392-0.940; p = 0.025] and, as it can be observed in the Kaplan-Meier plot, higher levels of 
FOXP3 were associated with a better prognosis (Figure 23e-f). This association seems to be 
discordant with previous work in which the presence of FOXP3+ cells was associated with a 
poor prognosis in NSCLC (Petersen et al., 2006; Suzuki et al., 2013). However, our result could 
be explained by the fact that we are detecting mRNA expression levels from the tumour 
microenvironment, and therefore we do not know their origin. In fact, cancer cells positive for 
FOXP3 have been detected in several distinct types of cancer (Triulzi et al., 2013) and in breast 
cancer, its presence was associated with better OS (Ladoire et al., 2012). In lung cancer, a piece 
of work published in 2012 reported that FOXP3 expression in NSCLC tumour cells attenuated 
the unfavourable prognostic influence of the tumour-infiltrating Tregs also detected by IHC 
(Tao et al., 2012). Since we may be detecting FOXP3 mRNA produced by both Tregs and 
tumour cells, and the role of FOXP3 expression in the later is still unknown, this result should 
be interpreted with care. 
Finally, high expression levels of CD4 [HR, 0.641; 95% CI, 0.414-0.992; p = 0.046] 
(Figure 23g-h) and CD127 [HR, 0.543; 95% CI, 0.349-0.844; p = 0.007] (Figure 23i-j) were also 
correlated with longer PFS. High expression levels of CD127, which codes for interleukin-7 
receptor-α and is expressed on various cell types including naïve and memory T cells (Gregory 
et al., 2007), could indicate a high T cell infiltration into the tumour microenvironment, and 
therefore, could be a surrogate marker for an active anti-tumour response in this subgroup of 
patients. These results do not agree with a previous publication in which high IL7-R expression 
in tumours was associated with a worse outcome (Suzuki et al., 2013). This discrepancy could 
be explained by different reasons: 1) In the other study IL-7R expression was detected as 
positive IHC staining in tumour cells, whereas in our study we detected mRNA expression in 
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the tumour microenvironment, which could be enriched in mRNA from T cells as well as 
tumour cells; and 2) They only included stage I lung ADC patients, whereas we included 
patients with different histologies and stages. 
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Figure 23. Kaplan-Meier plots for OS and PFS according to gene expression levels. a-b) IL23A; c-d) 
LGALS2; e-f) FOXP3; g-h) CD4, and i-j) CD127. Gene expression levels were dichotomised according to 
the median. Blue line represents patients with low levels of expression, whilst green line represent 
patients with high levels of expression. P-values were calculated using the Kaplan-Meier test. 
ANALYSIS ACCORDING TO HISTOLOGY 
NSCLC is one of the most genomically diverse tumours, and there are a variety of 
molecularly-defined subsets of patients. Different driver mutations have been identified in SCC 
and ADC histologies, which have led to the assumption that they are molecularly different 
diseases. For this reason, survival analysis was also performed according to the patient 
histology. Results from univariate COX regression analysis for ADCs are provided in Table 17. 
However, SCC results are not included because we did not find any significant correlation for 
this subgroup of patients. 
  
Results & Discussion 
79 
 
Table 17. Results from survival analysis based on gene expression biomarkers for ADC patients. 
 OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
FOXP3 
High vs. Low 0.609 0.268-1.383 0.236 0.510 0.257-1.008 0.053 
CD4 
High vs. Low 0.848 0.385-1.866 0.682 0.760 0.366-1.363 0.300 
CD8 
High vs. Low 0.735 0.333-1.21 0.445 0.674 0.344-1.318 0.249 
CD25 
High vs. Low 0.419 0.180-979 0.045* 0.449 0.226-0.891 0.022* 
CD127 
High vs. Low 0.859 0.387-1.907 0.709 0.574 0.293-1.127 0.107 
CTLA4 
High vs. Low 0.336 0.143-0.790 0.012* 0.349 0.174-0.701 0.003* 
IL10 
High vs. Low 0.414 0.182-0.941 0.035* 0.477 0.242-0.940 0.033* 
TGFB1 
High vs. Low 1.056 0.478-2.335 0.893 1.107 0.570-2.152 0.763 
PD1 
High vs. Low 0.575 0.248-1.335 0.198 0.489 0.242-0.988 0.046* 
PDL1 
High vs. Low 0.698 0.308-1.582 0.389 0.672 0.332-1.360 0.269 
NRP1 
High vs. Low 1.189 0.520-2.721 0.682 1.308 0.654-2.616 0.447 
IL23A 
High vs. Low 0.281 0.091-0.866 0.027* 0.361 0.158-0.824 0.016* 
CCL2 
High vs. Low 0.614 0.279-1.35 0.226 0.541 0.280-1.043 0.067 
CCL22 
High vs. Low 0.943 0.428-2.076 0.884 0.910 0.467-1.774 0.783 
CD1C 
High vs. Low 0.571 0.256-1.273 0.171 0.575 0.293-1.126 0.106 
CD209 
High vs. Low 0.518 0.231-1.161 0.110 0.651 0.332-1.276 0.211 
IDO1 
High vs. Low 0.446 0.196-1.016 0.055 0.539 0.269-1.077 0.080 
LGALS1 
High vs. Low 0.864 0.642-1.789 0.716 0.9193 0.472-1.791 0.805 
LGALS2 
High vs. Low 0.234 0.092-0.595 0.002* 0.348 0.168-0.721 0.005* 
CLEC4 
High vs. Low 0.526 0.207-1.336 0.177 0.558 0.234-1.330 0.188 
The results were obtained using the univariate Cox regression method. Gene expression levels 
were dichotomised as high and low according to their median. CI, confidence interval; HR, 
hazard ratio; OS, overall survival; PFS, progression free survival; *p < 0.05. 
 
 
Results & Discussion 
80 
 
The univariate COX regression model performed with ADC patients (including ADCs 
and adenosquamous histologies), showed the same association between high IL23A and 
LGALS2 and better prognosis that were found in the entire cohort. CD25 was also associated 
with better OS [HR, 0.419; 95% CI, 0.180-979; p, 0.045] and longer PFS [HR, 0.449; 95% CI, 
0.226-891; p, 0.022]. Kaplan-Meier plots represented in Figure 24a and b, showed the survival 
differences between the two groups of patients. Few studies have focused on the expression 
of CD25 in NSCLC, and similar to other immune-related markers, these were performed using 
IHC methodologies. One example is a study published in 2012 in which double staining for 
CD3/CD8 and CD4/CD25 was performed in lung cancer patients from all stages. The authors 
observed that high numbers of stromal T-lymphocytes (both sets of staining) had a positive 
prognostic influence in NSCLC patients and were also an independent prognostic factor in 
ADCs (Kayser et al., 2012). 
CTLA4 also correlated with OS [HR, 0.336; 95% CI, 0.143-0.790; p, 0.012] and PFS [HR, 
0.349; 95% CI 0.174-0.701; p = 0.003] in this subset of patients. In this case, Kaplan-Meier plots 
revealed that for the group of patients with high CTLA4 expression levels the median OS was 
not reached, and for PFS it was 81.2 vs. 18.2 months (Figure 24c-d). This result is in agreement 
with previous work in NSCLCs (resected I-III) reporting that although CTLA4 did not show a 
statistically significant prognostic value, patients with higher CTLA4 expression levels 
experienced a 40% reduction in death risk, and a higher frequency of CTLA4 overexpression 
was found in non-squamous NSCLCs (Salvi et al., 2012). Similarly, in B-cell chronic lymphocytic 
leukaemia (CLL) cells patients with high CTLA4 mRNA levels were associated with a good 
clinical outcome (Joshi et al., 2007). The favourable effect of CTLA4 might appear in contrast to 
the notion that this receptor presents immunosuppressive characteristics, but could be 
explained by the fact that CTLA4 also mediates negative signals into tumour cells. Indeed, it 
has been observed that CTLA4 expression in early disseminated NSCLC cells (microscopic 
disease) might interact with B7 ligands, producing the inhibition of lung cancer cell 
proliferation (Contardi et al., 2005).  
Furthermore, we found that high levels of IL10 correlated with a higher OS [HR, 0.414; 
95% CI, 0.182-0.941; p = 0.035] and PFS [HR, 0.477; 95% CI, 0.242-0.940; p = 0.033]. Patients 
with high IL10 expression levels had a median of survival for OS of 81.2 vs. 37 months (p = 
0.030, Kaplan-Meier test) and for PFS the median was 49.3 vs. 18.8 months (p = 0.029, Kaplan-
Meier test; Figure 24e-f). IL10 is an anti-inflammatory, immunosuppressive cytokine with a 
double role in cancer. Its release by cancer and immune cells may result in the suppression of 
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cell mediated immunity, allowing tumours to proliferate, but this immunosuppression may 
also inhibit angiogenesis and therefore prevent cancer progression (Mocellin et al., 2005). 
 In NSCLCs, two older pieces of work report contradictory results: on the one hand 
increased IL10 production was associated with a worse prognosis (Hatanaka et al., 2000), while 
on the other hand, the lack of this cytokine also correlated with a worse outcome (Soria et al., 
2003). Since then, other studies have tried to elucidate the role of IL10 in NSCLC. For instance, 
it has been reported that IL10 expression by TAMs, but not by tumour cells, may play a role in 
the progression and prognosis of NSCLC (Zeni et al., 2007). Moreover, CD8+/IL10+ cells 
accumulated in the tumour stroma of patients with early stage NSCLC correlate with longer OS 
(Miotto et al., 2010).  
In a recent meta-analysis of cohort studies, the prognostic effect of different 
circulating inflammatory factors was evaluated and it was observed that IL10, among others, 
was not significantly associated with OS (Liao et al., 2014). Putting all of this data together, and 
given that IL10 can act as both an immune-stimulator and -inhibitor, the balance of these 
biological activities seems to be highly context-dependent. According to our results, in 
resected ADC patients the presence of high IL10 mRNA expression is a protective characteristic 
of the tumour microenvironment. 
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Figure 24. Kaplan-Meier plots for OS and PFS according to gene expression levels in ADCs. a-b) CD25; 
c-d) CTLA4; and e-f) IL10. Gene expression levels were dichotomised according to the median. Blue line 
represents patients with low levels of expression, whilst green line represents patients with high levels. 
P-values calculated using the Kaplan-Meier test. 
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1.4.4. EXPRESSION PROGNOSTIC SCORE 
We also decided to create a gene expression score based on a multi-gene signature, 
which can provide more accurate predictions than a model using single genes. For this 
purpose, we followed the steps described in the data analysis section of the materials and 
methods section. Based on univariate Cox regression analysis, expression of IL23, IL10, CCL2, 
PD1, and CTLA4 were moderately associated with mortality (|Z-score| >1.5; Figure 25).  
 
Figure 25. Univariate analysis of the expression of 20 immunoregulatory genes for OS. The genes are 
ranked based on their predictive power (univariate Z-score). Dashed lines indicate |Z-score|= 1.5. This 
criterion was used to select genes to include in the multivariate Cox regression model used to calculate 
the expression score. 
These genes were selected to construct the prognostic signature by introducing them 
into the multivariate model; the results are detailed in Table 18. Absolute regression 
coefficients from multivariate analysis were used to calculate the expression prognostic score. 
Table 18. Results from the multivariate model with genes included in the expression score. 
Variable 
Regression 
coefficient 
SE p-value HR 95% CI 
IL23A -0.016 0.067 0.804 0.984 0.862-1.122 
IL10 -0.077 0.129 0.550 0.926 0.719-1.192 
CCL2 -0.154 0.138 0.262 0.856 0.653-1.123 
PD1 -0.132 0.094 0.159 0.876 0.729-1.053 
CTLA4 -0.173 0.064 0.006 0.840 0.742-0.952 
CI, confidence interval; HR, hazard ratio; SE, standard error. 
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The formula to calculate the signature was the following: 
 
 
 
Kaplan–Meier log-rank analysis showed that patients with a high expression score have 
longer OS (NR vs. 42.9 months, p = 0.007) and longer PFS (82.6 vs. 23.4 months p = 0.011; 
Figure 26a-b). Furthermore, to evaluate the potential use of the score as a biomarker, we did a 
stratified analysis by TNM-staging and histology. We observed that when we stratified patients 
according to histology, the association between the ADC patient score and the prognosis was 
even stronger (OS: NR vs. 18.2 months, p = 0.001 and PFS: NR vs. 37 months, p = 0.001). 
 
Figure 26. Kaplan-Meier plots for OS and PFS according to the gene expression score. a) OS and, b) PFS. 
The score was divided as low and high according to its median. Blue line represents patients with low 
levels of expression, whilst green line represents patients with high expression scores. P-values were 
calculated using the Kaplan-Meier test. 
We identified a prognostic score, based on the expression of five immunosuppressive 
genes, which is associated with OS and PFS in NSCLC. Patients with a high expression score and 
therefore high expression levels of these genes had increased survival, which was even 
stronger in patients with ADC histology. This expression score comprised two immune 
checkpoint-related genes (CTLA4 and PD1), IL10 and IL23A (their association with survival is 
described above), and CCL2. 
 CCL2 is a chemokine responsible for the recruitment of monocytes during 
inflammatory responses, and it has been implicated in the development of multiple 
inflammatory disorders (Zhang et al., 2010). The correlation between CCL2 and NSCLC 
 (IL23A x 0.016) + (IL10 x 0.077) + (CCL2 x 0.154) + (PD1 x 0.132) + (CTLA4 x 0.173) 
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prognosis was recently assessed by IHC in a study analysing the expression of this chemokine 
in 134 stage I-IV patients. The authors concluded that the presence of CCL2 in NSCLCs 
predicted improved prognosis relative to its absence (Zhang et al., 2013). However, the 
prognostic role of CCL2 in cancer is controversial due to the existence of studies pointing out 
that its expression is associated with angiogenesis and tumour progression (Salcedo et al., 
2000); other work, e.g. in colorectal cancer, claim the contrary (Watanabe et al., 2008). It has 
been reported that CCL2 regulates the infiltration of inflammatory cells in tumour tissue, 
elevates the cytotoxic activity of monocytes and NK cells, and mediates the activity of 
macrophages. However, the interaction between macrophages and tumour cells is 
complicated because of the existence of two phenotypes: M1 and M2 macrophages. M1 
macrophages are activated by IL2 and IFNγ and produce antitumour activity (Deshmane et al., 
2009), whereas M2 macrophages promote tumour progression by stimulating angiogenesis 
through cytokines and proteases (Vande, I et al., 2006). 
Prognostic scores based on gene expression levels have been previously described in 
the literature. For instance, Endoh et al. assessed the prognostic value of 48 candidate genes 
previously identified in two studies using ADC patients. They identified an eight-gene 
prognostic score that could separate patients with different prognoses (Endoh et al., 2004). 
Similarly, Lau et al. found a three-gene classifier that stratified a cohort of 147 early-stage 
NSCLC patients with significantly different prognoses (Lau et al., 2007). Although several 
prognostic scores or classifiers have been reported for NSCLC so far, very few genes have been 
observed to overlap between any of these classifiers.  
1.4.5. IMMUNE CHECKPOINT SCORE 
Because two of the genes composing the gene expression score described above were 
immune checkpoint genes, we decided to study if a score composed only by the expression of 
CTLA4 and PD1 would also have a prognostic value. Furthermore, a prognostic score based on 
fewer genes is preferred both in terms of time and cost. Following the method described in the 
previous section we created a multivariate model including these two genes. Absolute 
regression coefficients from this analysis (Table 19) were used to calculate the immune 
checkpoint score: 
 
 
(PD1 x 0.116) + (CTLA4 x 0.058) 
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Table 19. Results from the multivariate analysis for OS based on PD1 and CTLA4 expression. 
Variable 
Regression 
Coefficient 
SE p-value HR 95% CI 
PD1 -0.116 0.075 0.121 0.890 0.769-1.031 
CTLA4 -0.058 0.035 0.102 0.944 0.881-1.012 
CI, confidence interval; HR, hazard ratio; SE, standard error 
Kaplan- Meier analysis showed that patients with a high immune checkpoint score had 
longer OS (NR vs. 40.4 months, p = 0.008) and longer PFS (82.6 vs. 23 months, p = 0.009; Figure 
27a-b). To evaluate the potential use of the score as a biomarker, we did a stratified analysis 
by TNM staging and histology. We found that for ADC patients, the association between a high 
immune checkpoint score and prognosis was stronger than for the entire cohort of patients 
(OS: NR vs. 34.4 months, p = 0.002 and PFS: NR vs. 16.2 months, p < 0.001). P-values obtained 
for OS and PFS were similar to the ones obtained using the five-gene expression score, which 
indicates that, in this case, there were no benefits to including a larger number of genes in the 
score, and therefore the immune checkpoint score is more practical. 
 
Figure 27. Kaplan-Meier plots for OS and PFS according to the immune checkpoint expression score. 
The score was divided as low and high according to its median. Blue line represents patients with low 
levels of expression, whilst green line represent patients with high scores. P-values were calculated 
using the Kaplan-Meier test. 
The immune checkpoint score encompasses the expression of two genes, CTLA4 and 
PD1, which have become of great interest in the last few years. This is because researchers 
have demonstrated the importance of how the immune checkpoint blockade leads to robust 
antitumour effects in patients with metastatic melanoma, NSCLC, and other tumour types. As 
previously mentioned, CTLA4 overexpression is more common in ADC and appears to be an 
independent prognostic factor in NSCLC (Salvi et al., 2012). In a similar way to CTLA4, PD1 is 
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also an immune checkpoint receptor with immunosuppressive properties. However, in 
contrast to CTLA4, PD1 is activated during the effector stages of T cell activation, interaction 
with its ligand (PDL1) occurs primarily in peripheral tissues instead of LNs, and importantly, it 
can be expressed in tumour tissue as well as in immune cells (Ott et al., 2013). 
PD1 expression in cancer has still not been thoroughly studied. In 2013, PD1 
expression on CD4+ and CD8+ T cells obtained from peripheral blood mononuclear cells 
(PBMCs), normal gastric mucosa, and gastric cancer tissue cells was evaluated by multicolour 
flow cytometry, which showed that its expression in gastric cancer patients was significantly 
higher than that of normal controls (Saito et al., 2013). In breast cancer, another study 
demonstrated that the presence of PD1+ TILs was associated with a poor prognosis (Muenst et 
al., 2013). To the best of our knowledge, so far only one piece of work has assessed the 
expression of PD1 in NSCLC tissues; the authors analysed the expression of PD1 and PDL1 in a 
cohort of 125 NSCLC patients in order to evaluate if they were differently expressed according 
to the presence or absence of EGFR mutations, ALK translocation, or KRAS mutations. Although 
they observed that the sensitivity to treatment was higher and the OS was longer in patients 
treated with EGFT TKIs when PDL1 expression was higher, no differences were observed for 
PD1 (D'Incecco et al., 2014). As for PDL1, recent work has analysed its expression in two large 
NSCLC patient cohorts, observing that high expression of PDL1 protein or mRNA was 
associated with a better outcome (Velcheti et al., 2014). However, we failed to obtain this 
correlation in our data when the prognostic value of the markers was analysed individually. 
This discrepancy could be explained by methodological differences: we performed RTqPCR 
whereas Velcheti et al. used IHC and in situ hybridisation. 
Our results indicate that the combination of these immune checkpoints, but not their 
individual expression, has a strong prognostic value in resected NSCLC. Although we found that 
CTLA4 correlated with survival in ADC patients, the p-values obtained for this subgroup of 
patients were more strongly correlated when CTLA4 was combined with PD1. This information 
could be very useful in NSCLC management, especially because many new and promising 
immune checkpoint blockade therapies are now becoming available.  
1.4.6. MULTIVARIATE ANALYSIS  
In order to select the best prognostic biomarker obtained from fresh frozen tissue in 
resected NSCLCs, we interrogated all the biomarkers that were significantly associated with 
prognosis (p < 0.05) and included them in a multivariate model for OS and PFS. In the OS 
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multivariate model the following variables were included: KRAS status, cluster classification, 
individual biomarkers such as CD25, IL23A, LGALS2, the expression score, and the immune 
checkpoint score. The variables included in the PFS model were: LN involvement, KRAS status, 
cluster classification, individual biomarkers such as FOXP3, CD4, CD127, IL23, LGALS2, the 
expression score, and the immune checkpoint score. Results obtained from this multivariate 
analysis indicated that KRAS status and the immune checkpoint score were independent 
biomarkers for both OS and PFS, and in the later, CD127 expression was also identified as an 
independent biomarker (Table 20).  
Table 20. Multivariate Cox regression model results, including all the significant variables. 
  OS  PFS  
Variables HR 95% CI p-value HR 95% CI p-value 
KRAS status 
Mutated vs. WT 
 
2.984 
 
1.338-6.659 
 
0.008 
 
3.807 
 
1.764-8.214 
 
0.001 
Immune checkpoint score 
High vs. low 
 
0.308 
 
0.156-0.609 
 
0.001 
 
0.527 
 
0.298-0.933 
 
0.028 
CD127 
High vs. low 
 
- 
 
- 
 
- 
 
0.513 
 
0.292-0.901 
 
0.020 
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival; WT, wild 
type. 
Multivariate analysis was also performed with significant results for ADC patients; the 
following variables were included in the model for OS: CD25, CTLA4, IL10, IL23A, LGALS2, 
cluster classification, the expression score, and the immune checkpoint score. In this case, only 
the immune checkpoint score proved to be an independent biomarker. For PFS, we included 
the same variables plus LN involvement and PD1. Again the immune checkpoint score was an 
independent prognostic factor as well as LN involvement (Table 21). Our results indicate that 
the immune checkpoint score is an independent biomarker for both OS and PFS, and 
moreover, its prognostic value proved to be stronger for OS than factors such as KRAS status in 
the entire cohort, or LN involvement in ADC patients.  
Table 21. Results from a multivariate Cox regression model including all the significant results for ADC 
patients.  
  OS PFS 
Variables HR 95% CI p-value HR 95% CI p-value 
Immune checkpoint score 
High vs. low 
 
0.131 
 
0.038-0.451 
 
0.001 
 
0.156 
 
0.063-0.388 
 
<0.001 
LN involvement 
Yes vs. No 
 
- 
 
- 
 
- 
 
3.896 
 
1.539-9.858 
 
0.004 
CI, confidence interval; HR, hazard ratio; LN, lymph node; OS, overall survival; PFS, progression free 
survival. 
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Expression scores are well established methods for separating patients into prognostic 
groups. In this study, we used RTqPCR, the gold standard method for gene expression 
quantification, because of its high sensitivity and specificity. Other advantages of this 
technology are that it requires a low RNA input, it is less time consuming than other methods, 
and it is robust and flexible. Thus, RTqPCR is clinically applicable for detecting patient 
subgroups with specific prognostic characteristics. This is of great importance because current 
clinicopathological staging methods have limited success in predicting patient survival and 
great outcome uncertainty for same-stage NSCLC cancers remains: we still cannot predict 
which patients will be cured and which ones will suffer recurrence or death after surgical 
resection. It is remarkable that we have found an independent prognostic biomarker, defined 
as the immune checkpoint score, which identifies a subset of NSCLC patients with a better 
outcome. Two recent publications in the Nature journal indicated that the expression of 
immune checkpoints, PD1 and PDL1, in infiltrating immune cells was correlated with better 
responses to immune checkpoint blockade treatment. The findings suggest that the presence 
of these biomarkers might indicate that these tumours have already been recognised by the 
immune system, and therefore they are key predictors of clinical treatment responses (Herbst 
et al., 2014; Tumeh et al., 2014). If these predictive markers are a reflection of a pre-existing 
immune recognition, and taking the theory that predictive markers are also likely to be of 
prognostic value into account (Angell and Galon, 2013), our results suggest that immune 
checkpoint marker expression may also be of future value as a new prognostic NSCLC 
biomarker. They may also have some therapeutic value for managing NSCLC via emerging 
targeted immunotherapies, especially immune checkpoint blockade-based therapies, and so 
further studies to asses both of these uses should be conducted in order to better understand 
these processes. 
In summary, in this part of the study we identified some biomarkers based on the 
expression of immune-related genes, especially immunoregulatory cells and processes. 
Unsupervised hierarchical analysis revealed that patients were grouped according to their 
gene expression levels and patient clusters with higher expression of these biomarkers were 
associated with better outcomes. Some of these biomarkers presented a significant association 
with survival when individually analysed or combined into expression scores. In fact, one score 
comprising two immune checkpoint-related genes was found to be an independent prognostic 
factor. Interestingly, the prognostic value of most of these biomarkers was amplified in ADC 
patients.  
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2. ANALYSIS IN FORMALIN-FIXED PARAFFIN EMBEDDED SAMPLES 
In this part of the study a set of immunoregulatory biomarkers was assessed in the 
different compartments of the tumour microenvironment: the tumour itself and the adjacent 
stroma. It is important to assess the specific location of a given marker in the tumour 
microenvironment because its prognostic value may be different or even opposite depending 
on where it is expressed. 
2.1. PATIENT CHARACTERISTICS 
For this purpose FFPE samples from 122 patients (102 patients included in the previous 
section and 20 more from another hospital) were studied. The most relevant demographic and 
clinicopathological characteristics are shown in Table 22. 
Table 22. The clinicopathological characteristics of patients included in the FFPE-analysis. 
Characteristics N % 
Age at surgery (median, range) 65 [26-85] 
Gender   
Male 104 85.4 
Female 18 14.6 
Stage   
I 72 59 
II 26 21.3 
IIIA 24 19.7 
Histology   
SCC 58 47.5 
ADC 51 41.8 
Others 13 10.7 
Performance Status   
0 70 57.4 
1-2 35 28.7 
NS 17 13.9 
Differentiation grade   
Poor 29 23.8 
Moderate 48 39.3 
Well 28 23 
NS 17 13.9 
Smoking Status   
Current 59 48.4 
Former 46 37.7 
Never 17 13.9 
EGFR   
Wild type 43 35.2 
Mutated 9 7.4 
NS 70 57.4 
KRAS   
Wild type 83 68 
Mutated 14 11.5 
NS 25 20.5 
ADC, adenocarcinoma; SCC, squamous; NS, not specified; EGFR, epidermal growth factor receptor. 
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2.2. GENE EXPRESSION ANALYSIS 
2.2.1. LASER CAPTURE MICRODISSECTION AND RNA ISOLATION 
Laser capture microdissection was carried out in order to separately obtain tumour 
and stroma areas from FFPE samples. First, we selected specific areas of at least 107 μm2 on 5 
μm HE stained sections and then we performed the microdissection on 10 μm membrane-slide 
sections. Figure 28 shows two examples of how the areas were selected for the different 
NSCLC histologies.  
 
Figure 28. Examples of areas selected for laser capture microdissection. The figure represents areas 
selected for microdissection, areas of tumour cells are highlighted in red and areas composed of 
adjacent stroma are highlighted in black. a) Adenocarcinoma tumour and b) squamous cell tumour. 
RNA was isolated from microdissected areas of at least 107 μm2 from the tumour and 
stroma compartments. The median RNA concentration for tumour areas was of 46.8 [range: 8–
194.7] ng/μl and for stroma areas it was of 38 [range: 4.8-202.5] ng/μl. The RNA quantity 
obtained in 10 of the 122 cases included was not enough for further analysis. The quality of 
RNA isolated was assessed by capillary electrophoresis. In the majority of the samples the RIN 
was under 7, which was expected due to the nature of the fixation process, however this did 
not produce an adverse impact on the subsequent gene expression analysis. 
2.2.2. ASSESSMENT OF PRE-AMPLIFICATION UNIFORMITY 
We then checked whether all amplicons were uniformly amplified during the pre-
amplification process. We assessed the expression of a human reference cDNA (preamplified 
and at a concentration of 0.3 ng/μl) and the Cts obtained were included in the equation 
described in the material and methods section. Genes with ΔΔCt values within ±1.5 were 
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considered to be uniformly amplified (Table 23). As recommended by the manufacturer, we 
used CDKN1B as the endogenous reference gene. 
Table 23. Results of the pre-amplification uniformity test for the gene expression assays. 
GENES ΔΔCt GENES ΔΔCt GENES ΔΔCt 
CCL2 1.399 CD114 -0.617 IL7RA -0.920 
CCL22 0.953 CLEC4C 0.036 IL8 -1.367 
CCL5 -0.263 CSF1R 1.173 ITGAM 0.101 
CD1C 0.953 CSF3R -0.617 ITGB2 -0.675 
CD209 1.276 CTLA4 -1.163 LAG3 -1.279 
CD34 0.077 CXCL12 1.393 LGALS1 0.262 
CD4 -0.444 CXCR4 -0.088 LGALS2 -1.414 
CD40 0.503 FOXP3 -0.165 MMP2 -0.222 
CD40LG -0.723 IDO1 -0.805 NRP1 0.273 
CD44 -0.634 IL10 1.475 TGFB1 -0.199 
CD80 -1.423 IL13 -0.167 THBD 1.010 
CD86 1.232 IL23A 0.539 TNF 0.750 
CD8 -0.300 IL2RA 0.040 GITR 0.779 
CD97 0.064 IL4RA 1.043 - - 
A ∆∆CT values close to zero indicate pre-amplification uniformity. 90% of targets typically produce ∆∆CT 
values within ±1.5. CDKN1B was used as a reference gene. 
All the genes for which uniformity could be assessed proved to be correctly amplified. 
However, the uniformity of CD33, INFG, IL12B, and IL4 could not be evaluated because the 
threshold cycles for the 0.3 ng/μl template were undetermined. 
2.2.3. RELATIVE MESSENGER RNA EXPRESSION OF IMMUNOREGULATORY 
GENES IN TUMOUR AND ADJACENT STROMA COMPARTMENTS 
Forty-four genes relevant to tumour immunoregulation were assessed by relative gene 
expression analysis in 122 tumour and stroma area samples that were microdissected from 
FFPE samples obtained from resected NSCLC patients. All the analysed genes could be 
amplified using the selected primers/probes except IL13 and IL4. In addition, the CD33, INFG, 
CLEC4 and IL12B genes could not be studied further because more than 50% of the samples 
had undetermined values. Thus, a total of 38 genes were included in this analysis. 
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The expression of five endogenous genes (ACTB, GAPDH, GUSB, HPRT1, and CDKN1B) was 
tested in a subset comprising approximately 30% of the samples in order to establish the best 
internal control using geNorm software, with the GAPDH and CDKN1B being the best 
combination. Consequently, a normalisation factor was calculated based on the expression of 
these two endogenous genes using the geometric mean (Vandesompele et al., 2002). 
Furthermore, relative expression of the genes analysed in the tumour and stroma was 
normalised against a pre-amplified reference cDNA.  
A gene was considered to be overexpressed in the tumour or stroma compartment 
compared to the reference cDNA when the median of the relative gene expression or fold-
change was above 2 and, it was considered to be downregulated when the fold-change was 
below 0.5. We observed strong overexpression of five genes CD25 (19.46X, 11.59X), FOXP3 
(4.96X, 4.08X), CTLA4 (2.89X, 3.02X), CD80 (4.62X, 2.87X), and TGFB1 (3.24X, 2.117X) in both 
the tumour and stroma compartments, respectively, and one gene, MMP2 (3.25X), was 
overexpressed only in the stroma. On the other hand, we found downregulation of eleven 
genes: LGALS2 (0.04X, 0.01X), ITGB2 (0.46X, 0.27X), IL4R (0.22X, 0.17X), CD97 (0.23X, 0.15X), 
CD40 (0.16X, 0.13X), CD34 (0.28X, 0.11X), CCL2 (0.10X, 0.04X), CXCL12 (0.25, 0.07X), THDB 
(0.24X, 0.09X), CD1C (0.35X, 0.34X), and TNF (0.39X, 0.27X) in both tumour and stroma 
respectively. Moreover, six genes were downregulated only in the tumour compartment: 
LGALS1 (0.39X), IL10 (0.39X), CD40LG (0.41X), CD209 (0.31X), ITGAM (0.27X), and CSF1R 
(0.37X) (Figure 29). 
The continuous cross-talk between cancer cells and tumour microenvironment-
associated cells has a significant role in tumour carcinogenesis and tumour progression. The 
tumour microenvironment is a crucial source of angiogenic cytokines, proteases and other 
factors that are important for maintaining intercellular communication. The immune cells that 
can be present in both tumour and stroma compartments are also of great importance. Gene 
expression analysis of immunoregulatory markers indicated that genes related to the presence 
of T cells and other immunoregulatory cells were overexpressed in both tumour and stroma 
locations. The overexpression of the Treg-related genes FOXP3, TGFB1, and CTLA4 was also 
observed. MMP2 was overexpressed in the stroma but not the tumour compartment which 
could be due to its role in degrading extracellular matrix so that the tumour can metastasise. 
On the other hand, we found that other genes such as the chemokines CCL2 and CXCL12, 
which are related to MDSCs and TAMs, were downregulated in the tumour and stroma 
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compartment. Some genes were downregulated only in the tumour, which might indicate that 
the infiltration of certain types of immune cells may be concentrated in the stroma 
compartment instead of the tumour nest. 
We then analysed if there were significant differences between the gene expression 
levels in tumour versus stroma. We found significant differences for several genes (see Table 
24) and in most of the cases the expression was higher in stroma than in tumour areas. This 
information could indicate differences in the immune infiltrate present in each compartment 
and more importantly, it justifies gene expression analysis at the compartment level because 
biomarkers may have diverging prognostic impacts depending on whether they are expressed 
in tumour or in stroma locations. 
The role of stromal cells is becoming increasingly understood, and it is probable that 
they also contribute to the development of the inflammatory phenotype. Although they are 
typically associated with wound healing through the deposition of extracellular matrix, 
fibroblasts have important roles in both immune modulation and angiogenesis (Gajewski et al., 
2013). The evidence suggests that in general the stroma and the microenvironment activate 
homeostatic tissue repair mechanisms that include cellular and molecular events traditionally 
considered to pertain to either angiogenic or immunosuppressive mechanisms (Motz and 
Coukos, 2011). Moreover, molecular profiling of stromal cells from a variety of different 
human tumour specimens has yielded information of prognostic value, further highlighting the 
critical role that the tumour microenvironment plays in directing tumour development. 
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Figure 29. Relative mRNA expression of the genes analysed in the tumour and stroma compartments. 
In this graphic the relative gene expression is represented as the mean of the log2-normalised data. 
Results represent the mean ± SEM.  
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Table 24. Relative expression levels of genes with significant differences between tumour and stroma. 
GENE TUMOUR STROMA P-value GENE TUMOUR STROMA P-value 
CCL2 0.046 0.104 <0.001 CD97 0.153 0.234 <0.001 
CCL5 0.888 1.459 <0.001 CXCR4 0.618 0.738 0.003 
CSF3R 0.536 0.688 0.020 CXL12 0.070 0.255 <0.001 
CSF1R 0.376 1.029 <0.001 FOXP3 4.081 4.965 0.007 
CD127 0.555 0.942 0.001 IL10 0.397 0.887 0.002 
ITGAM 0.276 0.636 <0.001 IL23A 0.861 1.619 0.013 
CD209 0.315 0.782 <0.001 IL4R 0.174 0.229 0.012 
CD25 11.593 19.464 <0.001 ITGFB2 0.275 0.462 <0.001 
CD34 0.117 0.281 <0.001 LAG3 0.668 0.806 0.012 
CD4 1.075 1.791 <0.001 LGALS1 0.392 0.944 <0.001 
CD44 0.771 1.014 0.009 MMP2 0.956 3.250 <0.001 
CD80 2.875 4.625 <0.001 TGFB1 2.117 3.244 <0.001 
CD86 0.960 1.697 <0.001 THBD 0.094 0.244 <0.001 
CD8 1.011 1.470 0.002 NRP1 0.854 1.663 <0.001 
Tumour and stroma were compared for each gene using a pair-wise Wilcoxon test. 
2.2.4. UNSUPERVISED CLUSTERING ANALYSIS  
Unsupervised hierarchical clustering analysis was performed in order to classify 
patients and genes based on the similarity of their expression pattern. Before starting, some 
genes were excluded from the analysis due to similar expression among patients or because 
they did not pass the filter (expression data in more than 80% of the samples). We ran a 
hierarchical analysis with gene expression data from both the tumour and stroma 
compartment to test if the samples clustered according to their compartment. Although the 
clusters were enriched in samples from the same compartment, they did not completely 
separate (data not included).  
We then separately performed the hierarchical analyses with expression data from the 
tumour and stroma compartments. Using gene expression data from the stroma 
compartment, patients were classified into two major subgroups: Cluster I (n = 32) and Cluster 
II (n = 49). Patients in Cluster I had lower expression levels for most of the genes, whilst 
patients in Cluster II presented higher levels of expression in general, although there were 
subgroups with variable expression (Figure 30). 
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Figure 30. Hierarchical cluster based on gene expression data from the stroma compartment. Patients 
in the original cohort were clustered into a tree hierarchy based on the expression of 32 genes. Red 
indicates high expression and green indicates low expression.  
Hierarchical analysis performed with gene expression data from the tumour 
compartment also revealed two major subgroups: Cluster I (n = 51) and Cluster II (n = 39). 
Cluster II presented homogeneously lower gene expression levels (except from one specific 
region in the heat map). The expression pattern in Cluster I was more heterogeneous 
(although there was a tendency towards higher expression levels). Some gene expression 
patterns could be observed, for instance genes related to inflammation such as THBD, IL8, 
MMP2, and CSFR3 were grouped into the same cluster, as well as genes related to Tregs such 
as CD127, CD25, FOXP3, and CD4 (Figure 31). 
Gene expression analysis according to the compartment has been previously reported 
in other studies where sample microdissection and RNA isolation were also considered to be 
critical steps in order to obtain reliable results. For instance, using this approach a gene 
expression profile with elevated expression of genes related to extracellular matrix 
remodelling was identified exclusively in epithelial cells in breast cancer (Vargas et al., 2012). 
In colorectal cancer, a differential expression pattern with several MMPs and angiogenic 
cytokines in tumour cells compared to adjacent tumour stroma was observed. Moreover, 
cluster analysis showed that the expression of MMPs and angiogenic cytokines in stromal cells 
was tumour-site-dependent (Kahlert et al., 2014). The fact that we observed differential 
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patterns of expression in tumour and stroma cells points towards the differences between 
these two compartments in the tumour microenvironment. 
 
Figure 31. Hierarchical cluster based on gene expression data from the tumour compartment. Patients 
in the original cohort were clustered into a tree hierarchy based on expression of 32 genes. Red 
indicates high expression and green indicates low expression.  
2.3. CORRELATION OF BIOMARKERS WITH CLINICOPATHOLOGICAL 
VARIABLES 
The Mann-Whitney U test revealed that there were several significant associations 
between the expression of different genes in tumour or/and stroma compartments and 
clinicopathological variables such histology, stage, and mutational status (see Table 25). The 
expression of several genes, such as TNFα, CD97, and NRP1 was associated with histology, and 
their expression levels were higher in ADC tumours. The stage of the disease was correlated 
with the expression of IL10, ITGAM, and CD115 in the tumour compartment and with the 
expression of CD40 and LGALS2 in the stroma compartment; in all cases the expression was 
higher in patients with stage I vs. II/III cancer. Turning to the mutational status, KRAS 
correlated with CSF1R and IL4: in both cases patients with mutated versions of this gene 
presented higher expression levels of CSF1R and IL4. Patients with a mutated EGFR gene 
showed reduced IL8 expression compared to the wild type group, whereas CD40LG expression 
was higher in the EGFR mutated group. 
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Chi-square tests showed that when analysing the tumour compartment, there were 
significantly more ADC patients in Cluster I and more SCC patients in Cluster II (p = 0.007) and, 
moreover, there were more patients with larger tumours (larger than 3.5 cm) in Cluster II (p = 
0.001). These results agree with observations from individual correlations where patients with 
higher gene expression levels were grouped into Cluster I, which also contained significantly 
more ADC patients. Thus, ADC patients presented higher expression rates of 
immunoregulatory genes in the stroma and the tumour compartments. Although, to the best 
of our knowledge, this is the first study to assess expression differences in immune-related 
genes (especially immunoregulatory genes) between lung ADC and SCC, previous work has 
shown that ADC patients presented higher Treg infiltration rates than SCC patients (Black et al., 
2013). 
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Table 25. Significant correlations between gene expression values and clinicopathological variables. 
Gene 
 
Variable p-value 
 
Gene 
 
Variable p-value 
    Histology   
 
    Stage   
   SCC ADC   
 
   I II/IIIA   
CD8 T 0.624 1.299 0.044 
 
IL10 T 0.631 0.262 0.027 
S 1.094 1.648 0.008 
 
ITGAM T 0.360 0.242 0.032 
CD4 T 0.742 1.406 0.024 
 
CSF1R T 0.476 0.234 0.041 
S 1.335 2.034 0.008 
 
CD40 S 0.240 0.123 0.013 
LAG3 T 0.545 0.843 0.008 
 
LGALS2 S 0.052 0.037 0.035 
S 0.626 1.163 0.008 
 
   KRAS status   
CD97 T 0.080 0.221 <0.001 
 
    WT Mutated   
S 0.176 0.282 0.014 
 
CSF1R T 0.354 0.941 0.018 
CD80 T 1.740 3.499 0.029 
 
IL4R T 0.148 0.389 0.022 
S 3.571 5.732 0.037 
 
   EGFR status   
IL23A T 0.592 1.225 0.019 
 
    WT Mutated   
S 1.205 2.003 0.021 
 
IL8 S 1.289 0.368 0.025 
NRP1 T 0.377 1.749 <0.001 
 
CD40LG S 0.449 1.867 0.026 
S 1.135 2.130 <0.001 
      ITGB2 T 0.102 0.482 <0.001 
      CSF1R T 0.256 0.550 0.032 
      IL4R T 0.079 0.252 0.001 
      CCL5 T 0.555 0.938 0.018 
      CD34 T 0.081 0.153 0.014 
      LGALS1 T 0.303 0.474 0.014 
      MMP2 T 0.559 1.212 0.018 
      CD86 T 0.575 1.059 0.021 
      CSFR3 T 0.267 0.633 0.002 
      IL10 S 0.627 1.261 0.014 
      TNF S 0.172 0.474 <0.001 
      CD1C S 0.199 0.631 0.004 
      CSF3R S 0.461 0.834 0.003 
      IL23A S 1.205 2.003 0.021 
      CD40 S 0.128 0.227 0.029 
      CXCR4 S 0.606 0.945 0.020 
      ADC, adenocarcinoma; SCC, squamous cell carcinoma;  
T, tumour; S, stroma; WT, wild type. 
Results & Discussion 
101 
 
2.4. BIOMARKER SURVIVAL ANALYSIS 
2.4.1. CLINICOPATHOLOGICAL VARIABLES 
Of the 122 resected NSCLC patients included in this part of the study, 68 (55.7%) 
relapsed and 67 (54.9%) died. The median follow-up was of 53.3 months [range: 1-113]. The 
results obtained in the univariate analysis using the Cox regression method are shown in Table 
26. The only variable that was associated with prognosis in this set of patients was the tumour 
size (p = 0.025); patients with tumours more than 3.5 cm had a shorter PFS. 
Table 26. Results from survival analysis based on clinicopathological variables. 
 OS PFS 
Variable HR [95% CI] p-value HR [95% CI] p-value 
Gender 
      Male vs. Female 3.558 0.864-14.656 0.079 2.157 0.782-5.952 0.138 
Age (years) 
      >65 vs. ≤ 65 1.707 0.970-3.003 0.064 1.217 0.730-2.028 0.452 
Stage 
      II/IIIA vs. I 0.785 0.447-1.379 0.400 1.048 0.634-1.734 0.854 
Histology 
      ADC vs. SCC vs. Others 0.806 0.515-1.262 0.346 1.061 0.709-1.586 0.773 
Tumour size 
      >3.5 cm vs. ≤ 3.5 cm 1.218 0.694-2.135 0.492 1.806 1.079-3.024 0.025* 
LN involvement 
      Yes vs. No 1.224 0.669-2.239 0.512 1.289 0.743-2.237 0.366 
PS 
      1/2 vs. 0 1.291 0.687-2.424 0.427 1.469 0.838-2.577 0.179 
Differentiation grade 
      Poor vs. Well/Moderate 0.991 0.521-1.885 0.979 1.042 0.585-1.856 0.888 
Smoking status 
      Former/Current vs. Never 1.427 0.513-3.975 0.496 1.314 0.564-3.058 0.527 
EGFR 
      Wild type vs. Mutated 0.426 0.097-1.864 0.257 1.019 0.379-2.744 0.970 
KRAS 
      Mutated vs. Wild type 1.914 0.744-4.926 0.178 1.901 0.800-4.518 0.146 
CI, confidence interval; EGFR; epidermal growth factor receptor; HR, hazard ratio; LN, lymph node; OS, 
overall survival; PFS, progression free survival; PS, performance status; *p < 0.05. 
2.4.2. HIERARCHICAL CLUSTERS 
Survival analysis carried out with cluster groups obtained from the gene expression 
data showed that patients in stromal Cluster I had a worse PFS than in Cluster II (17.4 vs. 44.3 
months, p = 0.006; Figure 32b). With regard to the tumoural clustering, patients in Cluster II 
had a worse OS than patients in Cluster I (34.4 vs. 70.4 months, p = 0.005) as well as a shorter 
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PFS (19.1 vs. 32.5 months, p = 0.010; Figure 32c-d). As we previously observed when analysing 
clusters obtained from fresh-frozen samples, groups of patients with higher immune-related 
gene expression had better outcomes.  
Here we found an association between stromal clusters and PFS, but tumoural clusters 
were also associated with PFS and OS. Other studies have previously reported the prognostic 
value of expression signatures according to specific compartments in the tumour 
microenvironment. For instance, in a study carried out in breast cancer using microdissection 
and microarray technologies, a new stroma-derived prognostic predictor that stratified disease 
outcome, independently of standard clinical prognostic factors, was identified. Interestingly, 
the presence of immune cells within the stroma was diminished in individuals in the poor-
outcome cluster. Instead, stroma from individuals in the poor-outcome cluster showed 
increased hypoxic and angiogenic response markers and a decrease in the expression of 
chemokines that stimulate NK cell migration and mediate pro-survival signals in T lymphocytes 
(Finak et al., 2008). Another group analysed expression signatures in the tumour and stroma 
compartment of SCC cells from NSCLC patients, and observed that many markers related to 
longer survival were predominantly expressed in the stroma, particularly MHC-II complex 
genes (Bendrat et al., 2012). 
These results provide insight into the importance of immunoregulatory markers in 
NSCLC prognosis, and indicate that tumour and stroma are independent entities inside the 
tumour microenvironment, with different characteristics due to the differences in immune cell 
infiltration. Cluster analysis has provided a global vision of the impact of immunoregulatory 
markers on prognosis, however these results must also be dissected in order to assess which of 
these markers have a prognostic role when individually analysed. 
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Figure 32. Kaplan-Meier plots for OS and PFS according to clustering classification. a-b) Clusters 
obtained from stroma gene expression data and, c-d) clusters obtained from tumoural data. Blue line 
represents patients classified in Cluster I and green line represent patients in Cluster II. P-values were 
obtained using the Kaplan-Meier test. 
2.4.3. INDIVIDUAL BIOMARKERS 
The prognostic impact of the analysed genes that were involved in tumour 
immunoregulation was assessed both for their expression in tumour and in adjacent stroma by 
univariate COX regression analysis. For this purpose the gene expression levels were 
dichotomised according to the median of each one. The results obtained from these univariate 
analyses are shown in Tables 27 and 28. 
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Table 27. Results from the survival analysis based on gene expression biomarkers in stroma areas. 
STROMA 
 OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
FOXP3 
High vs. Low 0.772 0.413-1.441 0.416 0.869 0.498-1.515 0.620 
CD4 
High vs. Low 0.942 0.536-1.655 0.835 1.235 0.744-2.050 0.415 
CD8 
High vs. Low 0.521 0.285-0.954 0.035* 0.728 0.430-1.234 0.239 
CD25 
High vs. Low 1.565 0.864-2.837 0.139 1.612 0.944-2.754 0.080 
CD127 
High vs. Low 0.822 0.448-1.508 0.526 0.936 0.545-1.607 0.810 
TLA4 
High vs. Low 0.873 0.454-1.681 0.686 0.579 0.321-1.042 0.068 
NRP1 
High vs. Low 1.170 0.667-2.053 0.584 1.038 0.624-1.726 0.885 
LAG3 
High vs. Low 0.828 0.424-1.617 0.581 1.004 0.562-1.796 0.989 
GITR 
High vs. Low 0.616 0.195-1.943 0.408 0.620 0.256-1.505 0.291 
TGFB1 
High vs. Low 0.720 0.404-1.283 0.265 0.889 0.531-1.489 0.655 
IL10 
High vs. Low 0.949 0.374-2.411 0.913 0.756 0.345-1.652 0.483 
LGALS1 
High vs. Low 1.320 0.748-2.332 0.338 1.091 0.654-1.820 0.738 
LGALS2 
High vs. Low 1.485 0.634-3.478 0.362 0.891 0.444-1.788 0.745 
IDO1 
High vs. Low 0.824 0.435-1.558 0.551 0.827 0.470-1.458 0.512 
ITGAM 
High vs. Low 1.441 0.792-2.622 0.232 1.313 0.770-2.241 0.317 
ITGB2 
High vs. Low 1.162 0.652-2.069 0.611 1.038 0.613-1.756 0.891 
CD97 
High vs. Low 0.841 0.459-1.539 0.573 0.958 0.560-1.640 0.876 
IL4R 
High vs. Low 0.928 0.505-1.704 0.810 0.966 0.560-1.665 0.900 
CD209 
High vs. Low 1.031 0.508-2.094 0.933 0.831 0.442-1.560 0.564 
CD1C 
High vs. Low 0.794 0.337-1.871 0.597 1.232 0.603-2.519 0.567 
CD86 
High vs. Low 0.610 0.320-1.160 0.132 0.794 0.451-1.399 0.424 
CD80 
High vs. Low 0.545 0.279-1.067 0.077 0.698 0.393-1.238 0.218 
CD34 
High vs. Low 0.764 0.416-1.402 0.384 0.655 0.375-1.144 0.137 
CD40 
High vs. Low 0.976 0.420-2.267 0.954 0.898 0.448-1.803 0.763 
CD40LG 
High vs. Low 1.068 0.447-2.552 0.883 1.175 0.571-2.415 0.661 
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TNF 
High vs. Low 0.396 0.110-1.431 0.158 0.922 0.331-2.568 0.877 
IL8 
High vs. Low 1.335 0.736-2.421 0.341 1.274 0.745-2.179 0.376 
MMP2 
High vs. Low 0.925 0.526-1.629 0.788 1.069 0.642-1.781 0.798 
THBD 
High vs. Low 0.876 0.460-1.669 0.687 1.074 0.605-1.907 0.808 
CSF1R 
High vs. Low 1.304 0.717-2.371 0.384 1.076 0.630-1.836 0.789 
CSF3R 
High vs. Low 0.692 0.361-1.324 0.266 0.588 0.330-1.049 0.072 
IL23A 
High vs. Low 0.950 0.527-1.714 0.866 0.838 0.491-1.430 0.518 
CCL2 
High vs. Low 0.954 0.476-1.911 0.895 0.963 0.523-1.775 0.904 
CCL22 
High vs. Low 1.473 0.629-3.450 0.372 1.296 0.638-2.631 0.473 
CCL5 
High vs. Low 0.471 0.259-0.858 0.014* 0.700 0.415-1.181 0.181 
CXCL12 
High vs. Low 0.668 0.369-1.210 0.183 0.652 0.384-1.107 0.113 
CXCR4 
High vs. Low 0.819 0.455-1.474 0.505 0.855 0.501-1.460 0.567 
CD44 
High vs. Low 0.955 0.545-1.672 0.871 1.150 0.691-1.913 0.591 
Gene expression levels dichotomised as high and low according to their median. The results were 
obtained using a univariate Cox regression method. CI, confidence interval, HR, hazard ratio; OS, overall 
survival; PFS, progression free survival; *p < 0.05. 
Univariate Cox regression analysis showed significant associations between CD4 and 
CD8 expression levels and survival in NSCLCs. In particular, we observed that CD4 expression in 
the tumour compartment was correlated with OS [HR, 0.491; 95% CI, 0.269-0.896; p = 0.021] 
and PFS [HR, 0.585; 95% CI, 0.347-0.986; p = 0.044]. Kaplan-Meier analysis performed to 
obtain survival plots indicated that patients with high CD4 expression had a better OS (81.2 vs. 
42.9 months, p = 0.018) and longer PFS (37.8 vs. 23 months, p 0.042; Figure 33a-b). CD8 was 
also significantly correlated with OS [HR, 0.340; 95% CI, 0.182-0.636; p = 0.001] and PFS [HR, 
0.417; 95% CI, 0.243-0.716; p = 0.002]. In fact, the Kaplan-Meier test revealed that high levels 
of CD8 expression were associated with better survival (OS: 81.2 vs. 37.2 months, p < 0.001 
and PFS: 81.2 vs. 19.4 months, p = 0.001; Figure 33c-d). In the stroma compartment no 
significant results were obtained for CD4 gene expression, and only for OS but not PFS for CD8 
[HR, 0.521; 95% CI, 0.285-0.954; p = 0.035].  
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Table 28. Results from the survival analysis based on gene expression biomarkers in tumour areas. 
TUMOUR 
 OS PFS 
Variable HR [95% CI] p-value HR [95% CI] p-value 
FOXP3 
High vs. Low 0.407 0.214-0.773 0.006* 0.521 0.298-0.911 0.022* 
CD4 
High vs. Low 0.491 0.269-0.896 0.021* 0.585 0.347-0.986 0.044* 
CD8 
High vs. Low 0.340 0.182-0.636 0.001* 0.417 0.243-0.716 0.002* 
CD25 
High vs. Low 0.792 0.433-1.447 0.447 0.772 0.448-1.331 0.352 
CD127 
High vs. Low 0.592 0.320-1.096 0.095 0.626 0.362-1.083 0.094 
CTLA4 
High vs. Low 0.811 0.431-1.525 0.515 0.825 0.470-1.450 0.504 
NRP1 
High vs. Low 0.757 0.420-1.362 0.353 0.912 0.539-1.543 0.731 
LAG3 
High vs. Low 0.513 0.284-0.924 0.026* 0.649 0.382-1.102 0.109 
GITR 
High vs. Low 0.859 0.318-2.320 0.765 0.736 0.337-1.607 0.442 
TGFB1 
High vs. Low 0.534 0.298-0.957 0.035* 0.703 0.422-1.171 0.176 
IL10 
High vs. Low 0.887 0.307-2.561 0.824 1.176 0.489-2.829 0.718 
LGALS1 
High vs. Low 1.019 0.576-1.803 0.948 1.263 0.754-2.113 0.375 
LGALS2 
High vs. Low 0.872 0.438-1.735 0.695 1.013 0.548-1.873 0.967 
IDO1 
High vs. Low 0.573 0.313-1.052 0.072 0.598 0.348-1.027 0.062 
ITGAM 
High vs. Low 0.941 0.519-1.706 0.842 0.715 0.416-1.228 0.224 
ITGB2 
High vs. Low 1.162 0.652-2.069 0.611 0.647 0.376-1.115 0.117 
CD97 
High vs. Low 0.659 0.367-1.183 0.163 0.772 0.456-1.307 0.335 
IL4R 
High vs. Low 1.293 0.702-2.382 0.410 1.267 0.730-2.200 0.401 
CD209 
High vs. Low 0.346 0.167-0.713 0.004* 0.302 0.157-0.581 0.000* 
CD1C 
High vs. Low 0.527 0.223-1.249 0.146 0.738 0.364-1.497 0.400 
CD86 
High vs. Low 0.739 0.401-1.364 0.334 0.791 0.456-1.371 0.403 
CD80 
High vs. Low 0.478 0.243-0.941 0.033* 0.811 0.455-1.443 0.475 
CD34 
High vs. Low 0.712 0.395-1.285 0.260 1.002 0.592-1.697 0.993 
CD40 
High vs. Low 0.479 0.206-1.112 0.087 0.551 0.271-1.122 0.101 
CD40LG 
High vs. Low 0.426 0.165-1.101 0.078 0.498 0.223-1.111 0.088 
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TNF 
High vs. Low 0.522 0.178-1.533 0.237 0.596 0.242-1.465 0.259 
IL8 
High vs. Low 1.012 0.556-1.844 0.968 0.624 0.363-1.072 0.088 
MMP2 High 
vs. Low 0.485 0.262-0.896 0.021* 0.594 0.350-1.007 0.053 
THBD 
High vs. Low 1.175 0.607-2.276 0.632 1.570 0.871-2.829 0.134 
CSF1R 
High vs. Low 0.782 0.437-1.398 0.407 0.827 0.489-1.399 0.478 
CSF3R 
High vs. Low 0.878 0.463-1.663 0.689 0.820 0.465-1.443 0.490 
IL23A 
High vs. Low 0.514 0.283-0.934 0.029* 0.634 0.374-1.074 0.090 
CCL2 
High vs. Low 0.852 0.415-1.749 0.662 0.963 0.523-1.775 0.904 
CCL22 
High vs. Low 0.316 0.131-0.760 0.010* 1.296 0.638-2.631 0.473 
CCL5 
High vs. Low 0.639 0.350-1.169 0.146 0.622 0.361-1.071 0.087 
CXCL12 
High vs. Low 0.753 0.410-1.385 0.362 0.881 0.511-1.517 0.647 
CXCR4 
High vs. Low 0.920 0.513-1.650 0.781 0.976 0.575-1.656 0.928 
CD44 
High vs. Low 0.663 0.374-1.174 0.159 0.784 0.472-1.301 0.346 
Gene expression levels dichotomised as high and low according to their median. The results were 
obtained using a univariate Cox regression method. CI, confidence interval; HR, hazard ratio; OS, overall 
survival; PFS, progression free survival; *p < 0.05. 
CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, 
monocytes, macrophages, and DCs. The CD4 T helper lymphocyte is responsible for 
orchestrating two different but overlapping cytokine patterns that influence other effector 
cells and in turn shape the pattern of the inflammatory response. CD4 has been widely 
assessed in the tumour microenvironment by IHC, but little has been published regarding its 
expression at the mRNA level. Contradictory results have been reported regarding the 
presence of CD4+ cells in different types of cancer. Some publications associate their presence 
with a better prognosis in pancreas adenocarcinoma and oesophageal squamous carcinoma 
(Cho et al., 2003; Fukunaga et al., 2004), whereas in others tumours , like in renal cell cancer, 
the presence of CD4+ cells was correlated with shorter survival (Bromwich et al., 2003). In lung 
tumours, multivariate analyses show a low risk of death for SCC patients with a relatively high 
percentage of CD4+ lymphocytes (da Costa et al., 2012). Other authors have reported that the 
presence of stromal CD4+ lymphocytes correlates with improved survival (Al-Shibli et al., 2008; 
Hald et al., 2013; Wakabayashi et al., 2003). However, in our study mRNA expression levels of 
CD4 in stroma were not associated with prognosis. 
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Figure 33. Kaplan-Meier plots for OS and PFS according to gene expression markers in the tumour 
compartment. a-b) Tumoural CD4 and c-d) tumoural CD8. Gene expression levels were dichotomised 
according to their medians. The blue line represents patients with low expression levels, whilst the 
green line represents patients with high expression levels. P-values were obtained using the Kaplan-
Meier test. 
CD8 is a transmembrane glycoprotein that serves as a co-receptor for the TCR, which is 
predominantly expressed on the surface of cytotoxic T cells, but can also be found on NK cells, 
cortical thymocytes, and DCs. The presence of CD8+ cells in tumour specimens has been 
associated with a good prognosis in virtually every tumour in which it has been analysed 
(Fridman et al., 2012). Ruffini et al. showed that CD8+ cells in NSCLCs were associated with 
prolonged survival, but only in a subset of SCCs (Ruffini et al., 2009). However, in our study this 
correlation was observed in the entire cohort, including ADC patients. Other studies have also 
reported that high CD8+ cell infiltration in stroma was a favourable prognostic factor in NSCLC 
(Al-Shibli et al., 2008; Hiraoka et al., 2006a).  
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Another marker with a prognostic value when analysed only within the tumour nest 
was FOXP3. Univariate COX regression analysis showed that it correlates with both OS [HR, 
0.407; 95% CI, 0.214-0.773; p = 0.006] and PFS [HR, 0.521; 95% CI, 0.298-0.911; p = 0.022]. 
Patients with high levels of FOXP3 had a better OS (NR vs. 37.2 months, p = 0.005, Kaplan-
Meier log rank), and longer PFS (35.3 vs. 22.1 months, p = 0.020, Kaplan-Meier log rank). 
Interestingly, FOXP3 gene expression in stroma was not associated with prognosis (Figure 34a-
b). This result is in line with our observations, described in the previous section, that higher 
levels of FOXP3 in the whole tumour were correlated with a better prognosis, although these 
results might seem controversial because FOXP3 is a specific Treg marker. As previously 
discussed, we analysed the mRNA expression markers present in the whole tumour 
microenvironment and therefore it is not possible to know which specific cells express this 
transcription factor. Therefore in this section we decided to evaluate the prognostic value of 
FOXP3 taking its location into consideration. The fact that FOXP3 was found to correlate with a 
better outcome in the tumour but not in the stroma compartment reinforces the theory that 
tumour cells may also express FOXP3. 
 
Figure 34. Kaplan-Meier plots for OS and PFS according to FOXP3 gene marker expression in the 
tumour compartment. a) OS and, b) PFS. Gene expression levels were dichotomised according to their 
median. Blue line represents patients with low levels of expression, whilst the green line represents 
patients with high levels of expression. P-values were calculated using the Kaplan-Meier test. 
Other less-studied immunoregulatory genes were also associated with survival in our 
patient cohort. For instance, CCL5 expression levels in the stroma compartment were 
associated with patient survival [HR, 0.471; 95% CI, 0.259-0.858; p = 0.014]. Patients with high 
levels of CCL5 expression levels had a longer OS (70.4 vs. 37.2 months, p = 0.012), as shown in 
the Kaplan-Meier plot (Figure 35a). C-C chemokine ligand 5 (CCL5), also known as Regulated 
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upon Activation, Normal T-cell Expressed, and Secreted (RANTES), is expressed by T 
lymphocytes, macrophages and platelets, and plays an active role in recruiting a variety of 
leukocytes into inflammatory sites including T cells, macrophages, eosinophils, and basophils 
(Aldinucci and Colombatti, 2014). In collaboration with certain cytokines that are released by T 
cells such as IL2 and IFNγ, CCL5 induces the activation and proliferation of particular NK cells to 
generate C-C chemokine-activated killer cells (Soria and Ben-Baruch, 2008). CCL5 production is 
relevant to the induction of proper immune responses against tumours but it is also associated 
with cancer progression and metastasis (Hanahan and Coussens, 2012). 
A number of solid tumours express CCL5 and/or CCR5, but the involvement of this pair 
of genes in cancer progression and development has only been studied in depth in some 
malignancies. CCL5 expression by breast tumour cells is a valuable prognostic factor for 
detection of stage II breast cancer in patients at risk for disease progression (Yaal-Hahoshen et 
al., 2006). In lung cancer, CCL5 mRNA expression by tumour cells in patients with stage I lung 
adenocarcinoma was associated with improved survival (Moran et al., 2002). The authors 
pointed out that the reasons for the different prognostic values obtained from one tumour 
type to another remain unknown and therefore may be worthy of future study. A recent 
publication showed that low plasma levels of CCL5 at the time of diagnosis (in patients treated 
with EGFR-TKIs) were significantly associated with long-term survival. These results suggest 
that the network of pro-inflammatory cytokines was affected by EGFR-TKI treatment and that 
the patient outcome may be influenced by the status of plasma pro-inflammatory cytokines at 
diagnosis (Umekawa et al., 2013). 
In the tumour nest, more markers proved to have a prognostic value than in the 
stroma compartment. For instance, we found an association between gene expression levels 
and OS for LAG3 [HR, 0.513; 95% CI, 0.284-0.924; p = 0.026], and patients that had high 
expression levels of this marker had better outcomes (69 vs. 36.2 months, p = 0.023 Kaplan-
Meier test; Figure 36a). LAG3 was cloned over 20 years ago as a CD4 homologue, but its 
function as an immune checkpoint was not defined until 2005 when it was shown to have a 
role in enhancing the function of Treg cells. LAG3 is one of various immune-checkpoint 
receptors that are coordinately upregulated on both Treg and anergic T cells, and PD1 and 
LAG3 are commonly co-expressed on anergic or exhausted T cells (Pardoll, 2012). LAG3 
blockade, alone and in combination with nivolumab, is currently being explored in early-phase 
investigations (Creelan, 2014). To the best of our knowledge, the prognostic value of LAG3 has 
not yet been assessed in NSCLCs or in any other tumour types. Therefore our results are the 
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first to indicate the positive prognostic value of this immune checkpoint, which may have a 
role in cancer that is similar to PD1. However, further studies are still required to validate the 
prognostic role of LAG3 and to evaluate if LAG3 blockade is of any clinical use for 
immunotherapy. 
 
Figure 35. Kaplan-Meier plots for OS and PFS according to CCL5 gene expression in the stroma 
compartment. a) OS and, b) PFS. Gene expression levels were dichotomised according to their medians. 
The blue line represents patients with low levels of expression, whilst the green line represent patients 
with high levels of expression. P-values were calculated using the Kaplan-Meier test. 
Another marker which was significantly associated with OS when expressed in the 
tumour compartment was TGFB1 [HR, 0.534; 95% CI, 0.298-0.957; p = 0.035]. The group of 
patients with higher TGFB1 expression levels had a better OS (46.6 vs. 74.3 months, p = 0.032 
Kaplan-Meier test; 36b). The TGFB1 signalling pathway plays a critical and dual role in the 
progression of human cancer: during the early phase of tumour progression, TGFB1 acts as a 
tumour suppressor, but it promotes processes that support tumour progression such as 
tumour cell invasion, dissemination, and immune evasion. Consequently, the functional 
outcome of the TGFB1 response is strongly dependent on the context of the cell, tissue, cancer 
type, etc. (Meulmeester and Ten, 2011). Most of the studies reporting TGFB1 expression 
assessed its expression using two different approaches: IHC or enzyme-linked immunosorbent 
assay (ELISA). Using the first approach Valkov et al. observed that high TGFB1 expression was 
an independent negative prognostic factor for disease-specific survival (DSS) in soft tissue 
sarcomas (Valkov et al., 2011). Other work using the second approach showed that serum 
TGFB1 levels were elevated in breast cancer patients and that this had a favourable prognostic 
value (Ciftci et al., 2014). In NSCLC, recent work assessed TGFB1 expression using IHC in 105 
samples and reported that patients with positive TGFB1 and negative Eps15 homology domain 
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1 (EHD1) expression had much longer survival times than patients with other combinations 
(Gao et al., 2014). However, other studies have reported the opposite prognosis for high 
TGFB1 expression levels (Zhao et al., 2010). 
 
Figure 36. Kaplan-Meier plots for OS according to gene expression levels in the tumour compartment. 
a) LAG3 and b) TGFB1. Gene expression levels were dichotomised according to their medians. The blue 
line represents patients with low levels of expression, whilst the green line represents patients with high 
levels of expression. P-values were calculated using the Kaplan-Meier test. 
Expression of CD209 in the tumour compartment was also associated with a better OS 
[HR, 0.346; 95% CI, 0.167-0.713; p = 0.004] and longer PFS [HR, 0.302; 95% CI, 0.157-0.581; p < 
0.001], and Kaplan-Meier plots (Figure 37a-b) indicated that patients with high expression 
levels of CD209 had a better OS (34.4 vs. 81.2 months, p = 0.003) and PFS (16.2 vs. 81.2 
months, p < 0.001). This is the first study to explore the prognostic value of CD209, which is 
also known as DG-SIGN. DC-SIGN is a type II transmembrane C-type lectin receptor that is 
mostly expressed on myeloid DCs, but can also be expressed in macrophages. DCs have often 
been denominated master immune response regulators and several groups have proposed 
vaccination strategies aimed at targeting antigens to DCs for the treatment of cancer (van et 
al., 2013). In a recent publication, the expression of soluble DC-SIGN (sDC-SIGN) and its 
receptor was evaluated by ELISA in the serum of patients with colon cancer, and by IHC in 
cancer tissue, showing that high levels of sDC-SIGN were indicative of much longer survival 
times (Jiang et al., 2014). Although in this publication it was the soluble form that had a 
prognostic value, our observations are in line with these results. In summary, it seems that 
CD209 expression may indicate the presence of DCs which might have a positive impact on the 
tumour microenvironment. Therefore follow-up studies with larger cohorts should be carried 
out in order to validate the prognostic value of this very promising immune-marker. 
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Figure 37. Kaplan-Meier plots for OS and PFS according to CD209 gene expression levels in the tumour 
compartment. a) OS and, b) PFS. Gene expression levels were dichotomised according to their medians. 
The blue line represents patients with low levels of expression, whilst the green line represent patients 
with high levels of expression. P-values were calculated using the Kaplan-Meier test. 
Univariate analysis was also performed in ADC and SCC patients separately. The 
number of patients was quite low but some of the statistically significant results obtained in 
the entire cohort were also observed. In ADC patients, we found that tumoural expression 
levels of CD4, CD8, and FOXP3, but not the rest of the markers, were associated with survival. 
In SCC patients CD8 expression in the stroma and CD209 expression in the tumour were 
correlated with OS and PFS (Supplementary Table 2). 
2.4.4. COMBINED BIOMARKERS 
In this part of the study combined biomarkers were assessed in order to evaluate the 
prognostic value of some of the biomarkers together. Only the combinations that were 
associated with survival have been included. First we analysed the CD25 and CD127 
combination. Although FOXP3 is a specific marker of regulatory T cells, these can also be 
defined as T cells expressing high levels of CD25 and low levels of CD127 (Liu et al., 2006). 
Therefore, we decided to evaluate the prognostic role of this combination in both the tumour 
and stroma compartments. To do this we calculated the ratio of CD25 to CD127 for both 
sample sets, which showed that patients with a high ratio level in the stroma compartment 
(patients with high CD25 expression and low CD127 expression) had a worse OS [HR, 2.089; 
95% CI, 1.093-3.991; p = 0.026] and shorter PFS [HR, 1.882; 95% CI, 1.066-3.322; p = 0.029]; 
the differences in the median survival rates for OS were 42.9 vs. 81.2 months (p = 0.023, 
Kaplan-Meier test) and for PFS it was 19.1 vs. 35 months (p = 0.029, Kaplan-Meier test; Table 
29; Figure 38). 
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Figure 38. Kaplan-Meier plots for OS and PFS according to the combination of CD25 and CD127 in the 
stroma compartment. a) OS and, b) PFS. Gene expression levels were dichotomised according to their 
medians. The green line represents patients with high levels of the ratio, whilst the blue line represents 
patients with low levels. P-values were calculated using the Kaplan-Meier test. 
This combination of markers has been previously used to isolate Tregs from the T cell 
population (Yu et al., 2012); therefore, our results might indicate that patients with a Treg 
phenotype in the stroma compartment have worse survival rates than the other groups of 
patients. However, since the expression of these markers was assessed at the mRNA level, 
their specific cell origin remains unknown. No previous studies have evaluated the CD25 and 
CD127 combination at the mRNA level; however the frequency of CD4+ CD25high CD127low cells 
assessed by flow cytometry in patients with gastric cancer suggested that these cells are 
present at higher frequencies in patients with advanced stages of the disease (Shen et al., 
2009). 
We also decided to further study the prognostic value of conventional T cell markers 
such as CD4 (a T helper cell marker), and CD8 (a T cytotoxic cell marker) in combination with 
FOXP3, the most specific Treg marker so far found. To do this we calculated new variables 
based on the ratio of these markers. From the different combinations that were tested by 
univariate Cox regression analysis, we found that the ratio between FOXP3 expression 
assessed in the stroma compartment, and the expression of CD4 and CD8 in the tumour nest, 
had a prognostic value. In fact, patients with high FOXP3 expression levels in the stroma and 
low CD4 levels in the tumour, or high FOXP3 levels in stroma and low CD8 levels in the tumour, 
had worse survival rates. In particular, patients with a high Foxp3 stroma/CD4 tumour ratio 
had a worse OS [HR, 2.341; 95% CI, 1.179-4.649; p = 0.015], with a median survival of 46.6 vs. 
81.2 months (p = 0.012, Kaplan-Meier test) and a worse PFS [HR, 2.070; 95% CI, 1.149-3.730; p 
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= 0.015], with a median survival of 19.4 vs. 37.8 months (p = 0.013, Kaplan-Meier test; Figure 
39a-b). As for the FOXP3 stroma/CD8 tumour ratio, patients with a high ratio had a worse OS 
[HR, 2.141; 95% CI, 1.083-4.232; p = 0.029] and PFS [HR, 1.830; 95% CI, 1.012-3.310; p = 0.046]. 
Kaplan-Meier plots (Figure 39c-d) indicated that the median survival was shorter than in the 
low ratio group for both OS (46.4 vs. 74.3 months, p = 0.025) and PFS (23 vs. 37.8, months p = 
0.042; Table 29). Although, we cannot be certain about the origin of any of these markers due 
to the nature of the methodology we used, we can say that the proportion of certain immune 
mRNA markers in the different locations of the tumour microenvironment have a prognostic 
value. To the best of our knowledge, no similar studies have been reported so far, and any 
attempt to evaluate the proportion of immune cells has always been made by IHC.  
The ratio between FOXP3 expression in the stroma to its expression in the tumour was 
also evaluated. The rationale for doing this analysis was that high FOXP3 expression in the 
tumour compartment alone was correlated with better survival rates, but patients with high 
expression levels of the same marker in the stroma in comparison to the expression of CD4 
and CD8 in the tumour had shorter survival rates. Thus, to further analyse this matter, we 
calculated a new ratio (FOXP3 stroma/FOXP3 tumour ratio), observing that patients with high 
levels of FOXP3 in stroma and low levels of FOXP3 in tumour had a worse OS [HR, 3.150; 95% 
CI, 1.464-6.777; p = 0.003], with a median survival of 42.9 months vs. NR (p = 0.002, Kaplan-
Meier test) and a shorter PFS [HR, 2.962; 95% CI, 1.545-5.679; p = 0.001] with a median 
survival of 19.4 months vs. NR (p = 0.001 Kaplan-Meier test; Figure 39e-f; Table 29).  
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Table 29. Results from univariate Cox regression analysis of combined biomarkers. 
  OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
Ratio CD25 stroma/ 
 CD127 stroma 
High vs. low 2.089 1.093-3.991 0.026* 1.882 1.066-3.322 0.029* 
Ratio FOXP3 stroma/ 
CD4 tumour 
High vs. Low 2.341 1.179-4.649 0.015* 2.070 1.149-3.730 0.015* 
Ratio FOXP3 stroma/ 
CD8 tumour 
High vs. Low 2.141 1.083-4.232 0.029* 1.830 1.012-3.310 0.046* 
Ratio FOXP3 stroma/ 
FOXP3 tumour 
High vs. Low 3.150 1.464-6.777 0.003* 2.962 1.545-5.679 0.001* 
Gene expression levels dichotomised as high and low according to their medians. CI, confidence interval; 
HR, hazard ratio; OS, overall survival; PFS, progression free survival; *p < 0.05. 
From these results we infered that the prognostic value of FOXP3 expression depends 
on its location. When we analysed FOXP3 expression in the stroma compartment alone no 
association with survival was observed. However, if we take what is happening in the tumour 
at the same time into account, the picture changes and a subgroup of patients with high 
expression levels of FOXP3 in the stroma but low expression levels in the tumour associated 
with worse survival emerge. The reasons behind this phenomenon remain unknown, but one 
could hypothesise that FOXP3 expressed by other cells, such as tumour cells for instance (Tao 
et al., 2012), may attenuate the negative prognostic effect of FOXP3 expression by Tregs in the 
stroma compartment. In order to obtain further insight into this problem and to elucidate 
what is happening in the tumour microenvironment in NSCLCs, the presence of Tregs in situ 
was assessed by IHC and its prognostic consequences were analysed. 
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Figure 39. Kaplan-Meier plots for OS and PFS according the ratios calculated. a-b) FOXP3 stroma/ CD4 
tumour ratio, c-d) FOXP3 stroma/CD8 tumour ratio, and e-f) FOXP3 stroma/FOXP3 tumour ratio. Gene 
expression levels were dichotomised according to their medians. The blue line represents patients with 
low levels, whilst the green line represents patients with high levels. P-values were calculated using the 
Kaplan-Meier test. 
Results & Discussion 
118 
 
2.4.5. GENE EXPRESSION SCORE 
Gene expression levels obtained in this part of the study were also used to find a score 
associated with patient survival. As described in a previous section, and following the criteria 
from Lossos et al. (Lossos et al., 2004), genes were selected to comprise the expression score 
according to their Z-scores. Expression levels of CD80, CXCL12, and CCL22 were selected for 
construction of the stroma score, whilst expression of CD25, CD4, TGFB1, CD44, CD1C, and 
THBD were used to construct the tumour score (Figure 40). 
 
Figure 40. Univariate analysis of 37 genes analysed in order to assess their association with the overall 
survival (OS). The genes are ranked based on their predictive power (univariate Z-score). Dashed lines 
indicate |Z-score| = 1.5. Blue bars represent the Z-scores. This criterion was used for selecting genes to 
include in the multivariate Cox regression model used to calculate the expression score. 
These genes were selected to construct the prognostic signatures by introducing them 
into multivariate models; the results from these are detailed in Table 30 and Table 31. Positive 
regression coefficients from multivariate analysis indicate that the genes are associated with 
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longer survival, whilst genes with negative regression coefficients are associated with shorter 
survival. The expression scores were classified as high or low according to their median. 
Table 30. Results from the multivariate model with genes included in the stromal expression score. 
Variable 
Regression 
coefficient 
SE p-value HR 95% CI 
CD80 -0.034 0.036 0.339 0.966 0.900-1.037 
CXCL12 -1.176 0.651 0.070 0.308 0.086-1.103 
CCL22 0.030 0.013 0.024 1.030 1.004-1.058 
CI, confidence interval; HR, hazard ratio; SE, standard error. 
Table 31. Results from the multivariate model with genes included in the tumoural expression score. 
Variable 
Regression 
coefficient 
SE p-value HR 95% CI 
CD25 -0.027 0.016 0.085 0.973 0.944-1.004 
CD4 -0.197 0.169 0.242 0.821 0.590-1.143 
TGFB1 -0.112 0.140 0.424 0.894 0.679-1.177 
CD44 -0.575 0.267 0.031 0.562 0.333-0.948 
CD1C 0.246 0.083 0.003 1.280 1.088-1.504 
THBD 2.205 0.782 0.005 9.072 1.959-42.015 
CI, confidence interval; HR, hazard ratio; SE, standard error. 
Therefore, the formula used for the stroma score was: 
  
The formula used for the tumour score was: 
 
 
The prognostic impact of tumour and stroma expression scores were then evaluated, 
observing that: a) the stroma-expression score did not correlate with survival, and b) a high 
tumour-expression score significantly correlated with worse OS (33.4 vs. 99 months, p = 0.001) 
as well as with shorter PFS, although this latter association was weaker (19.4 vs. 35.4 months, 
p = 0.026; Figure 41a-b). Because a high tumour-expression score was correlated with worse 
survival, it should be considered as a risk score. 
(CD80 x -0.034) + (CXCL12 x-1.176) + (CCL22 x 0.030) 
(CD25 x -0.027) + (CD44 x -0.575) + (CD1C x 0.246) + 
(THBD x 2.205) + (CD4 x -0.197) + (TGFB1 x -0.112) 
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The association between the tumour-risk score (TRS) and the clinicopathological 
variables was assessed, and a correlation between this score and tumour size (≤ 3.5 and > 3.6 
cm) was observed (p = 0.006, Chi-square test). Patients with larger tumour sizes were more 
likely to be classified as having a high expression-TRS. When stratified according to the tumour 
size, the tumour-expression score was associated with OS in patients with large tumours (23.8 
vs. NR months, p = 0.001). 
 
Figure 41. Kaplan-Meier plots according to the tumour risk score (TRS). a) OS and, b) PFS. The score 
was divided into low and high according to its median. The blue line represents patients with low levels 
of expression, whilst the green line represents patients with high score levels. P-value calculated using 
the Kaplan-Meier test. 
There was no correlation between survival and the stroma expression score, which 
comprised the expression of genes related to immune cell trafficking and antigen presentation. 
This lack of correlation is in line with results observed in individual gene expression survival 
analysis in the stroma compartment, with the exception of CD8 and CCL5. However, 
unsupervised hierarchical analysis, based on gene expression data from the stroma 
compartment, revealed two clusters with different prognostic values. The fact that the 
combination of a larger number of genes was related to the prognosis of patients in the 
stroma compartment, but very few significant associations were observed when a small group 
of genes or single genes were analysed, might be an indication of the complexity of the 
stroma, which is composed of a variety of cells, apart from infiltrating immune cells. 
On the other hand, the tumour risk score comprised the expression of six genes (CD25, 
CD44, CD1C, THBD, CD4, and TGFB1), some of which are related to the presence of immune 
cells such as lymphocytes and DCs, involved in immunoregulation and inflammation. In 
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particular, CD25 is expressed in a variety of immune cells including activated CD4 T cells, as 
well as in Tregs; CD44 is implicated in migration after T cell activation and is related to memory 
T cells (Zoller, 2011); CD1C is an APC marker but also marks some types of MDSCs; CD4 is a T 
helper cell marker and TGFB1 is an immunosuppressive factor. The last component of the 
score was THBD, which was given the biggest weight in the equation. This gene encodes a 
transmembrane glycoprotein, known as thrombomodulin, which has potent anticoagulant 
activity and also has anti-inflammatory functions mediated via a variety of molecular 
mechanisms. Thrombomodulin is implicated in the production of activated protein C and in the 
suppression of thrombin, a potent inflammatory reaction stimulator which regulates the 
proliferation and activation of lymphocytes and monocytes (Li et al., 2012). Moreover, 
thrombomodulin inhibits neutrophil and monocyte adhesion to endothelium as well as 
complement activation. However, insufficient information is currently available regarding its 
role in cancer (Conway, 2012). 
The expression of these genes is likely to be correlated with the immune-state of the 
tumour nest and it might provide information regarding the cross-talk that takes place 
between the tumour cells and immune cells present there. Our results indicate the presence of 
markers related to immune cells that may produce a response against tumour cells, as well as 
the possible presence of immunosuppressive factors and immunoregulatory cells. Although 
future research is needed, it is possible that this prognostic score, or a similar inflammatory or 
immune-related biomarker, may be able to identify patients who are more or less likely to 
respond to immunotherapy.  
Multiple gene expression-based scores that are predictive for survival outcomes have 
been identified in the last few years. Here, we used a predictive model based on the 
multivariate analysis first reported by Lossos et al. (Lossos et al., 2004) and slightly modified by 
Schetter et al. (Schetter et al., 2009). In the latter study, the authors reported an expression 
pattern of inflammatory-related genes in the tumour and paired non-cancerous tissues that 
was an independent prognostic marker for colon adenocarcinoma patients, and which 
indicated the importance that inflammatory cells, and consequently immune cells, have in the 
cancer prognosis. 
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2.4.6. MULTIVARIATE ANALYSIS 
In this section multivariate analysis was performed with biomarkers that were 
significantly associated with prognosis (p < 0.05). To construct OS and PFS multivariate models, 
we introduced the following variables: individual gene expression values correlated with 
survival in both the tumour and stroma compartments (detailed in the section 2.4.3), the 
significant combinations (section 2.4.4), expression clusters, and tumour risk score. In the PFS 
model the tumour size was also included. The results for OS indicated that the expression of 
CD8 in the stromal compartment was an independent prognostic biomarker, whereas for PFS 
the resulting independent biomarkers were the expression of CD8 in the tumour and the ratio 
between the expression of CD25 and CD127 in the stroma compartment (Table 32). 
Table 32. Results from multivariate Cox regression model including all the significant factors from this 
part of the study. 
  OS  PFS  
Variables HR 95% CI  p-value HR 95% CI p-value 
Stromal CD8 expression 
High vs. Low 
0.171 0.048-0.610 0.007 - - - 
Tumoural CD8 expression 
High vs. Low 
- - - 0.219 0.098-0.490 <0.001 
Ratio CD25 stroma/ 
 CD127 stroma 
High vs. Low 
- - - 2.601 1.220-5.547 0.013 
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival. 
The main conclusion that can be drawn from these results is that CD8 expression plays 
a pivotal role in the tumour microenvironment in NSCLCs. The objective here was to obtain 
surrogate markers of the tumour microenvironment immunity and to assess their prognostic 
value. High expression of CD8 mRNA may indicate the presence of high numbers of cytotoxic T 
cells, which have an important role in antitumour immunity, as demonstrated in a number of 
different cancer types, like for instance, breast cancer (Ali et al., 2014). CD8 T cells can 
circumvent many of the barriers inherent in cancer-induced stroma, while optimizing T-cell 
specificity and producing antitumour effects (Kawai et al., 2008).  
The other biomarker that was found to be an independent prognostic factor for PFS 
was the CD25/CD127 ratio in the stroma compartment. It was observed that patients with high 
ratio levels, and therefore high CD25 expression, and low CD127 expression in the stroma had 
worse survival rates. As previously mentioned, this combined biomarker has also been used to 
analyse Treg infiltration in some studies. Because this phenotype is correlated with worse 
survival, and Tregs have been previously associated with this outcome (Shimizu et al., 2010), 
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one might think that the stroma of these patients could be populated with this subset of 
immune cells and that their presence there would have a prognostic value. However, this 
association was not observed in the tumour compartment. Therefore it would be interesting to 
reassess the presence of Tregs in the stroma compartment in situ in order to corroborate 
these findings. 
Altogether, the results detailed in this part of the study indicate the importance of the 
immune system in the tumour microenvironment and how the expression of immune-related 
genes has a different prognostic impact depending on its location. To further validate these 
results and to gain greater insight into the immune picture in the NSCLC microenvironment, 
the presence of three different types of immune cells was assessed by IHC, as detailed in the 
following section of this thesis. 
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Figure 42. Positive cells for CD4, CD8 and FOXP3 in normal human tonsil samples. The figures 
represent positive staining for CD4 and CD8 in lymphocyte cytoplasm and in the nucleus for FOXP3. 
Original magnification, X200. 
B) TUMOUR MICROENVIRONMENT INFILTRATING IMMUNE CELLS 
1. IHC ANALYSIS OF CD4, CD8, AND FOXP3 
 IHC analysis was performed in 84 FFPE tumour samples in order to detect the presence of 
certain tumour-infiltrating immune cells in the tumour and the tumour-associated stroma in 
NSCLCs. We assessed three protein markers, each of them characteristic of one type of 
immune cell: CD4 (helper T cells), CD8 (cytotoxic T cells), and FOXP3 (regulatory T cells). The 
system used for this analysis was a Dako Autostainer Link 48 combined with a Dako EnVision™ 
FLEX detection system. A negative and a positive control were included in each run. The 
positive control for the three antibodies was human normal tonsil tissue (recommended on 
the data sheet); all the preparations were referred back to these controls. In tonsil tissue 
samples, positive CD4 and CD8 staining was observed in the cytoplasm of lymphocytes, and in 
the nucleus for FOXP3 staining (Figure 42). We did not observe any positive staining in the 
negative controls included. 
2. DETECTION OF INFILTRATING IMMUNE CELL MARKERS 
Under HPF (X400) magnification each sample was semiquantitatively scored for the 
degree of immune cell infiltration into the tumour nest and tumour-associated stroma. Three 
types of immune cells were studied: CD4+, CD8+, and FOXP3+ cells. CD4+ cells were detected in 
all the assessable samples, although in 13 (15.5%) of the 84 samples, positive cells were only 
found in the stroma location in which there were significantly more positive TILs (pair-wise 
Wilcoxon test, p < 0.001; Figure 45a). The number of CD4+ cells ranged from 1 to 76 (median: 
18.8, mean: 20.2) per HPF in the stroma location and from 0 to 21 (median: 1.8, mean: 3.5) per 
HPF within the tumour. Patients were classified with low or high CD4+ cell infiltration in the 
Results & Discussion 
125 
 
tumour or stroma location according to the median calculated in each case. Examples of IHC 
images representing different CD4+ cell scores in the tumour and stroma are shown in Figure 
43. 
 
Figure 43. Representative immunohistochemical CD4 staining. Microscopic immunohistochemical 
images of NSCLC samples with CD4
+
 cell staining. a) Tumour area with low CD4
+
 cell infiltration, b) 
tumour area with high CD4
+
 cell infiltration, c) stroma area with low CD4
+
 cell infiltration and, d) stroma 
area with high CD4
+
 cell infiltration. Original magnification X200. 
CD8+ cells were also detected in all the assessable samples, and were present 
throughout tumours, with a tendency towards a stromal location (pair-wise Wilcoxon test, p < 
0.001; Figure 45b). The number of CD8+ cells ranged from 3 to 73 (median: 29.8, mean: 29) per 
HPF in the stroma location and from 1 to 82 (median: 5.6, mean: 8.5) per HPF within the 
tumour. Patients were classified as having low or high CD8+ cell infiltration in the tumour and 
stroma location according to the median calculated in each case. Examples of IHC images 
representing different CD8+ cell infiltration scores in tumour and stroma locations are shown in 
Figure 44. 
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Figure 44. Representative immunohistochemical CD8 staining. Microscopic immunohistochemical 
images of NSCLC samples with CD8
+
 staining cells. a) Tumour area with low CD8
+
 cell infiltration, b) 
tumour area with high CD8
+
 cell infiltration, c) stroma area low high CD8
+
 cell infiltration and d) stroma 
area with high CD8
+
 cell infiltration. Original magnification, X200 
The presence of FOXP3+ cells was evaluated by two different approaches. First, the 
percentage of infiltrating lymphocytes with nuclear-staining in both the tumour and stroma 
compartments was defined and graded as: no staining, less than 10% positive lymphocytes, 10-
33%, and more than 33% of the total number of lymphocytes present in these areas. FOXP3+ 
cells were detected in 80 (95.2%) of the 84 assessable samples, although in 8/80 (10%) of the 
samples, positive cells were only found in the stromal location, and in one sample (1.8%), 
positive cells were only found in the tumour compartment. Most of the cells in the samples, in 
both the stroma (60.8%) and tumour compartment (85.7%), were less than 10% FOXP3 
positive (detailed information is provided in Table 33). This percentage was established as a 
cut-off value for the dichotomisation of FOXP3+ cells into low and high percentages. 
Furthermore, the total number of FOXP3+ cells per HPF was also assessed. Again, there 
were significantly more positive TILs (pair-wise Wilcoxon test, p < 0.001; Figure 45c) in the 
stroma than in the tumour compartment. The number of FOXP3+ cells ranged from 0 to 45 
(median: 11.6, mean: 13.7) per HPF in the stroma location and from 0 to 15 (median: 1, mean: 
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1.6) per HPF within the tumour. Patients were classified as having low or high FOXP3+ cell 
infiltration in tumour or stroma location according to the median calculated in each case. 
Examples of IHC images representing different FOXP3+ cell scores in the tumour and stromal 
locations are shown in Figure 46. 
Table 33. Percentages of FOXP3
+
 cells in either the stroma or the tumour compartment. 
 
Stroma Tumour 
 
N % N % 
No staining 5 6.0 12 14.3 
< 10% 46 54.8 60 71.4 
10-33% 32 38.1 11 13.1 
>33% 1 1.2 1 1.2 
The percentage of infiltrating cells with nuclear FOXP3
+
 staining in either the tumour or the stroma 
compartments was defined and graded as no staining, less than 10% positive cells, 10-33%, and more 
than 33% positive cells from the total number of cells present in these areas. 
 
Figure 45. Box plots representing the levels of positive cells in the stroma and tumour compartments. 
a) CD4
+
 cells per HPF in either the stroma or the tumour, b) CD8
+
 cells per HPF in either the stroma or 
the tumour and c) FOXP3
+
 cells per HPF in either the stroma or the tumour. 
As we wanted to study the presence of Treg cells in the tumour microenvironment, we 
focused only on the expression of FOXP3 in lymphocytes. However, the number of articles 
reporting the expression of this transcription factor in other types of cells, especially epithelial 
malignant cells, has increased exponentially in recent years. In fact, it has been suggested that 
FOXP3 is expressed in carcinoma cells in all cancer types except in ovarian carcinoma (Triulzi et 
al., 2013). For instance, FOXP3 expression was detected immunohistochemically in the tumour 
cells of 24/39 patients with pancreatic carcinoma; subcellular FOXP3 staining in these patients 
was mostly cytoplasmic in some patients, but predominantly nuclear in others (Hinz et al., 
2007). In breast cancer carcinomas, FOXP3 staining was localised predominantly in the 
Results & Discussion 
128 
 
cytoplasm, although both cytoplasmic and nuclear staining was present in some specimens 
and a few showed only nuclear staining (Ladoire et al., 2011; Merlo et al., 2009). A study by 
Tao et al. (Tao et al., 2012) on NSCLC specimens revealed tumour cell FOXP3 expression in 31% 
of patients, and in another immunohistochemical analysis on NSCLC tissues, FOXP3 staining 
was consistently nuclear and was stronger in tumour cells than in adjacent normal bronchial 
epithelium (Dimitrakopoulos et al., 2011).  
Although we did observe what seemed to be positive tumour cell staining, this is not 
reported here for various reasons: 1) the aim of this part of the study was to analyse the 
presence of FOXP3+ cells which have an immunosuppressive role (Tregs); 2) FOXP3 expression 
in tumour cells needs to be further investigated and validated, and the role of its expression in 
these cells is still unknown; and 3) the possible tumour staining in our set of samples needs to 
be further evaluated in order to totally discard any possible background effects. Thus, the 
study of FOXP3 positive staining in tumour cells is beyond the objectives of this study. 
 
Figure 46. Representative immunohistochemical FOXP3 staining. Microscopic immunohistochemical 
images of NSCLC samples with FOXP3
+
 staining cells. a) Tumour area with low FOXP3
+
 cell infiltration, b) 
tumour area with high FOXP3
+
 cell infiltration, c) stroma area low FOXP3
+
 cell infiltration and d) stroma 
area with high FOXP3
+
 cell infiltration. Original magnification, X200. 
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3. CORRELATION BETWEEN INFILTRATING IMMUNE CELLS AND 
CLINICOPATHOLOGICAL VARIABLES  
Correlations between the presence CD4+, CD8+, and FOXP3+ cells infiltrating the 
tumour and stroma compartments and clinicopathological variables were assessed using the 
Chi-square test. We observed a correlation between EGFR status and the presence CD4+ cells 
(p = 0.047; Figure 47a). In particular, patients with mutated EGFR presented high levels of CD4+ 
cells in the stroma; this could be explained by the fact that somatic mutations in the EGFR 
gene produce new peptides that are not recognized as self-antigens by the immune system 
and therefore CD4+ T helper cells might be recruited in order to produce an immune response. 
In this regard, the detection of IgG responses to EGFR-derived peptides in a recent study 
suggested that the presence of CD4+ cells may be a promising method for prognostication of 
NSCLC patients receiving gefitinib (Azuma et al., 2014).  
Furthermore, smaller tumours (less than 3.5 cm) were correlated with the presence of 
higher numbers of tumour-stroma infiltrated CD8+ cells  (p = 0.047; Figure 47b), suggesting that 
these cells are recruited in the early stages of tumour development, when the immune 
response is more robust, in order to stop tumour growth. A higher number of CD4+ cells in the 
stroma was also observed in patients with an ADC histology (p = 0.03; Figure 47c). This is a 
tendency which has already been observed in previous analyses performed in this study: 
higher expression of genes related to immune response and immunoregulation were more 
frequently observed in ADC patients. In addition, a higher percentage of FOXP3+ cell infiltration 
in the stroma compartment was associated with a worse PS (p = 0.005), which could be 
indicative of more aggressive disease (Figure 47d). 
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Figure 47. Histograms showing the association between clinicopathological variables and immune cell 
infiltration. Statistically significant associations with a) EGFR status, b) tumour size, c) histology and d) 
PS. Histograms show the percentage of patients. P-values were calculated using the chi-square test. 
4. IMMUNE CELL INFILTRATION SURVIVAL ANALYSIS 
4.1. THE PROGNOSTIC ROLE OF INDIVIDUAL IMMUNE CELLS 
The density of immune cells detected by IHC in the tumour nest and tumour-
associated stroma was independently assessed for its ability to predict patient survival. The 
results, detailed in Table 34, showed that the presence of T helper lymphocytes (CD4+ cells) 
alone was not associated with prognosis either in tumour or stroma compartments. This result 
is in concordance with previous work, in which the presence of CD4+ cells did not correlate 
with NSCLC survival (Hernandez-Prieto et al., 2014; Liu et al., 2012). However, other studies 
reported that the presence of these cells in the NSCLC tumour stroma was correlated with 
better prognosis (Al-Shibli et al., 2008; Wakabayashi et al., 2003).  
However, it should be considered that CD4+ T cells from a heterogeneous population of 
immune cells with different phenotypes and different functions in the tumour 
microenvironment. Th1 CD4+ T cells are a subtype of immune cells with antitumour properties, 
whereas other types of CD4+ T cells such as Th2, Th17, and Tregs are suspected to stimulate 
cancer growth, although this functional distinction has to be placed into the context of each 
tumour type (Fridman et al., 2011). Therefore, the fact that we detected subpopulations of 
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immune cells with opposing action upon the tumour may explain the lack of prognostic 
significance in our set of patients. 
Table 34. Survival analysis results based on individual immune cell infiltration. 
 OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
Tumoural CD4
+
 cells 
High vs. Low 0.908 0.499-1.653 0.753 0.931 0.531-1.632 0.803 
Stromal CD4
+ 
cells 
High vs. Low 0.655 0.359-1.193 0.166 0.750 0.428-1.315 0.315 
Tumoural CD8
+
 cells 
High vs. Low 0.493 0.267-0.910 0.024* 0.525 0.295-0.936 0.029* 
Stromal CD8
+ 
 cells 
High vs. Low 0.774 0.426-1.408 0.402 0.698 0.396-1.232 0.215 
Tumoural FOXP3
+
 cells 
High vs. Low 1.088 0.458-2.585 0.849 1.253 0.559-2.806 0.584 
Stromal FOXP3
+
  cells 
High vs. Low 1.929 1.058-3.518 0.032* 1.608 0.907-2.850 0.104 
Patients were classified as having low or high positive cell infiltration in the tumour or stroma locations 
according to the medians calculated in each case. The results were obtained using a univariate Cox 
regression method. CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free 
survival. 
In contrast, the presence of T cytotoxic lymphocytes (CD8+ cells) in the tumour nest 
was significantly associated with better OS [HR, 0.493; 95% CI, 0.267-0.910; p = 0.024] and PFS 
[HR, 0.525; 95% CI, 0.295-0.936; p = 0.029], which was also reflected in the Kaplan-Meier plots 
for OS (73.9 vs. 40.4, months, p = 0.021) and PFS (56.8 vs. 23 months, p = 0.026; Figure 48a-b). 
Among the tumour infiltrating immune cells, CD8+ cytotoxic lymphocytes form the effector 
arm of adaptive immunity and are thought to have protective roles against tumours, including 
lung cancer (Suzuki et al., 2011). Their prognostic role has been studied in several types of 
tumour and, in general, their presence is correlated with better disease outcomes. For 
instance, in breast cancer a large (n = 12,439 patients), recently published, multicentre study 
showed that intratumoural and stromal CD8+ lymphocytes were independently associated with 
a reduced risk of death from cancer (Ali et al., 2014). In a similar analysis in NSCLC, Al-Shibli et 
al. assessed the presence of CD8+ cells, among other immune cells, by performing tissue 
microarrays on 335 resected stage I to IIIA NSCLCs. They observed that high CD8+ lymphocyte 
infiltration was associated with better survival in both tumoural and stromal areas (Al-Shibli et 
al., 2008). 
In previous studies, in which the influence of the tumour compartment was not 
evaluated, a correlation between the presence of CD8+ lymphocytes and tumour cell 
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apoptosis, as well as a vigorous antitumour immune response in NSCLCs was observed 
(Tormanen-Napankangas et al., 2001; Verdegaal et al., 2007). The fact that we found an 
association with survival only when we analysed the presence of CD8+ cells in the tumor 
compartment could be explained by previous finding suggesting that antitumour cytokines 
contributing to tumour suppression act mainly in the stroma, whist on tumour cells this 
antitumour activity is more often mediated by molecules such as perforin or Fas ligand, which 
are expressed by CD8+ cells (Blankenstein, 2005). 
We also observed that patients with a higher percentage of FOXP3+ cells in the stroma 
compartment had worse OS [HR, 1.929; 95% CI, 1.058-3.518; p = 0.032], with a median survival 
of 37.2 vs. 68 months (p = 0.029, Kaplan-Meier test) in this group of patients (Figure 48c). 
FOXP3+ cells or Tregs are a specific subset of the T cell repertoire which have been 
demonstrated to be involved in decreasing the antitumour response (deLeeuw et al., 2012). 
Previous studies have assessed the prognostic value of Tregs in tumour samples from NSCLC 
patients; Shimizu et al. demonstrated that patients with NSCLC (stages I-IIIB) containing three 
or more Tregs infiltrating the tumour in 10 HPFs had significantly worse RFS, and among 
patients with node-negative NSCLC, this was an independent prognostic factor (Shimizu et al., 
2010). An increased Treg count was also found to be associated with worse OS and RFS in 
another study with I-IIIA stage NSCLC, in which it was also observed that positive tumour cell 
staining attenuated the prognostic value of Treg infiltration (Tao et al., 2012). 
In a recent study, the clinical impact of the tumour microenvironment was evaluated in 
stage I lung adenocarcinoma (n = 956). Using tissue microarrays and IHC, Suzuki et al. 
investigated eight types of tumour-infiltrating cells in the tumour nest and tumour-associated 
stroma, observing that a high density of stromal FOXP3+ cells was associated with a shorter 
RFP (Suzuki et al., 2013). This result, which is in line with our observations, emphasizes the 
importance of assessing the location of TILs within the tumour microenvironment. In fact, the 
importance of immune cells in the tumour stroma in NSCLC has been shown in a study with 
patients with stages I-IIA of the disease; this work demonstrated the presence of tertiary de 
novo lymphoid structures in the tumour microenvironment, a structure they termed the 
tumour-induced bronchus-associated lymphoid tissue (Ti-BALT). Moreover, the presence of 
mature dendritic cells in the Ti-BALT correlated with prolonged OS (Dieu-Nosjean et al., 2008). 
In breast cancer, a study reported that the presence of Tregs within lymphoid infiltrates 
surrounding the tumour, but not within the tumour itself, was associated to a higher risk of 
relapse and death. The authors elegantly provided evidence that this clinical observation could 
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result from the selective recruitment of Tregs within lymphoid infiltrates of breast tumours 
where they are locally activated (likely through tumour-associated antigen recognition) leading 
to their in situ proliferation and prevention of conventional T cell activation (Gobert et al., 
2009). We hypothesise that this explanation could be extrapolated to lung tumours, in which 
the importance of lymphoid structures has already been reported, and the prognostic value of 
Tregs located in the stroma has been observed in our results and in previous studies. 
 
Figure 48. Kaplan-Meier plots for OS and PFS according the density of immune cells infiltrating the 
tumour microenvironment. a-b) Tumoural CD8
+
 cells and c-d) stromal FOXP3
+
 lymohocytes. Densities 
were dichotomized according to the median expression values. The blue line represents patients with 
low infiltratinon, whilst the green line represents patients with high infiltration. P-values were calculated 
using the Kaplan-Meier test. 
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4.2. PROGNOSTIC ROLE OF THE COMBINATION OF IMMUNE CELLS 
Since the survival analysis carried out in the previous section showed a prognostic 
value for the proportion of conventional T lymphocytes (defined by the CD4 and CD8 markers) 
and regulatory T cells (defined by FOXP3 expression) at the mRNA level, we decided to 
corroborate these results by analysing the proportion of these types of immune cells in situ. 
Univariate survival analysis showed that patients with high FOXP3+ cell infiltration in the 
stroma and low CD4+ cell infiltration in the tumour presented worse OS [HR, 2.385; 95% CI, 
1.095-5.194; p = 0.029], with a survival median of 17.4 vs. 66.9 months (p = 0.024, Kaplan-
Meier test; Figure 49a-b). The other variable studied compared cytotoxic T cells with Tregs, 
indicating that patients with high FOXP3+ cell infiltration in the stroma and low CD8+ cell 
infiltration in the tumour also presented worse OS [HR, 2.391; 95% CI, 1.195-4.787; p = 0.014] 
and shorter PFS [HR, 2.046; 95% CI, 1.036-4.043; p = 0.039]. Kaplan-Meier plots showed that 
the survival median for OS was 17.4 vs. 68.8 months (p = 0.011) and for PFS it was 15.3 vs. 35.9 
months (p = 0.035; Figure 49c-d). 
Table 35. Survival analysis results based on the proportion of immune cell infiltration.   
  OS PFS 
Variable HR 95% CI p-value HR 95% CI p-value 
FOXP3
+
 stroma/ CD4
+
 tumour 
↑FOXP3
+
 stroma/↓CD4
+
 tumour 
vs. Other combinations 
2.385 1.095-5.194 0.029 1.936 0.897-4.177 0.092 
FOXP3
+
 stroma/ CD8
+
  tumour 
↑FOXP3
+
 stroma/↓CD8
+
 tumour 
vs. Other combinations 
2.391 1.195-4.787 0.014 2.046 1.036-4.043 0.039 
The results shown in the table are for the combination specified vs. other combinations. The results 
were obtained using a univariate Cox regression method. CI, confidence interval; HR, hazard ratio; OS, 
overall survival; PFS, progression free survival. 
In addition to type, density, and location, we have demonstrated that the relative 
proportion of pro- and antitumour immune cells is also an important parameter to study when 
analysing tumour-infiltrating cells. In this case, the proportion of helper and cytotoxic cells, to 
regulatory T cells in different tumour microenvironment locations had a prognostic value in 
resected NSCLCs. The first study to investigate the correlation between FOXP3+ Treg cells, 
tumour infiltrating lymphocytes, and lung cancer survival was carried out by Petersen et al. 
(Petersen et al., 2006). They observed that patients with stage I NSCLC who had a higher 
proportion of tumour Tregs relative to TILS (defined as CD3+ T cells) had a significantly higher 
risk of recurrence. They pointed out that since Tregs exert their effect by inhibiting antitumour 
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T cells, they should always be considered in the context of total TILs. In another important 
piece of work, tumours containing high levels of stromal FOXP3 and low levels of stromal CD3 
were considered to be high-risk and this parameter was found to be a strong predictor of 
disease recurrence (Suzuki et al., 2013). 
It should be taken into consideration that previous work has assessed CD3+ cells, i.e. 
every T cell, without making any distinction between helper and cytotoxic T cells. To the best 
of our knowledge, ours is the first study reporting the prognostic value of the combination of 
Tregs and conventional T cells, and which differentiates the type of lymphocytes which 
infiltrate the tumour in resected NSCLCs. In advanced NSCLC, the prognostic and predictive 
value of different types of infiltrating immune cells has also been previously investigated: the 
results indicated that the ratio of FOXP3+/CD8+ TILs was an independent predictor of poor 
response to platinum-based chemotherapy (Liu et al., 2012). However, neither TIL subtypes 
alone, nor their ratio was correlated with OS.  
Over the last decade, the analysis of large libraries of annotated human tumours has 
allowed researchers to identify prognostic markers based on immune cell infiltration. In this 
regard, colorectal cancer has been extensively studied and represents the paradigm of these 
findings. It has been shown that not only the overall density of memory CD45RO+/CD8+ T cells 
was important, but also the location of the immune microenvironment (infiltration inside the 
tumour core and at its invasive margin). These observations have led to the definition of an 
“immunoscore”, based on quantifying the density of infiltrating T cells using two marker 
combinations (CD8/CD45RO or CD3/CD8) in these two regions of the tumour 
microenvironment to define a score ranging from 0 to 4, which predicts the PFS and OS in 
colorectal cancers up to stage III with a high degree of significance (Galon et al., 2006; Galon et 
al., 2012; Pages et al., 2009). The clinical application of the immunoscore is currently being 
validated in a multicentre international study. It should be noted that the immunoscore is 
defined by the infiltration of cells that have been traditionally linked to antitumour properties, 
and therefore, to a better outcome. In contrast, we have demonstrated that analysing 
different types of immune cells, such as cytotoxic and regulatory T cells, in combination could 
also provide good information regarding patient outcome. 
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Figure 49. Kaplan-Meier plots for OS and PFS according to the proportion of FOXP3
+
 cells in the stroma 
to CD4
+
 and CD8
+
 cells in the tumour. a-b) Combination of FOXP3
+
 cells in the stroma/CD4
+
 cells in the 
tumour, and c-d) FOXP3
+
 cells in the stroma/CD8
+
 cells in the tumour. The green line represents patients 
with the combination of interest, whilst the blue line represents patients with other combinations. P-
values were calculated using the Kaplan-Meier test. 
4.3. MULTIVARIATE ANALYSIS 
In this part of the study we performed multivariate analyses with the biomarkers 
described in the previous sections, in this case positive immune cells identified by IHC, which 
were significantly associated with survival. Moreover, we also included the clinicopathological 
variables that presented prognostic value in this subset of patients. Thus, the OS multivariate 
model was composed of tumoural CD8+ cells, stromal FOXP3+ cells, FOXP3+ stroma/CD4+ 
tumour, and FOXP3+ stroma/CD8+ tumour expression, whereas the PFS model was composed 
of tumoural CD8+ cells and FOXP3+ stroma/CD8+ tumour expression. Gender, LN involvement, 
and PS were correlated with survival in the univariate analysis, and so they were also included 
in both multivariate models. The results, which are detailed in Table 36, indicated that the 
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presence of CD8+ cells in the tumour compartment was an independent prognostic biomarker 
for OS and PFS. Moreover, the presence of FOXP3+ cells in the stroma compartment was also 
found to be an independent prognostic factor for OS. 
Table 36. Results from the multivariate Cox regression model including all the significant results from 
this part of the study. 
 
OS PFS 
Variables HR 95% CI p-value HR 95% CI p-value 
Tumoural CD8
+
 cells 
High vs Low 0.386 0.175-0.850 0.018 0.305 0.137-0.680 0.004 
Stromal FOXP3
+
  cells 
High vs Low 2.203 1.109-4.379 0.024 - - - 
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival. 
Infiltrating immune cells have been shown to have prognostic value in several solid 
malignancies, including colorectal, ovarian, and breast cancer; Galon et al. have advocated the 
use of three important parameters of tumour infiltrating lymphocytes (type, density, and 
location) to predict clinical outcomes in patients. Results from these analyses suggest that the 
prognostic value of this immunophenotype may be more powerful than traditional staging 
(Galon et al., 2012). In this part of the study, we investigated three infiltrating immune cell 
markers and found that CD8+ cells in the tumour compartment and FOXP3+ cells in the stroma 
compartment were independent prognostic factors. Indeed, this immune pattern remained 
the only significant criterion over any other clinicopathological variables for PFS and OS.  
The positive prognostic value of CD8+ cell infiltration in the tumour compartment may 
indicate an ongoing immune response against the tumour. Presuming that this infiltrate 
includes tumour-antigen specific T cells that have been activated spontaneously in response to 
the growing tumour, perhaps through immune system surveillance mechanisms (Bui and 
Schreiber, 2007), these cells would be attempting to control the tumour, and would thus 
create a favourable clinical outcome. However, how a subset of patients can generate a CD8+ T 
cell response against tumour-associated antigens, apparently in the absence of pathogen 
involvement, remains an enigma. Two hypotheses have been postulated: one suggests the 
likely participation of stress-associated or damage-associated molecular patterns that may 
trigger innate immune activation and provide a bridge toward adaptive immunity. The other 
hypothesis explains the presence of T cells in the tumour microenvironment because of the 
generation of tertiary lymphoid structures (TLSs). As their presence is also associated with the 
accumulation of CD8+ effector T cells, it is conceivable that spontaneous priming of an 
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antitumour T cell response leads to chronic inflammation in the tumour microenvironment 
that subsequently generates signals for TLS generation (Gajewski et al., 2013). 
The other independent prognostic factor was the presence of FOXP3+ cells in the 
stroma compartment. FOXP3 is a Treg marker: a subset of lymphocytes that, as previously 
explained, is known to suppress the host immune response. In patients with lung cancer, Tregs 
are thought to play protumour roles in all histological subtypes (Petersen et al., 2006). 
Interestingly, our results indicated that FOXP3 in the stroma (and not in the tumour nest) was 
associated with survival, emphasising the importance of assessing the location of immune cells 
within the tumour microenvironment. In addition, these findings have significant implications 
for devising potential immunomodulatory therapies. For instance, in patients with high FOXP3+ 
cells infiltrating the stroma compartment an intervention that decreases FOXP3 and that 
increases other positive immune cells, such as CD8+ cells, would likely be beneficial. Beyond 
their cytostatic characteristics, some conventional chemotherapeutic agents were found to 
affect the adaptive immune system, resulting in the inhibition of Tregs function or viability, 
and thereby enhancing antitumour immunity. Interestingly, cyclophosphamide has been 
shown to modulate the tumour immune microenvironment by depleting Tregs (Le and Jaffee, 
2012). Paclitaxel, a taxane-based chemotherapeutic agent that is currently the most widely 
used in the clinic, was found to specifically impair cytokine production and viability in FOXP3+ 
Treg cells but not in FOXP3– CD4+ effector T cells (Zhu et al., 2011). Ipilimumab, an antibody 
that is specific for CTLA4, blocks an important inhibitory signal for activated T cells, thereby 
bolstering T cell responses and decreasing Treg cell-dependent immune suppression (Peggs et 
al., 2009). Studies that aim to deplete Treg cells in patients with cancer are hampered by the 
fact that Treg cells do not express an exclusive surface molecule that can be targeted. 
Therefore novel strategies are needed that permit specific Treg cell targeting and therefore 
elimination of their suppressive function. 
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C) CORRELATION BETWEEN IMMUNE CELL INFILTRATION AND 
IMMUNOREGULATORY GENE EXPRESSION 
1. CORRELATION BETWEEN THE CD4+, CD8+, AND FOXP3+ CELL 
COUNT AND THE GENE EXPRESSION LEVELS OF THESE MARKERS 
1.1. GENE EXPRESSION DATA FROM FRESH-FROZEN SAMPLES 
In this section we wanted to correlate the expression of CD4, CD8, and FOXP3 at the 
protein level (detected as positive cells by IHC) with their mRNA expression levels (assessed by 
RTqPCR). In order to better analyse these correlations, we compared gene expression levels 
without normalising to normal tissue, so that only tumour tissue expression was considered. 
This step was made because it allows comparison of the total number of positive cells with the 
absolute expression of the genes in the tumour, and not in the tumour compared to normal 
tissue. As for the positive cell count, because they were originally evaluated in tumour and 
stroma compartments separately, an average of tumoural and stromal cell counts was 
calculated for each patient. A Spearman test (R statistic) revealed a correlation between mRNA 
expression levels and the positive cells count for CD4 (p = 0.013, R2 = 0.326), CD8 (p = 0.007, 
R2 = 0.345), and FOXP3 (p = 0.003, R2 = 0.374; Figure 50). Although these are positive results, 
because they indicate that mRNA expression could be a good surrogate marker for actual 
immune cells, they do not confirm that these proportions are equivalent at the protein level, 
which may be due to possible effects from post-transcriptional and post-translational 
modifications.
 
Figure 50. Correlation between mRNA expression levels and the number of immune cells positive by 
immunohistochemistry in the tumour microenvironment. a) CD4, b) CD8, and c) FOXP3. R represents 
the Spearman correlation coefficient. 
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1.2. GENE EXPRESSION DATA FROM FORMALIN-FIXED PARAFFIN-
EMBEDDED SAMPLES 
The correlation between mRNA expression levels and positive-cell count was also 
evaluated independently in tumour and stroma compartments using the data obtained from 
FFPE microdissected samples. In order to better analyse this correlation we compared gene 
expression levels without normalising to human reference cDNA, as justified in the previous 
section. In this case, we only observed a correlation between the presence of CD8+ cells and 
CD8 gene expression levels in the stroma compartment (p = 0.029, R2 = 0.261) and the tumour 
nest (p = 0.008, R2 = 0.311; Figure 51).  
 
Figure 51. Correlation between mRNA expression levels and the number of or immune cells positive 
by immunohistochemistry for CD8 in the tumour microenvironment. a) In the tumour compartment 
and, b) in the stroma compartment. R represents the Spearman correlation coefficient. 
The lack of FOXP3 correlation can help us to understand some of the results we 
obtained in previous sections. High FOXP3 expression in the tumour compartment was 
associated with better survival but no correlation was observed for the stroma compartment 
when the prognostic value was analysed at the mRNA level. We hypothesised that the positive 
prognostic value might be due to the fact that not only Tregs express FOXP3 in the tumour 
compartment. Therefore, this lack of correlation, together with the fact that high FOXP3+ cell 
infiltration in the stroma compartment had a negative prognostic impact, reinforces our 
hypothesis that FOXP3 mRNA is not exclusively expressed by Tregs in the tumour 
microenvironment and that other cells, presumably tumour cells, as already suggested (Tao et 
al., 2012), could also be a source of FOXP3 mRNA.  
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2. THE IMMUNE CONTEXTURE CHARACTERISATION ASSOCIATED 
WITH THE PRESENCE OF IMMUNE CELLS 
Immune cell infiltrates are heterogeneous between tumour types, and are very diverse 
from patient to patient. In fact, as we have demonstrated in previous sections, the differences 
in density, location, and proportion of pro- and antitumour immune cells between different 
individuals with NSCLC affects their clinical outcome. Once the prognostic value of these 
tumour-infiltrating immune cells has been established other questions arise. For instance, it 
would be interesting to better understand the key elements involved in shaping the immune 
microenvironment in which these immune cells are present, or in other words, to further 
explore the immune contexture of these microenvironments.  
According to the authors who first proposed the “immunoscore”, the immune 
contexture is defined as the type, density, location and functional orientation of the immune 
cells within distinct tumour regions (Angell and Galon, 2013). The immune contexture 
represents the complexity of the immune parameters within the tumour microenvironment 
and is associated with patient survival (Galon et al., 2013). The functional orientation of the 
immune contexture is characterised by immune signatures that might reflect the functional 
characteristics or the molecular phenotypes of the immune cell infiltrate. In order to analyse 
these functional characteristics, gene expression patterns related to different immune 
processes and the presence of different immune cells were studied in specific groups of 
patients. Therefore, in this part of the study, we investigated whether there are significant 
differences in gene expression patterns according to CD4+, CD8+, and FOXP3+ cell infiltration.  
2.1. CORRELATION BETWEEN INFILTRATING IMMUNE CELLS AND 
EXPRESSION PATTERNS IN FRESH-FROZEN SAMPLES 
Firstly, the correlation of specific sets of genes analysed at the mRNA level in fresh-
frozen samples, and the level of infiltration of three types of immune cells, was assessed in the 
whole NSCLC tumour microenvironment. Although a Mann-Whitney U test revealed no 
association between the expression patterns and CD4+ cell infiltration (Figure 52a) individual 
expression of CCL22 (p = 0.020) and PDL1 (p = 0.022) did positively correlate. Correlation with 
CCL22 could indicate the active recruitment of naïve and memory T cells, including Tregs, from 
blood into the tumour microenvironment (Fridman et al., 2012), and correlation with PDL1 
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might mean that when the CD4+ cell density increases, PDL1 expression also increases in the 
tumour microenvironment in order to suppress lymphocyte function (Pardoll, 2012). 
Patients with higher CD8+ cell infiltration in the tumour microenvironment presented 
higher gene expression for gene groups related to TAMs, APCs, and immune cell trafficking 
processes (Figure 52b). Moreover, individual analysis showed that CD8+ cell infiltration was 
associated with TGFB1 (p = 0.039), PDL1 (p = 0.018), CCL22 (p = 0.001), and IDO1 (p = 0.036). In 
this case, a high density of CD8+ cells in the tumour microenvironment was correlated with an 
expression pattern that indicates an active immune response, in which immune cells, 
especially APCs, might be present. On the other hand, correlation with individual genes might 
also point towards the likelihood that the tumour is trying to disarm the immune response by 
releasing immunosuppressive factors and chemokines that have previously been associated 
with the recruitment of immunoregulatory cells, especially Tregs (Curiel et al., 2004). 
Finally, the presence of FOXP3+ cells in the tumour microenvironment was significantly 
associated with three of the four groups of genes analysed: genes related to Tregs, immune 
checkpoints, immunosuppressive factors, and TAMs, APCs, and immune cell trafficking 
processes (Figure 52c). Individual analysis showed that infiltration of these lymphocytes was 
positively associated with expression levels of CD25 (p = 0.001), CD127 (p = 0.002), TGFB1 (p = 
0.030), PDL1 (p = 0.003), CCL2 (p = 0.025), CD1C (p = 0.022), and IL23A (p = 0.041). A heat map 
displaying gene patterns according to the density of FOXP3+ cells in the tumour 
microenvironment is shown in Figure 53; high levels of FOXP3+ cell infiltration in the tumour 
microenvironment were associated with upregulation of the cluster referring to the Treg 
profile, as well as with individual genes related to Tregs. This positive correlation was also 
observed in the case of the immune checkpoint group because some of these markers are also 
expressed by Tregs (Pardoll, 2012).  
Furthermore, correlation with the presence of other immune cells and trafficking 
processes was also observed. Although this correlation was observed in tumours with high 
levels of CD8+ cell infiltration, the polarisation of these cells could be different, thus facilitating 
a more immunosuppressive microenvironment. Thus a greater number of genes must be 
studied in order to better understand the processes that are taking place, especially within 
different locations within the tumour. Therefore, we carried out the same analysis with data 
obtained from FFPE samples in which a larger number of genes were independently analysed 
in the tumour and stroma compartments. 
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Figure 52. Gene expression patterns analysed in fresh-frozen samples according to a) CD4
+
, b) CD8
+
 
and c) FOXP3
+
 cells in the tumour microenvironment. Expression patterns of genes related to 
regulatory T cells (Tregs), immune checkpoints, immunosuppressive factors, TAMs, and APCs and 
immune cell trafficking processes according to the level of immune cell infiltration. The relative gene 
expression is represented as the log2-median of the expressions obtained for each gene. In the figures, 
the asterisks represent Mann-Whitney U significance test levels as follows: *p = 0.05-0.01 and **p < 
0.01. 
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Figure 53. Heat map representation of the expression pattern of genes analysed in fresh-frozen 
samples according to the presence of FOXP3
+ 
cells in the tumour microenvironment. Expression 
patterns of genes related to regulatory T cells (Tregs), immune checkpoints, immunosuppressive factors, 
TAMs, APCs, and immune cell trafficking processes according to the level of immune cell infiltration. 
Patients are plotted according to their level of FOXP3
+ 
cell infiltration per HPF, and thus are divided into 
patients with high and low levels of infiltration. Gene expression is represented as the log2-median of 
the expression obtained for each gene and the asterisks represent Mann-Whitney U significance test 
levels as follows: *p =  0.05-0.01, ** p < 0.01. 
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2.2. CORRELATION BETWEEN INFILTRATING IMMUNE CELLS AND 
EXPRESSION PATTERNS IN FORMALIN-FIXED PARAFFIN-
EMBEDDED SAMPLES 
In this part of the study we investigated if there were significant differences in the 
expression patterns of specific sets of genes analysed at the mRNA level and the infiltration of 
the three types of immune cells assessed in the tumour and stroma locations. A Mann-
Whitney U test revealed that patients with high levels of CD4+ cells in the tumour 
compartment expressed higher levels of genes linked to Tregs, MDSCs, TAMs, and other APCs, 
whereas no correlation was found in the stroma compartment (Figure 54a-b). Thus, high CD4+ 
cell infiltration might indicate the possible infiltration of immunosuppressive cells, among 
other immune cells, into the tumour microenvironment. However, no changes in the 
expression patterns were linked to the presence of these cells in the stroma compartment. 
Moreover, the immune contexture characterised by high levels of CD4+ cell infiltration did not 
have a prognostic impact. 
Of special interest is the analysis of expression pattern differences between tumours 
with high and low numbers of CD8+ cells, due to the positive prognostic value that infiltration 
of these cells into the tumour compartment presented. Tumours with higher levels of CD8+ cell 
infiltration expressed significantly higher levels of genes related to immunosuppressive factors, 
chemokines and their receptors, MDSCs and TAMs, and other APCs (Figure 54c-d). Moreover, 
significant positive correlations were observed between higher levels of CD8+ cell infiltration 
and the expression of certain individual genes such as IDO1 (p < 0.001), CCL5 (p = 0.005), 
CD209 (p = 0.031), CD86 (p < 0.001), and IL23A (p = 0.008; Figure 55). Interestingly, IL8 was 
inversely correlated with high levels of CD8+ cell infiltration (p = 0.015). We also found a 
significant correlation between the expression of genes related to chemokines and their 
receptors in the stroma compartment.  
The microenvironment characterised by high CD8+ cell infiltration seems to fit a T cell-
inflamed phenotype, consisting of infiltrating T cells, chemokines and their receptors, and the 
possible presence of APCs which are required to activate CD8+ cytotoxic cells by presenting 
tumour antigens to them. If these were the only types of cells acting in the tumour 
microenvironment the immune system would likely have a higher chance of completely 
eliminating tumour cells. However, as it can be interpreted from these gene expression 
patterns, other processes also take place. In fact, tumours with high levels of CD8+ cell 
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infiltration express higher levels of markers related to immunosuppressive factors. One of 
these factors is IDO1, a key metabolic enzyme implicated in tryptophan catabolism. Its immune 
suppression functions are due to decreased tryptophan availability and the generation of 
tryptophan metabolites, culminating in multipronged negative effects on the T lymphocytes in 
proximity to IDO-expressing cells, notably on proliferation, function, and survival (Godin-Ethier 
et al., 2011). Interestingly, mechanistic studies in mice revealed that upregulated expression of 
IDO and PDL1 depended on the presence of CD8+ T cells within the tumour microenvironment 
(Spranger et al., 2013). 
Moreover, a higher MDSC expression pattern was also observed, indicating the 
possible presence of these cells when there is high CD8+ cell infiltration. MDSCs have been 
implicated in indirectly altering anti-tumour immune responses by contributing to the tumour 
microenvironment suppressive network. However, it is still unclear which subset of MDSCs 
might be responsible for T cell suppression, or what the specific nature of MDSC suppression 
is. In fact, it has been observed that MDSCs intricately influence different CD8+ T-cell activation 
events in vitro, whereby some parameters are suppressed while others are stimulated 
(Schouppe et al., 2013). 
Also of interest are the positive correlations observed between CD8+ cell infiltration 
and genes such as CD209 and IL23A. In previous sections, it has been observed that high 
expression of these markers was associated with longer survival, which might indirectly point 
to the presence of high numbers of CD8+ cells, and indeed, a positive effect on the prognosis. 
The only inverse correlation observed in this study was with IL8 expression. This is a 
proinflammatory CXC chemokine associated with the promotion of neutrophil chemotaxis and 
degranulation. The expression of IL-8 receptors on cancer cells, endothelial cells, neutrophils, 
and tumour-associated macrophages suggests that the IL8 secretion by cancer cells may have a 
profound effect on the tumour microenvironment. IL8 receptor activation on endothelial cells 
is known to promote an angiogenic response, inducing the proliferation, survival, and 
migration of vascular endothelial cells (Waugh and Wilson, 2008). Thus, IL8 expression might 
be associated with a more aggressive type of immune contexture in which antitumour 
immunity is less important and processes like angiogenesis might play a more active role. 
Finally, the presence of FOXP3+ cells did not correlate with any expression patterns 
either in the tumour or in the stroma compartment (Figure 54e-f). Individual analysis showed 
that only the CTLA4 gene was positively correlated with high levels of FOXP3+ cell infiltration in 
the stroma compartment. 
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Figure 54. Gene expression patterns in tumour and stroma locations according to a) tumoural CD4
+
 
cell infiltration, b) stromal CD4
+
 cell infiltration, c) tumoural CD8
+
 cell infiltration, d) stromal CD8
+
 cell 
infiltration, e) tumoural FOXP3
+
 cell infiltration, and f) stromal FOXP3
+
 cell infiltration. Gene 
expression patterns represent regulatory T cells (Tregs), immunosuppressive factors, chemokines and 
their receptors, inflammation processes, myeloid-derived suppressor cells (MDSCs), tumour associated 
macrophages (TAMs), and other antigen presenting cells (APCs) according to the immune cell infiltration 
level. The relative gene expression level is represented as the log2-median of the expressions obtained 
for each gene. In the figures, the asterisks represent Mann-Whitney U significance test levels as follows: 
*p = 0.05-0.01, and **p < 0.01. 
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Figure 55.  Heat map representation of patterns of genes related to immunoregulation according to 
CD8
+ 
cell infiltration in the tumour nest. Gene expression patterns represent regulatory T cells (Tregs), 
immunosuppressive factors, chemokines and their receptors, inflammation processes, myeloid-derived 
suppressor cells (MDSC), tumour associated macrophages (TAMs), and other antigen presenting cells 
(APCs) according to the level of immune cell infiltration. Patients are plotted according to their CD8
+ 
cell 
infiltration levels in each HPF, and thus, are divided into patients with high and low levels of infiltration. 
Gene expression is represented as the log2-median of the expressions obtained for each gene and the 
asterisks represent Mann-Whitney U significance test levels as follows: *p = 0.05-0.01, ** p < 0.01. 
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According to these results, we postulated the existence of two major tumour 
microenvironment phenotypes. One major subset presents a T cell-inflamed phenotype 
consisting of infiltrating T cells, which reflects innate immune cell activation, and in which 
immunoregulation processes are activated in order to resist immune attack. The other major 
phenotype lacks this T-cell inflamed phenotype and resists immune attack through immune 
system exclusion or ignorance. These differences may be due to the antigens presented in the 
tumour. On one hand, some tumour antigens are shared by different types of tumours and 
were identified as possible therapeutic targets, however, many of these shared antigens are 
also expressed at some level by self-tissues, which can lead to immunological tolerance. On the 
other hand, neoantigens generated by point mutations in normal genes, which are unique to 
individual tumours, can result in much more potent antitumour immune response which tries 
to control the tumour via immune effector cells, thus creating a more favourable clinical 
outcome (Gajewski et al., 2013) 
It is remarkable that even with the activation of this immunosuppressive network, the 
immune contexture dominated by high levels of CD8+ cell infiltration is associated with longer 
survival. Therefore, our results indicate that patients with a tumour microenvironment in 
which the immune system is able to recognise tumour antigens and activate a potent immune 
response, are more likely to have better outcomes, and that the activation of the 
immunosuppressive network is a consequence of this immune response. In fact, the group of 
patients with low levels of CD8+ cell infiltration presented lower levels of immunosuppressive 
cell and process pattern expression, and it was associated with worse survival. The positive 
correlation of immunosuppressive markers with improved outcome and improved therapy 
responses has also been described in other studies (Denkert et al., 2014; West et al., 2013). 
Although the presence of FOXP3+ cells in the stroma compartment was correlated with 
worse OS, we did not observe any differences in the expression pattern analysed. However, it 
is known that these cells play an important role in tumour progression. Interestingly, the 
negative prognostic value of the presence of FOXP3+ cells in the stroma compartment was 
increased in the subgroup of patients with low levels of CD8+ cell infiltration in the tumour 
compartment. This observation might indicate that there may be crosstalk between these two 
types of immune cells.  
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3. CORRELATION BETWEEN INFILTRATING IMMUNE CELLS AND 
IMMUNOREGULATION GENE EXPRESSION SIGNATURES  
In this section we assessed if there was any correlation between the type, density, and 
location of immune cells and gene expression signatures of prognostic value. The term 
“expression signature” refers to a group of genes whose expression pattern is uniquely 
characteristic of a biological phenotype. Thus, clusters and expression scores with prognostic 
value were included in this analysis. Among the gene expression signatures obtained from 
fresh-frozen samples, we observed a significant correlation with the immune checkpoint score 
and CD8+ cell infiltration (Figure 56). Patients with a high immune checkpoint score (those with 
longer survival medians), had a higher number of CD8+ cells in their tumour microenvironment 
(p = 0.030). High immune checkpoint scores might reflect high levels of CD8+ cell infiltration 
and therefore high levels of antitumour activity, which could explain the association with 
longer survival. In addition, the immune checkpoint score was identified as an independent 
prognostic factor which indicated its possible utility in clinical practice. 
Figure 56. Correlation between the immune 
checkpoint expression score obtained in fresh-
frozen samples and CD8
+ 
cell infiltration levels in 
the tumour microenvironment. Error bars 
represent the 95% CI of the mean. 
 
 
 
 
As for the expression signatures obtained from FFPE samples, and independently 
obtained from tumour and stroma locations, we observed two correlations, both in the 
tumour compartment. Firstly, patients grouped in tumoural Cluster I had significantly a higher 
levels of CD8+ cell infiltration (p = 0.001; Figure 57a). This cluster comprised a group of patients 
with a more heterogeneous gene expression pattern compared with patients in Cluster II (who 
had low levels of CD8+ cell infiltration), although there was a tendency for higher gene 
expression levels. It is also important that the group of patients, who had significantly better 
survival, also had high levels of CD8+ immune cell infiltration. 
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Finally, we also found an association between the tumour risk score and tumoural 
CD8+ cell infiltration: patients with a high tumour risk score presented less CD8+ cell infiltration 
(p = 0.004; Figure 57b). The tumour risk score was composed of the expression of 6 genes, 
some of which had a negative regression coefficient (indicating their protective value) while 
others had a positive regression coefficient, indicating that they were associated with an 
increased risk. Among these 6 genes the one with the strongest effect on the score was THBD. 
Because THBD plays an anti-inflammatory role, the high tumour risk score might indicate that 
this patient subgroup has a phenotype lacking T cell-inflamed properties. Therefore their 
tumours might be ignored by their immune systems and are likely to be more aggressive than 
tumours with a low tumour risk score. No correlation was observed between these expression 
signatures and CD4+ or FOXP3+ cell infiltration. 
 
Figure 57. Correlation between the expression signatures obtained from FFPE samples and CD8
+ 
cell 
infiltration. a) Correlation with the tumoural clusters and, b) correlation with the tumour risk score. 
Error bars represent the 95% CI of the mean. 
  
Results & Discussion 
152 
 
D) INTEGRATION OF RESULTS FROM STUDY I 
Study I focused on the analysis of prognostic biomarkers related to immunoregulatory 
processes in patients with resected NSCLCs (stages I-IIIA). Although most of these patients are 
treated with curative intent, the associated survival is less than optimal with the 5-year 
survival ranging from 50% for stage IA to 15% for stage IIIA (Burotto et al., 2014). Currently, 
there are still shortfalls in the approach used for selecting patient adjuvant therapies based on 
the surgical stage alone. Thus, the great challenge is to identify patients at the greatest risk of 
recurrence and their potential response to specific treatments, avoiding any unnecessary 
chemotherapy-associated toxicities. Therefore, it is essential to discover new biomarkers that 
could help physicians in the management of the disease. Over the last decade, the field of 
tumour immunology has changed, and it is now accepted that the immune system plays a 
pivotal role in cancer. The potential effect of the patient’s immune system on clinical outcome 
is important not only for the identification of prognostic markers, but also markers that predict 
treatment-response. Thus, the study of immune-related markers, especially those implicated 
in immunoregulatory processes, could provide valuable prognostic information about resected 
NSCLCs that could help in future clinical practice. 
In this study, the prognostic value of immune-related markers was analysed in patients 
with resected NSCLCs using different approaches. In the first part of the study, the aim was to 
identify molecular biomarkers by RTqPCR. This technology is considered to be the gold 
standard in gene expression quantification and some of its major advantages are its speed, 
sensitivity, and the low amount of RNA that it requires. The analysis of gene expression 
biomarkers was first assessed in fresh-frozen tumour and normal lung tissue samples. An 
introductory analysis indicated the existence of different groups of patients according to their 
expression pattern, and the group of patients who expressed high levels of immune-related 
and immunoregulatory genes survived longer. Individual survival analysis also revealed 
associations between markers like IL23A, FOXP3, and LGALS2 with better outcomes. 
Furthermore, a score composed of the expression of immune checkpoint related genes was 
constructed following a mathematical model. A high immune checkpoint score was associated 
with longer OS and PFS, and was demonstrated to be an independent prognostic biomarker, 
along with KRAS status. Because immune checkpoint blockade demonstrated promising clinical 
results in NSCLC patients, due to the activation of antitumour immunity (Creelan, 2014), the 
fact that high immune checkpoint scores were correlated with better survival seemed 
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paradoxical. However, previous studies have also demonstrated that the expression of 
individual immune checkpoint genes was associated with better outcomes (Salvi et al., 2012; 
Velcheti et al., 2014). 
In the light of these results, and because of increasing evidence suggesting that 
biomarkers can present distinct prognostic values depending on where they are expressed, in a 
second approach, gene expression levels were assessed separately in the tumour nest and the 
adjacent stroma. For this purpose, microdissected FFPE samples were used to better 
understand the prognostic value of immunoregulatory markers, by analysing a larger number 
of genes. Although fresh-frozen samples were of higher quality than FFPE samples, the latter 
are easy to obtain and allowed us to work with the tumour and stroma compartments 
separately. Unsupervised clustering analysis using these gene expression data indicated the 
existence of groups of patients with distinct outcomes. Patients with over-representation of 
immunoregulation genes in both tumour and stroma compartments had longer survival. 
Moreover, individual survival analysis indicated that several markers had a positive prognostic 
value when present in the tumour compartment (CD4, CD8, FOXP3, LAG3, and CD209 among 
others) but only two genes (CD8 and CCL5) were correlated with survival when expressed in 
the stroma compartment. Finally, an expression prognostic score, comprising the expression of 
six genes (CD25, CD4, TGFB1, CD44, CD1C, and THBD) in the tumour compartment, allowed the 
identification of a subgroup of patients with an increased risk of progression and death. 
Taking the results from both approaches into account, we observed that clustering 
analysis in both types of samples indicated that, in general, the groups of patients expressing 
higher amounts of immunoregulatory genes had better outcomes. However, individual 
analysis of the markers yielded different results. For instance, in fresh-frozen samples markers 
such as IL23A and LGALS2 had a prognostic value that was not corroborated when their 
expression was assessed in the tumour and stroma compartments separately. On the other 
hand, the prognostic value of FOXP3, the most specific marker of Tregs, was observed in both 
types of samples. In particular, high levels of FOXP3 expression were associated with longer 
survival when present in the whole tumour samples and in the tumour nest, but not in the 
stroma compartment. This positive prognostic value differs from previous studies, suggesting 
that the presence of Tregs is associated with worse outcomes due to their inhibition of the 
antitumour immune response (Petersen et al., 2006). Thus, we hypothesised that Tregs might 
not be the only cells that express FOXP3 in the tumour microenvironment. Other authors have 
observed that tumour cells can express FOXP3, and that this expression attenuates the 
Results & Discussion 
154 
 
negative prognostic value of the presence of high numbers of Tregs (Tao et al., 2012). 
Therefore, the expression of FOXP3 by tumour cells and not by Tregs could be responsible for 
the positive prognostic value of this marker in the whole tumour and in the tumour nest. 
We also observed that conventional T cell markers, such as CD4 and CD8, had a 
positive prognostic value when analysed in the tumour, and in the case of CD8, also in the 
stroma compartment. Furthermore, combining these biomarkers with FOXP3 allowed a group 
of patients with comparatively worse survival to be identified, as defined by high levels of 
FOXP3 in the stroma and low levels of CD4 or CD8 in the tumour. Although the expression of 
FOXP3 in the stroma was not correlated with survival, the combination of high CD25 
expression levels and low CD127 levels, which are also characteristics of the Treg phenotype, 
was associated with worse PFS in this compartment. This combination, along with CD8 
expression in tumour nest, were identified as independent prognostic factors for PFS, whereas 
only the expression of CD8 in the stroma was a significant prognostic factor for OS.  
To further validate these results and to gain a greater insight into the immune picture 
in the NSCLC microenvironment, the presence of CD4+, CD8+, and FOXP3+ positive cells was 
assessed by IHC in the same FFPE samples in the third part of the study. Survival analysis 
revealed that CD8+ cell infiltration in the tumour compartment was associated with longer 
survival, whereas FOXP3+ cell infiltration in the stroma was associated with the opposite 
outcome. However, FOXP3+ cells infiltrating the tumour nest were not associated with any 
prognostic factor, which differs from its positive prognostic value when analysed at the mRNA 
level. This might indicate that Tregs are not the only cells that express FOXP3 in the tumour 
microenvironment; the negative prognostic role of FOXP3+ cell infiltration in the stroma 
compartment agrees with the prognostic value of the combined biomarker, defined by high 
CD25 and low CD127 expression levels in the stroma compartment, which may indicate that 
this combined biomarker could possibly be used as a surrogate marker for the presence of 
Tregs. 
Furthermore, the negative prognostic value of the combined biomarkers (indicating 
high levels of FOXP3 in the stroma and low levels of CD4 or CD8 in the tumour) was 
corroborated in situ with the results from IHC analysis. CD8+ cell infiltration in the tumour 
compartment remained an independent prognostic factor for OS and PFS; moreover, FOXP3+ 
cell infiltration was also found to be an independent predictor for OS. Therefore, it seems that 
the strongest prognostic value lies in the presence of CD8 markers present at both the mRNA 
and protein levels. The presence of FOXP3+ cells could also be used in order to distinguish a 
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subtype of patients with worse survival and who could benefit from adjuvant chemotherapy, 
especially with drugs such as cyclophosphamide that can modulate or deplete Tregs (Le and 
Jaffee, 2012). 
In order to further explore the immune contexture in resected NSCLC patients, we 
combined the results obtained by the different approaches. The objective was to evaluate if 
there were differences between immunoregulatory expression patterns in patients with high 
and low infiltration of CD4+, CD8+, or FOXP3+ cells. Gene expression patterns from fresh-frozen 
samples indicated that patients with higher CD8+ cell infiltration in the tumour 
microenvironment presented higher expression of genes related to APCs and the immune 
response but also higher expression of immunoregulatory markers. In contrast, high levels of 
FOXP3+ cell infiltration in the tumour microenvironment were associated with the upregulation 
of the clusters of Tregs, and with immune cell trafficking and immune checkpoint markers. As 
for the results obtained from tumour and stroma FFPE samples, we observed that high levels 
of CD8+ cell infiltration in the tumour nest were associated with a T cell-inflamed phenotype 
characterised by higher expression of genes related to innate immune response as well as 
immunosuppressive pathways. However, no significant differences were observed in patients 
with high and low levels of FOXP3+ cell infiltration. Therefore, our results indicate that patients 
with high levels of CD8+ cell infiltration (those with better outcomes) seem to present active 
immune responses, which could be activated by immune system recognition of tumour 
antigens, whilst also presenting feedback activation of immunosuppressive pathways. 
Importantly, the positive correlation of immunosuppressive markers and improved outcome 
has also been observed in other types of tumour (Denkert et al., 2014). 
Finally, the correlation between the different expression signatures with prognostic 
value and the level of immune cell infiltration was assessed. Of note, the immune checkpoint 
score calculated from fresh-frozen sample data was positively correlated with CD8+ cell 
infiltration, whereas the tumour risk score, calculated from FFPE sample data, presented a 
negative correlation. Thus, the immune checkpoint score may reflect a favourable immune 
context in which the immune system recognises the tumour, whereas the opposite situation 
may be occurring in the tumours of patients with high risk scores. This score, whose main 
component (THDB) has anti-inflammatory properties, might reflect a detrimental immune 
context characterised by the lack of T-cell inflammation that leads to an immune response. 
In summary, in this study several prognostic immune-related biomarkers were 
identified in resected NSCLCs. Our results indicated that, in general, patients with high 
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expression of immunoregulatory markers presented better outcomes. Furthermore, immune 
contexture analysis revealed that tumours with high levels of cytotoxic T cell infiltration, 
whose presence was correlated with longer survival, expressed high levels of immune 
response markers as well as immunoregulation markers. Taken together, our results indicate 
the existence of two possible immune-scenarios in NSCLCs. In the first, the tumour is 
recognised by the immune system and a T-cell response is activated, which in turn activates 
immunoregulatory pathways. In this case patients had better outcomes. In the second 
scenario, which is associated with worse outcomes, the immune system does not recognise 
the tumour and there is no immune response activation, therefore immunoregulatory 
pathway activation is not required. These results provide new insight into the tumour 
immunity field in NSCLC, and could be useful in the future development of prognostic and 
therapeutic tools. 
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STUDY II. BIOMARKERS IN ADVANCED NON-SMALL CELL LUNG 
CARCINOMA  
A) ANALYSIS OF GENE EXPRESSION BIOMARKERS IN BLOOD 
SAMPLES 
In this study the analysis of immunoregulatory biomarkers was assessed in order to 
evaluate the viability of detecting mRNA markers in the peripheral blood of patients with 
advanced NSCLC. Determining the presence of biomarkers in peripheral blood has some 
advantages over using patient tumour biopsies: the collection of the sample is minimally 
invasive, it allows patients to be monitored during the disease, and more importantly, it 
permits biomarkers to be determined in every single patient even if there is no surgical or 
biopsy specimens available from the tumour. The latter is of great importance in patients with 
a diagnosis of advanced NSCLC because their tumours are not resected as part of the 
treatment, thus no tumour tissue sample is available (Hanash et al., 2011). Furthermore, the 
information acquired from a single biopsy provides a spatially and temporally limited snap-
shot of a tumour and might fail to reflect its heterogeneity. A liquid biopsy, or blood sample, 
can provide information about the genetic landscape of all the cancerous lesions present 
(primary and metastases) as well as offering the opportunity to systematically track genomic 
evolution (Crowley et al., 2013). 
The following describes our first approach to assessing immunoregulatory biomarkers 
in peripheral blood by determining the expression of 11 genes related to immune response, 
Tregs, and MDSCs. We aimed to obtain initial insights into possible changes in tumour 
immunoregulation process markers in patient blood samples, to correlate these results with 
clinicopathological variables, and to evaluate their prognostic, diagnostic, and predictive value 
in advanced NSCLC. 
1. PATIENT CHARACTERISTICS AND SAMPLES ANALYSED  
This retrospective study included 49 patients with advanced NSCLC enrolled in a 
multicentre study coordinated by the Spanish Lung Cancer Group. Peripheral blood samples 
(2.5 ml) were collected and stored in PAXgene™. RNA was extracted from blood samples 
obtained at two time points: before treatment and after three cycles of chemotherapy with 
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docetaxel and cisplatin. The most relevant demographic and clinicopathological characteristics 
of the cohort are shown in Table 37. The median patient age was 57.8 [37-75] years, 89.8 % 
were male and 55.2 % had ADC. Moreover, 85.7% of the patients were diagnosed at stage IV of 
the disease and 51% had a PS of 1. Our control group comprised 54 anonymous, age- and 
gender-matched, healthy volunteers without any acute or chronic inflammatory conditions. 
From a total number 102 samples analysed, 49 were obtained pre-treatment, 25 post-
treatment, and 54 were from healthy donors. 
Table 37. Clinicopathological characteristics of the advanced NSCLC patients included in this study. 
Characteristics N % 
Age at surgery (median, 
range) 
57.8 [37-75] 
Gender   
Male 44 89.8 
Female 5 10.2 
Stage   
IIIB 7 14.3 
IV 42 85.7 
Histology   
ADC 27 55.2 
SCC 11 22.4 
Others 11 22.4 
Performance Status   
0 24 49 
1 25 51 
Response
a
   
PR 11 22.4 
SD 13 26.5 
PD 23 46.9 
NA 2 4.1 
ADC, adenocarcinoma; SCC, squamous cell carcinoma; PR, partial response; SD, stable disease; PD, 
progressive disease; NA, not available. 
a 
Tumour response was evaluated according to the Response 
Evaluation Criteria for Solid Tumours [RECIST] (Therasse et al., 2000). 
RNA was isolated from 2.5 ml peripheral blood samples, and an optimal RNA 
concentration was obtained for all samples: the median concentration obtained was 66.7 ng/μl 
(Range: 20.1-342.0). The quality and integrity of the RNA extracted was confirmed by capillary 
electrophoresis, with all the samples showing representative 18S and 28S RNA peaks in the 
electropherogram, and a RIN higher than 7. 
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2. RELATIVE GENE EXPRESSION 
In this study we evaluated the expression levels of different immunoregulatory 
markers, mainly related to two types of immunoregulatory cells: Tregs (FOXP3, CD25, CD4, 
CD8, CD127, and TGFB1), and MDSCs (CD97, CSFR1, IL4R, ITGAM, and ITGB2). The expression 
of three endogenous genes (ACTB, GAPDH, and GUSB) was tested in a subset of approximately 
30% of the samples in order to establish, using geNorm software, the best internal control, 
which was the combination of GAPDH and ACTB. Furthermore, relative expression was 
normalised against a reference sample, which in this case was the Jurkat cell line. In order to 
better visualise gene expression results, they are represented as the log2-median of 
expression. As shown in Figure 58, all the genes showed higher expression in samples than in 
the control cell line; ITGAM was the most abundantly expressed gene and TGBF1 had the 
lowest expression.  
 
Figure 58. Relative expression of the genes analysed in peripheral blood samples. The relative gene 
expression (fold-change) is represented as the log2-median of the expressions obtained for each gene in 
three samples: controls vs. advanced NSCLC patients before and after treatment with three cycles of 
chemotherapy with docetaxel and cisplatin. 
ITGAM is the subunit of the heterodimeric integrin alpha-M beta-2 (αMβ2) molecule, 
also known as macrophage-1 antigen (Mac-1) or complement receptor 3A (CR3A). ITGAM is 
expressed on the surface of many leukocytes involved in the innate immune system, including 
monocytes, granulocytes, macrophages, and NKs. It mediates inflammation by regulating 
leukocyte adhesion and migration (Solovjov et al., 2005). Moreover, ITGAM is expressed in 
every MDSC type and is frequently used as a marker to identify and isolate these cells 
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(Gabrilovich et al., 2012). Because it is expressed in several types of immune cells that can be 
found in peripheral blood, we expected its expression levels to be high, as for other markers 
also present on the surface of different immune cells, such a CD4+ and CSFR1+ cells. In contrast, 
TGFB1 showed the lowest expression in blood. This factor is released by immunosuppressive 
cells or tumour cells in order to reduce inflammation or to suppress tumour cell immune 
responses (Flavell et al., 2010). A Wilcoxon pair-wise test revealed significant differences in the 
expression of some of the markers before and after the treatment. These markers were CD97 
(p = 0.005), IL4R (p = 0.020), ITGB2 (p = 0.045), and TGFB1 (p < 0.001), and in all the cases their 
expression decreased after the treatment. These could indicate that chemotherapy based on 
docetaxel and cisplatin reduced the levels of circulating MDSC mRNA markers, as well as 
immunosuppressive factors like TGFB1. 
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B) ANALYSIS OF THE DIAGNOSTIC, PROGNOSTIC, AND PREDICTIVE 
VALUE OF IMMUNOREGULATORY BIOMARKERS 
1. THE DIAGNOSTIC VALUE OF THE GENES ANALYSED 
A Mann-Whitney U test revealed that there were significant differences in the gene 
expression levels in advanced NSCLC patients in comparison to healthy donors. Significant 
increases in gene expression levels were observed for CD4, CSF1R, CD8, CD127, FOXP3, and 
CD25 in controls in comparison to patients. On the other hand, ITGAM, CD97, and TGFB1 
showed significantly higher expression in the patient samples (Table 38). 
Table 38. Expression levels of the analysed genes in patients with advanced NSCLC or healthy donors. 
 
Genes CD4 CD8 CD25 CD97 CD127 
Controls Median 2,0427.3 471.755 12.549 39.283 405.758 
 
Minimum 4,688.6 83.847 3.591 2.312 161.441 
 
Maximum 4,1354.1 1,745.4 37.908 145.245 940.219 
Patients Median 9,237.7 334.346 8.808 51.585 289.747 
 
Minimum 1,532.6 66.970 2.644 30.276 55.423 
 
Maximum 3,0004.3 2,097.6 44.937 108.417 1,378.1 
 
p-value <0.0001 0.020 0.005 0.002 0.022 
 
Genes CSF1R FOXP3 IL4R ITGAM TGFB1 
Controls Median 4,522.7 65.033 16.591 6,5700.4 6.755 
 
Minimum 378.833 16.607 0.844 6101.445 0.806 
 
Maximum 1,2815.7 168.226 51.633 27,3741 12.159 
Patients Median 1,973.7 38.679 22.985 10,5587 8.239 
 
Minimum 349.823 9.753 11.333 5,4950.6 5.483 
 
Maximum 8181.007 120.539 78.758 17,8420 15.232 
 
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Because most of the genes analysed presented differences in gene expression levels 
between advanced NSCLC patients and controls, we decided to investigate their possible role 
as diagnostic biomarkers. For this purpose, we used the receiver operating characteristic (ROC) 
curve and area under the curve (AUC) metrics. The curves represent the relationship between 
the sensitivity and specificity of each biomarker. Statistically significant predictive models for 
distinguishing patients from controls could be constructed using TGFB1, ITGAM, IL4R, and 
CD97 which yielded AUCs of 0.770 (95% CI, 0.675-0.862), 0.816 (95% CI, 0.730-0.901), 0.704 
(95% CI, 0.604-0.804), and 0.681 (95% CI, 0.578-0.784) respectively (Figure 59), and significant 
differences were found between them (p < 0.001, Chi-square test). Using the ROC curve 
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coordinates, the Youden Index was calculated (sensitivity + specificity) for each biomarker and 
cut-off values that better distinguished between patients and controls were selected (Table 
39). ITGAM gene expression levels were the most suitable biomarker for discriminating 
patients and controls, with a sensitivity of 85.71 % and a sensitivity of 71.69 %. 
 
Figure 59. ROC curves representing the diagnostic value of the biomarkers. ROC curves represent the 
sensitivity and 1- specificity obtained when all the cut-off values for the markers are considered.  
The only marker studied that was sufficiently sensitive and specific to make it a 
candidate diagnostic biomarker was ITGAM, which is expressed by different immune cells such  
as macrophages, neutrophils, and other leukocytes. Although it is a marker used to identify 
MDSCs, which are immunosuppressive cells of interest in this study, ITGAM expression cannot 
be linked to this subtype of cells because of the nature of the methodology we used. However, 
this was not the only MDSC marker with higher expression in advanced NSCLC patients than in 
controls. In fact, other genes that are used along with ITGAM to identify MDSCs, such as CD97 
and IL4R, were also expressed in higher amounts in these patients than in controls. 
Table 39. Cut-off values that better distinguish between patients and controls. 
Genes Cut-off value Sensitivity Specificity Youden Index 
TGFB1 7.143 83.673 66.038 1.497 
ITGAM 7,6281.9 85.714 71.698 1.574 
IL4R 15.705 87.755 49.057 1.368 
CD97 40.017 77.551 52.830 1.304 
The table represents the gene expression cut-off values for each biomarker, with higher sensitivity and 
specificity selected using the Youden Index. 
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Haematopoietic abnormalities in tumour-bearing hosts, originally described as 
“neutrophilia” and characterised by the abundance of less mature cells, have long been 
observed. Mechanistically, this is associated with the tumour secretion of cytokines and 
chemokines that induces myeloid cell proliferation, cell accumulation, and tumour infiltration. 
Furthermore, not only do tumours secrete growth factors that induce myelopoiesis and 
chemokines that mobilise MDSCs, but they may also limit their maturation and differentiation, 
thereby contributing to their accumulation (Talmadge and Gabrilovich, 2013). Therefore, the 
presence of MDSCs could be one of the main reasons for the detected increase in ITGAM and 
other markers related to these immune cells in the peripheral blood of patients with advanced 
NSCLC. 
These results suggest that there are expression differences in some of the biomarkers 
analysed in advanced NSCLC patients vs. healthy controls, and that these changes are 
measurable using our methodological approach. The changes observed indicated a decrease in 
markers such as CD4, CD8, and CD25 in NSCLC patients, and an increase in markers related to 
MDSC. In fact, the expression of ITGAM allowed advanced NSCLC patients to be discriminated 
from controls with adequate sensitivity (85.7%) and specificity (71.6%), suggesting that these 
biomarkers have a diagnostic value which warrants further study in order to validate them. 
2. CORRELATION WITH CLINICOPATHOLOGICAL VARIABLES  
We observed significantly higher levels of CD97 and ITGAM in patients with a PS of 1 (p 
= 0.006 and p = 0.001, respectively; Figure 60) and higher levels of CSF1R and FOXP3 in 
patients with a PS of 0. Furthermore, male patients presented significantly higher levels of IL4R 
(p = 0.006) and ITGAM (p = 0.027; Figure 61). There was no significant association between 
gene expression levels and clinical characteristics such as tumour stage, histology, metastatic 
location, age, or treatment response.  
The presence of higher levels of expression of genes such as ITGAM and CD97 in 
patients with a worse PS at diagnosis might indicate that these patients have a more 
aggressive disease mediated by the increase of immunosuppressive cells, in this case MDSCs 
which expressed high levels of these markers (Gabrilovich and Nagaraj, 2009). To the best of 
our knowledge, this is the first time that higher expression of markers related to MDSCs (or 
other immune cells expressing ITGAM and IL4R) has been reported in male patients than in 
female patients. 
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Figure 60. Some examples of the correlation between performance status (PS) and immune-marker 
gene expression. a) CD97 and b) ITGAM. Error bars represent the 95% CI of the mean. 
 
Figure 61. Correlation between gender and immune-marker gene expression. a) IL4R and b) ITGAM. 
Error bars represent the 95% CI of the mean. 
As for clinical responses to the treatment, 11 patients (22.4 %) presented a PR, 13 
patients (26.5 %) had SD, and 23 patients (46.9%) had PD. Although a Wilcoxon pair-wise test 
revealed significant differences in the expression of some of the genes before and after the 
treatment, we did not observe any correlation between gene expression levels and responses 
to treatment. This rendered assessment of their possible role as predictive response-
biomarkers pointless. 
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3. SURVIVAL ANALYSIS 
Of the 49 patients with advanced NSCLC included in this part of the study, 46 (94%) 
relapsed and a total of 42 (85.7%) died. The median follow-up was of 9.63 months [range: 1.6-
39.9]. The prognostic value of the different clinicopathological variables and immune 
biomarkers was assessed using univariate a Cox regression for OS and PFS. The gene 
expression levels of the biomarkers analysed were dichotomised according to their individual 
medians. The results obtained in the univariate analysis by Cox regression are shown in Table 
40, and also show the hazard ratios and p-value for each marker.  
Table 40. Results obtained from survival analysis according to clinicopathological variables.  
  OS PFS 
Variable HR [95% CI] p-value HR [95% CI] p-value 
Gender  
        
Male vs. Female 0.729 0.259-2.056 0.551 0.459 0.163-1.291 0.140 
Age 
        
≤ 60 vs. > 60 0.513 0.277-0.951 0.034* 0.706 0.394-1.265 0.242 
Stage 
        
III vs. IV 0.694 0.303-1.591 0.388 0.907 0.397-2.070 0.816 
Histology 
        
ADC vs. SCC vs. Others 0.712 0.469-1.082 0.111 0.800 0.540-1.187 0.268 
PS 
        
0 vs. 1 2.554 1.361-4.792 0.003* 1.783 0.982-3.234 0.057 
Metastasis 
        
Local vs. Distant 1.031 0.547-1.945 0.924 1.001 0.544-1.843 0.997 
Results obtained using a univariate Cox regression method. HR, hazard ratio; LN, lymph node; OS, 
overall survival; PFS, progression free survival; PS, performance status; EGFR, epidermal growth factor 
receptor; *p < 0.05. 
Univariate analysis of clinicopathological variables showed that older patients, as well 
as those with a PS of 1, have worse OS (p = 0.034 and p = 0.003 respectively). However, no 
other significant association was found for the rest of the variables. Univariate analysis showed 
that none of the genes analysed in this part of the study had any prognostic value for advanced 
NSCLC when analysed individually (Table 41). This lack of association with survival could be 
explained by the low number of advanced NSCLC patients analysed. Therefore, these markers 
should be analysed in a larger cohort of patients where any possible differences between 
patients with low or high levels of these markers are more likely to be detected. The next step 
was to perform combined analysis with markers related to the same immunoregulatory cells 
or processes. From the different combinations tested, we observed that advanced NSCLC 
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patients with high CD25 and low CD127 expression levels in blood samples had worse OS (4.7 
vs. 9.8 p = 0.039) and shorter PFS (2.4 vs. 5.4 months, p < 0.001; Figure 62). 
Table 41. Survival analysis results obtained according to immunoregulatory marker expression.  
  OS PFS 
Variable HR [95% CI] p-value HR [95% CI] p-value 
CD4 
High vs. Low 
0.961 0.521-1.772 0.898 1.236 0.690-2.213 0.476 
CD8 
High vs. Low 
0.913 0.494-1.685 0.771 0.947 0.530-1.692 0.855 
CD25 
High vs. Low 
1.110 0.601-2.052 0.739 1.195 0.669-2.136 0.547 
CD127 
High vs. Low 
0.749 0.405-1.382 0.355 0.649 0.362-1.164 0.147 
FOXP3 
High vs. Low 
1.154 0.609-2.189 0.660 1.391 0.775-2.499 0.269 
TGFB1 
High vs. Low 
1.744 0.926-3.285 0.085 1.167 0.651-2.090 0.604 
CD97 
High vs. Low 
1.146 0.620-2.119 0.663 1.000 0.560-1.785 0.999 
CSF1R 
High vs. Low 
1.046 0.568-1.927 0.884 1.419 0.792-2.541 0.240 
IL4R 
High vs. Low 
1.319 0.717-2.426 0.373 0.949 0.529-1.701 0.860 
ITGAM 
High vs. Low 
1.137 0.616-2.098 0.681 1.001 0.560-1.791 0.996 
ITGB2 
High vs. Low 
0.796 0.432-1.467 0.465 0.717 0.401-1.284 0.264 
Gene expression levels dichotomised according to their medians. Results from univariate Cox regression 
method. CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival; *p 
< 0.05. 
As previously explained in this thesis, FOXP3 is a specific Treg marker, but the 
combination of high levels of CD25 and low levels of CD127 are also considered to be 
characteristic of Tregs. Therefore, this result may indicate that advanced NSCLC patients with a 
Treg phenotype, defined by high mRNA levels of CD25 and low levels of CD127 in blood, had 
worse survival than the rest of the patients. However, since we are detecting mRNA markers 
from all the nucleated cells in blood (including leukocytes and other non-haematological cells) 
we cannot elucidate the cellular origin of these markers. This combination of markers has 
previously been assessed in blood from patients with other types of cancer, but using other 
methodologies such as flow cytometry. In one of these studies the higher presence of CD4+ 
CD25high CD127low cells in patients with gastric cancer indicated patients with advanced stage of 
the disease (Shen et al., 2009). 
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Figure 62. Kaplan-Meier plots according to the combination of CD25 and CD127 expression in blood 
samples from advanced NSCLC patients. a) OS, and b) PFS. The green line represents patiens with high 
levels of CD25 and low levels of CD127 in the stroma while the blue line represents other combinations 
of these two markers. P-values were calculated using the Kaplan-Meier test. 
Finally, multivariate analysis was performed for OS, using the CD25 and CD127 marker 
combination and the age and PS variables which were significant from the univariate analysis. 
The results indicated that PS [HR, 2.67; 95% CI, 1.41-5.06; p = 0.003] and CD25high CD127low 
expression levels [HR, 2.01; 95% CI, 1.08-6.75; p = 0.045] were independent prognostic factors 
in advanced NSCLC. As for PFS, the only variable that was associated with this survival 
parameter was the CD25 and CD127 combination, and so it was not necessary to assess its 
independency from any other variable. The combination of high CD25 and low CD127 
expression levels was also associated with survival when analysed in the stroma compartment 
of resected NSCLCs. In this case the expression was assessed in FFPE tissue, in the stroma 
adjacent to tumour nest. We therefore concluded that the combination of CD25 and CD127 
might be a surrogate marker for the possible presence of Tregs in the tumour 
microenvironment. 
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C) INTEGRATION OF RESULTS FROM STUDY II 
In this study, the expression of immunoregulatory biomarkers was assessed in 
peripheral blood from advanced NSCLC patients. A liquid biopsy, or blood sample, can be 
obtained from patients in a non-invasive way, at any time during disease. It provides a clearer 
picture of tumour evolution over time and it can be used to address the tumour heterogeneity 
problem. The analysis of biomarkers in advanced NSCLC could provide useful information 
regarding adequate treatments and could also predict patient outcome.  
We analysed the expression of 11 genes in a cohort of advanced NSCLC patients, 
before and after treatment with three cycles of chemotherapy with docetaxel and cisplatin, 
and in a cohort of matched healthy patients. Gene expression analysis revealed differences in 
the expression of some of the biomarkers analysed. A decrease in genes related to immune 
response and an increase in markers related to MDSCs were observed in advanced NSCLC 
patients. In fact, the expression of one of these markers, ITGAM, was able to distinguish 
between patients and healthy controls with adequate sensitivity and specificity. Although 
some differences in the expression of MDSC gene markers were observed after treatment, 
none of the biomarkers correlated with treatment response and therefore no predictive 
biomarker was found. 
As for survival analysis, the combination of high CD25 and low CD127 expression levels 
identified a group of patients with worse OS and PFS. This combined marker was an 
independent prognostic factor. This combination, which might indicate a possible presence of 
the Treg phenotype in patient blood, could be used as a surrogate marker of tumour status in 
advanced NSCLC. 
 
  
 
 
 
 
 
 
 
 
 
 
V. CONCLUSIONS 
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1. Unsupervised hierarchical analysis of fresh-frozen specimens from resected 
NSCLCs according to their gene expression patterns revealed two clusters with 
different prognostic values. 
2. We demonstrated that in resected samples an immune checkpoint score, defined 
by CTLA4 and PD1 expression, was an independent prognostic factor; patients with 
high immune checkpoint scores had significantly longer survival times. 
3. FFPE samples from resected NSCLC tumour and stroma areas were separately 
analysed. We observed that combined biomarkers defined by high FOXP3 
expression levels in the stroma and low expression of CD4 or CD8 in the tumour 
compartment were associated with worse survival and these were validated in situ 
by IHC. 
4. High infiltration of CD8+ cells in the tumour compartment was associated with 
longer survival, whereas high infiltration of FOXP3+ cells, also defined as Tregs, in 
the stroma was associated with a worse outcome, and both variables were 
independent prognostic factors. 
5. In blood samples from advanced NSCLC patients, ITGAM was found to have a 
diagnostic value with adequate sensitivity and specificity, and the combination of 
high CD25 and low CD127 expression level, which are characteristic of a Treg 
phenotype, identified a subgroup of patients with worse outcomes. 
6. The integration of our results indicated that high infiltration rates of CD8+ cells into 
the tumour, which was associated with better survival, was correlated with gene 
expression patterns related to immune response and immunoregulation. 
Altogether, the results presented in this thesis suggest the existence of two possible 
immune-scenarios in resected NSCLCs. The first scenario is that of an inflamed 
microenvironment in which the tumour might be recognised by the immune system, thus 
activating the immunoregulatory pathways. This scenario correlates with a better prognosis, 
with the exception of Treg markers, which identify a group of patients with worse survival 
rates in both resected and advanced NSCLC. The second scenario presents no inflammation, 
which might indicate that the immune system does not recognise the tumour, and is 
associated with worse patient outcomes. 
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1. SUPPLEMENTARY TABLES  
Supplementary table 1. Efficiency results for the assays used in this study. The efficiency of each 
TaqMan® assay was evaluated by carrying out serial dilutions of a reference cDNA. 
Gen Slope Efficiency 
Percentage 
Efficiency 
ACTB -3.123 2.090 100 
CCL2 -3.095 2.104 100 
CCL22 -3.375 1.978 99 
CCL5 -3.469 1.942 97 
CD1C -2.9951 2.157 100 
CD209 -3.273 2.021 100 
CD25 -3.534 1.919 95 
CD33 -3.537 1.918 96 
CD34 -3.557 1.911 96 
CD4 -3.465 1.944 97 
CD40 -3.307 2.006 100 
CD40LG -2.510 2.090 100 
CD44 -3.643 1.881 94 
CD8 -3.0247 2.141 100 
CD80 -3.242 2.035 100 
CD86 -3.492 1.934 97 
CD97 -3.1091 2.097 100 
CDKN1B -3.705 1.862 93 
CSF1R -4.745 1.625 82 
CSF3R -3.132 2.086 100 
CTLA4 -3.373 1.979 99 
CXCL12 -3.541 1.916 96 
CXCR4 -3.539 1.917 96 
FOXP3 -3.387 1.974 99 
GAPDH -2.818 2.264 100 
GITR -3.371 1.980 99 
GUS -2.829 2.257 100 
HPRT -3.569 1.906 95 
IDO1 -3.559 1.910 95 
IFNG -2.780 2.289 100 
IL10 -3.348 1.989 99 
IL12B -2.528 2.487 100 
IL13 -3.397 1.969 98 
IL23 -3.302 2.009 100 
IL4R -3.358 1.985 99 
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IL8 -3.481 1.938 97 
ITGAM -3.327 1.998 100 
ITGB2 -3.433 1.955 97 
LAG3 -3.579 1.903 95 
LGALS1 -3.396 1.970 99 
LGALS2 -3.464 1.944 97 
MMP2 -3.898 1.805 90 
NRP1 -3.708 1.861 93 
PD1 -3.249 2.032 100 
PDL1 -3.681 1.869 94 
TGFB1 -3.617 1.890 95 
THBD -3.539 1.917 96 
TNF -3.343 1.991 100 
Efficiency values were measured using the CT slope method. This method involves generating a dilution 
series of the target template and determining the CT value for each dilution. A plot of CT versus log 
cDNA concentration is constructed.  
Supplementary Table 2. Survival analysis results obtained according to immunoregulatory markers 
expression in ADC and SCC separately using FFPE samples. Results from univariate survival analysis 
(using a Cox regression method) based on gene expression levels. 
 
OS  PFS 
 
ADENOCARCINOMA 
Variable HR [95% CI] p-value HR [95% CI] p-value 
Tumoural CD4 
High vs. Low 
0.265 0.101-0.694 0.007* 0.318 0.143-0.706 0.005* 
Tumoural CD8 
High vs. Low 
0.292 0.118-0.723 0.008* 0.290 0.130-0.650 0.003* 
Tumoural FOXP3 
High vs. Low 
0.339 0.120-0.953 0.040* 0.496 0.216-1.141 0.099 
 
SQUAMOUS CELL CARCINOMA 
Stromal CD8 
High vs. Low 
0.287 0.106-0.776 0.014* 0.325 0.136-0.776 0.011* 
Tumoural CD209 
High vs. Low 
0.214 0.061-0.749 0.016* 0.239 0.080-0.719 0.011* 
Gene expression levels dichotomised according to their medians. Results from univariate Cox regression 
method. CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival; *p 
< 0.05. 
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